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Alzheimer’s disease (AD) is a neurodegenerative disorder associated with progressive 
neuronal loss. Microglial cell activation in the central nervous system (CNS) may 
contribute to this process through the release of neurotoxic inflammatory mediators. 
Systemic inflammation, through signaling to the CNS, can further activate microglia and 
thus accelerate neurodegeneration. The apolipoprotein (APOE) ε4 allele has been 
associated with both an increased risk of developing AD and higher levels of 
inflammation. The aim of this study was to investigate the relationships between systemic 
inflammation, CNS inflammation, the APOE genotype, neuronal integrity and cognitive 
functioning in a cohort of elderly participants from the Western Cape region of South 
Africa. South Africa is a developing country where systemic infections are common and 
the ε4 allelic frequency is thought to be high. Sixty-eight cognitively healthy controls and 
60 AD participants were recruited. Participants underwent a full clinical and cognitive 
assessment. APOE genotyping was performed and the following systemic inflammatory 
markers were measured: erythrocyte sedimentation rate (ESR), white cell count, monocyte 
count, tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), transforming 
growth factor- beta (TGF-β), IL-10 and osteopontin. Forty-eight control and 32 AD 
participants were re-assessed after one-year. Thirty-three participants underwent proton 
magnetic resonance spectroscopy for the detection of myo-inositol (MI), a marker of glial 
activation, and N-acetylaspartate and N- acetylaspartylglutamate (NAA+NAAG), a 
neuronal integrity marker, in the posterior cingulate gyrus. Results showed that mild AD 
participants had higher ESRs and IL-1β levels when compared with moderate AD, more 
severe AD and control participants. High baseline levels of TNF-α, low baseline levels of 
IL-10 and the presence of the ε4 allele were independently associated with a greater 
cognitive decline in AD. MI was increased in more severe AD participants and tended to 
be negatively correlated with episodic memory performance. NAA+NAAG levels were 
lower in AD participants compared with controls. In conclusion, the inflammatory 
response in AD changed with disease progression. Pro-inflammatory systemic changes 
were seen early in the disease but glial activation in the CNS was observed later. Thus, 
systemic inflammation may drive CNS inflammation and neurodegeneration. The ε4 allele 
had a detrimental effect in AD. The mechanism by which ε4 exerts its detrimental effects 
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Alzheimer’s disease (AD) is a chronic age-related neurodegenerative disorder affecting 
cognition, mood, behaviour and daily functioning. AD is the most common cause of 
dementia and is the main cause of disability in older adults in the developed world (Burns 
& Iliffe, 2009).  
 
Although the exact prevalence of AD in South Africa is unknown, AD prevalence is 
known to increase exponentially with age (Gao, Hendrie, Hall, & Hui, 1998). The 2011 
South African census estimated that approximately 556 800 of the 5.8 million people living 
in the Western Cape were over the age of 65 (Statistics SA). The number of people over 
the age of 50 years in South Africa is also projected to rise from the estimated 8 million in 
2010 to 13.5 million in 2050 (U.S. Census Bureau, 2012). The rise in older adults will be 
accompanied by a rise in the prevalence of AD. The 2005 Delphi consensus concluded that 
there is already a high prevalence of AD in developing countries (Ferri et al., 2005). This 
study suggested that although there was a lower prevalence of dementia in Sub-Saharan 
Africa compared to European and North American countries, it was estimated that of the 
24.4 million people living with dementia in 2001, 60% lived in low- to middle-income 
countries (Ferri et al., 2005). Anecdotal evidence from clinics in the Western Cape, South 
Africa, also suggests that AD is not uncommon. 
 
AD is characterised by a cluster of neuropsychological deficits, commonly starting with 
memory impairment and gradually progressing into global cognitive deficits that include 
aphasia, apraxia, agnosia and visuospatial impairments. Behavioural and psychological 
symptoms such as delusions, hallucinations, depression, anxiety and apathy also 
accompany the progression of the disease (Rossor, 1993; Burns, Lawlor & Craig, 2004).  
 
Most patients who develop AD have a late, insidious onset. Familial forms of AD have an 
earlier onset but these cases account for approximately 1 to 6% of all AD cases (Bekris, 
Yu, Bird, & Tsuang, 2010). The latter include rare autosomal dominant forms of the 














presenilin-1 and presenilin-2 genes located on chromosomes 21, 14, and 1 respectively 
(Goate et al., 1991; Sherrington et al., 1995; Levy-Lahad et al., 1995).  
 
Many individuals who go on to develop AD can be identified during the prodromal phase 
of amnestic mild cognitive impairment (MCI). MCI is widely regarded as a transitional 
state between cognitively normal ageing and AD. An individual is regarded as having MCI 
when he/she has age-inappropriate memory decline, preserved general cognitive function 
and intact activities of daily living (Petersen et al., 2001a). Individuals diagnosed with MCI 
are up to 15 times more likely to develop AD, with an annual rate of conversion to AD 
from MCI estimated at 10 to 15% (Petersen et al., 2001b; Burns & Iliffe, 2009). Decline in 
cognition, from cognitively healthy to MCI to AD, may be assessed longitudinally using 
standardised cognitive tests that are quantifiable, reproducible, and for which normative 
data are available. Examples of these are the widely used Mini-mental State Examination 
(MMSE; Folstein, Folstein & McHugh, 1975) and the Cambridge Examination for Mental 
Disorders in the Elderly (CAMCOG; Huppert, Brayne, Gill, Paykel, & Beardsall, 1995).  
 
Although these cognitive and behavioural manifestations of AD and MCI are fairly easily 
recognized by clinicians, the actual diagnosis of AD or MCI can be a lengthy process as 
the diagnostic decision has to follow a logical sequence and has to include multiple lines of 
evidence. These sources include a history of change in cognitive function from a spouse, 
partner or other family member, cognitive testing, a physical examination, blood tests and 
brain imaging. There are no specific diagnostic tests for AD. A diagnosis of possible or 
probable AD depends on an evaluation of the overall clinical picture and exclusion of other 
possible causes of cognitive impairment (Dubois et al., 2007; Burns & Iliffe, 2009). A 
definitive diagnosis of AD is only possible following histopathological examination of 
brain tissue. Beta-amyloid (Aβ) plaques and neurofibrillary tangles are characteristic 
pathological features of the condition; these will be discussed later in the Introduction 
(McKhann et al., 1984). In most cases the clinical diagnosis has to be made in the absence 
of definitive pathology. Therefore, the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders 
Association (NINCDS / ADRDA) developed criteria for the diagnosis of possible or 














Table 1  
NINCDS / ADRDA Criteria for Possible and Probable Alzheimer’s Disease 
Possible Alzheimer’s Disease Probable Alzheimer’s Disease 
Presence of dementia symptoms, in the 
absence of any other neurological, 
psychiatric or systemic disorders. 
Dementia – established by a clinical 
examination, history, and documented with 
neuropsychological tests (e.g., MMSE < 23, 
CAMCOG < 80). 
 
Single, gradually progressive, severe 
cognitive deficit e.g. worsening amnestic 
syndrome. 
 
Deficits in two or more areas of cognition 
with progressive worsening of memory and 
other cognitive functions. 
Presence of a second systemic disease or 
brain disorder sufficient to produce 
dementia, but not considered to be the 
cause of dementia. 
Absence of systemic disorders or other 
brain diseases that could account for the 
memory and cognitive deficits. 
 No disturbances in consciousness. 
 
 Age of onset > 40; usually after the age of 
65. 
 
These criteria were published in 1984 and new criteria have since been proposed for the 
diagnosis of AD. Dubois et al. (2007) proposed new diagnostic criteria for research 
purposes. These criteria involve the use of biomarkers on neuroimaging and cerebrospinal 
fluid (CSF) analysis (Dubois et al., 2007). In 2011, the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease 
published new criteria that incorporated the expanding field of biomarkers (McKhann et 
al., 2011). They proposed the use of biomarker tests including positron emission 
tomography (PET) amyloid imaging; low CSF Aβ1-42 (a peptide fragment of Aβ) or 
elevated phosphorylated tau (McKhann et al., 2011). The use of the Pittsburgh compound 
B (PiB) in PET scanning was first published in 2004 by Klunk and colleagues (Klunk et 
al., 2004). The PiB compound is retained in areas of the cortex that contain significant Aβ 
deposits. PET imaging of the PiB compound has made it possible to measure or quantify 
the Aβ load in living patients. More recently, The Food and Drug Administration (FDA) in 
the United States approved the use of Amyvid (florbetapir F18 injection) as another PET 















Other AD pathology biomarkers are found in the CSF. Andreasen and colleagues (2001) 
found increased tau protein concentrations and decreased Aβ42 peptide levels in CSF of 
participants with probable AD. These authors noted that increased tau and decreased Aβ42 
have a predictive value for AD of greater than 90%. Although these markers are useful in a 
research setting, the National Institute on Aging-Alzheimer’s Association workgroup do 
not advocate the use of AD biomarker tests in clinical practice as the tests currently lack 
standardization. The tests are also expensive and currently not widely available. The core 
NINCDS /ADRDA clinical criteria have good diagnostic accuracy and utility in most 
patients and in everyday practice these criteria are still widely used (McKhann et al., 
2011). The accuracy of using the NINCDS / ADRDA diagnostic criteria has been 
established by Hogervorst and colleagues (2000). They investigated the inter-rater 
reliability and accuracy of independent medical doctors who used NINCDS/ADRDA 
criteria for the diagnosis of AD in patients. When compared with histopathological criteria, 
namely the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), the 
diagnostic accuracy was 90% when the clinician diagnosed NINCDS/ADRDA probable 
AD. This study therefore indicated that the clinical diagnosis of probable AD using the 
NINCDS/ADRDA criteria correlated very well with a positive histopathological diagnosis. 
 
There are numerous established risk factors for developing AD. The strongest of these risk 
factors remains increasing age.  
Age: The prevalence of AD rises incrementally from 0.6% in individuals aged 65 to 69 
years to 8.4% in individuals aged 85 years (Hebert et al., 1995). The prevalence of AD is 
approximately 45% in individuals over 90 years of age (Corrada, Brookmeyer, Berlau, 
Paganini-Hill, & Kawas, 2008).  
Family history: Individuals with a first-degree relative who suffered from AD have a 10 to 
30% increased risk of developing AD (Van Duijn et al., 1991). 
Genetic factors: Familial forms of AD are related to mutations in APP gene or the 
presenilin-1 and presenilin-2 genes (Goate et al., 1991; Levy-Lahad et al., 1995; 
Sherrington et al., 1995). Individuals with Down syndrome also have AD pathology earlier 
in life (Wisniewski, Wisniewski, & Wen, 1985; Lamere, Blusztajn, Yamaguchi, 
Wisniewski, Saido, & Selkoe, 1996). The trisomy of chromosome 21, where the APP gene 














1989). Aside from these inherited forms of AD, the Apolipoprotein E (APOE) gene has 
been strongly associated with the risk of developing AD in North America and Europe. 
The APOE gene has three common alleles (ε2, ε3 and ε4), and codes for a plasma protein 
involved with lipid transport. The presence of one or two ε4 alleles (heterozygous or 
homozygous) significantly increases the risk of AD. The odds ratio of developing AD with 
the ε2/ε2 or ε2/ε3 genotype is 0.6 whereas the odds ratio is 2.6 for the ε2/ε4 genotype, 3.2 
for the ε3/ε4 genotype and 14.9 for the ε4/ε4 (Farrer et al., 1997). Other genes implicated 
in the development of AD include variants of the gene encoding for clusterin (Schrijvers, 
Koudstaal, Hofman, & Breteler, 2011). More recently a rare missense mutation in the 
triggering receptor expressed on myeloid cells 2 (TREM2) gene has been identified in 
Icelanders. The TREM2 gene encodes for the triggering receptor expressed on myeloid 
cells 2, a glycoprotein thought to be involved in inflammation. The risk of developing AD 
in people with the TREM2 mutation has been shown to be similar to the risk of developing 
AD in people with the ε4 allele (Jonsson et al., 2013). 
Vascular risk factors: Vascular risk factors not only increase the risk of vascular dementia 
but also of AD. Numerous studies have shown an increased risk of AD with 
hypercholesterolemia, diabetes mellitus and hypertension (Whitmer, Sidney, Selby, 
Claiborne, Johnston, & Yaffe, 2005; Whitmer, Karter, Yaffe, Quesenberry, & Selby, 
2009). Smoking has also been associated with an increased risk in some studies; however 
others have not found an association (Almeida, Hulse, Lawrence, & Flicker, 2002).  
Lifestyle and Activity: An inverse relationship exists between physical activity and risk of 
AD. A large social network and having a partner also decreases the risk of AD (Fratiglioni, 
Paillard-Borg, & Winblad, 2004). Stress and high levels of the stress hormone cortisol 
increase an individual’s risk of developing AD (Lupien et al., 1998; Wilson et al., 2005). 
Education and Cognitive Reserve: Lower levels of education have been shown to increase 
the risk of developing AD (Kukull et al., 2002). Cognitive reserve is a term used to 
describe the brain’s resilience to pathological damage. Numerous studies suggest that a 
large cognitive reserve is associated with higher socio-economic status, higher educational 
attainment and having an occupation, higher levels of literacy, and more participation in 
leisure activities (Stern, 2009). A larger cognitive reserve allows for better coping when 
brain damage occurs, probably due to the increased complexity of pre-morbid neuronal 














The neuropathology of AD includes extensive cerebral atrophy and the accumulation of 
neurofibrillary tangles, Aβ plaques and atrophy (Braak & Braak, 1995). Neurofibrillary 
tangles consist of abnormally phosphorylated tau proteins that cause the collapse of the 
neuronal cytoskeleton (Rossor, 1993; Minghetti, 2005). Braak and Braak (1995) developed 
the Braak staging for AD based on the presence of neurofibrillary tangles. Neurofibrillary 
tangles are thought to follow a predictable sequence during disease progression. Braak and 
Braak (1995) divided the development of neurofibrillary tangles into 6 stages:  
Transentorhinal Stages I and II: Neurofibrillary tangles are confined to the 
transentorhinal cortex region (see Figure 1a). Clinically, stage I and II do not present with 
cognitive impairment because pathological changes are below the threshold at which 
clinical symptoms are noted.  
Limbic Stages III and IV: In stages III and IV there is little destruction of the 
cerebral cortex. Severe changes are found only in few allocortical regions (the 
hippocampal formation, entorhinal and presubicular regions) and the surroundings. Mild 
changes are noted in the entorhinal and transentorhinal regions as well as the hippocampus 
(see Figure 1b). Stage III and IV do not involve changes to the neocortex and therefore 
patients in these stages do not meet the neuropathological criteria for AD (CERAD). 
Impairment of cognitive functioning, particularly episodic memory, is noted in these 
stages.  
Neocortical Stages V and VI: Stage V and VI mark the later or end stages of AD. 
Neurofibrillary tangles are found in the cerebral cortex and severe destruction of the 
neocortical region is noted (see Figure 1c). Stage V and VI correspond with the CERAD 


























Figure 1: The Braak stages of AD. a) The transentorhinal stages I and II show 
neurofibrillary tangles (indicated by black dots) in the transentorhinal cortex (indicated by 
the arrow); b) stage III and IV represent the limbic stages. The limbic stages show 
destruction of the entorhinal (indicated by the arrow) and transentorhinal cortex as well as 
the hippocampus. c) the neocortical stages V and VI show destruction of the cortex and 
neocortical region. The first column of Figures a-c depicts a sagittal section through the 
brain. The second and third columns show a coronal view of the temporal region. The 
arrows point to the leading characteristics of each stage. 
From: H. Braak & E. Braak, 1995, Neurobiology of Aging, 16, p. 272 & p. 275. 
 
Aβ peptides are derived from the APP (see Figure 2). The APP is cleaved by enzymes 
called secretases. When β-secretase and γ-secretase cleave the APP, Aβ1-40 and Aβ1-42 are 
formed. The latter tend to aggregate into β-sheet fibrils that form extracellular Aβ plaques. 
These plaques are believed to be toxic to neurones. On the other hand, cleavage of the APP 
by α-secretase and γ-secretase, produce P3 fragments that are soluble, non-amyloidogenic 
and do not aggregate. Both pathways of APP cleavage occur in normal metabolism (Esch 



















Figure 2: The pathways of amyloid precursor protein (APP) degradation. In the 
amyloidogenic pathway, cleavage of APP by β-secretase forms an extracellular soluble 
sAPP-β fragment and a membrane bound C99 fragment. Further degradation of C99 by γ-
secretase forms extracellular Aβ and an APP intracellular domain (AICD; a soluble 
cytosolic fragment). In the non-amyloidogenic pathway, APP is cleaved by α secretase to 
yield a membrane bound C83 and extracellular sAPP-α. C83 is cleaved by γ-secretase to 
produce two short peptide fragments, p3 and AIDC. 
 
The amyloid hypothesis proposes that excessive Aβ accumulation is the key pathological 
feature of AD and responsible for the clinical presentation of patients. Familial forms of 
AD in which single mutations in the APP gene, located on chromosome 21, causes an 
increased accumulation of Aβ, support the amyloid hypothesis. The three copies of the 
APP gene also cause trisomy 21 Down syndrome patients to develop AD usually by the 
age of 40 years (Wisniewski et al., 1985; Lamere et al., 1996). Evidence to support the 
amyloid hypothesis also comes from studies showing that in AD there is an imbalance 
between the production and clearance of Aβ plaques. The imbalance leads to a higher 
quantity of Aβ in brain tissue, leading to more neuronal damage and progression of the 
disease process. Evidence for this hypothesis is provided by Mawuenyena et al. (2010). 
They found that the rate of Aβ production in late onset AD patients and controls was not 
significantly different. However, in AD patients the rate of clearance of Aβ was 30% 
slower than controls. A deficit in clearance is probably due to decreased transport of Aβ 
across the blood-brain barrier (BBB) or decreased cellular uptake by macrophages (Minati, 
Edginton, Bruzzone, & Giaccone, 2009).  
 
Newer evidence supporting the amyloid hypothesis comes from a genetic discovery. A 














Individuals with the A673T mutation produced less Aβ than individuals without the 
mutation. The mutation results in impaired β-secretase 1 cleavage of APP in carriers. This 
leads to a 40% reduction in the formation of amyloidogenic peptides. The mutation also 
seems to trump the APOE ε4 allele effect. In the study, 25 individuals with the mutation 
were homozygous for the ε4 allele. These individuals did not develop dementia despite 
their increased risk (Jonsson et al., 2012).  
 
In 2002, Thal and colleagues described the progression of Aβ deposition, classifying it into 
5 phases. The first phase includes Aβ deposition in the neocortex. This is followed by Aβ 
deposition in the allocortical regions in phase two. In the third phase, the putamen; caudate 
nucleus; substantia innominata; magnocellular cholinergic nuclei of the basal forebrain and 
the diencephalic nuclei contain Aβ plaques. Some brainstem nuclei exhibit Aβ deposition 
in the fourth phase. In the fifth phase deposition occurs in additional brainstem nuclei as 
well as the cerebellum (Thal, Rüb, Orantes, & Braak, 2002).  
 
Aβ and neurofibrillary tanlges accumulate in specific parts of the brain, such as the 
neocortex and hippocampus, as well as in certain cells of subcortical cholinergic nuclei 
(e.g. in the nucleus basalis of Meynert) that project to the cerebral cortex. The brunt of 
neurofibrillary tangles accumulation occurs in the hippocampus and entorhinal cortex. This 
may account for the early episodic memory difficulties seen in AD patients (Rossor, 1993; 
Dickson, Crystal, Bevona, Honer, Vincent, & Davies, 1995).  
 
Neurochemical and lesion studies have provided compelling evidence for the selective 
degeneration of cholinergic basal forebrain neurones in ageing and AD. The basal 
forebrain consists of a large group of cholinergic neurones. Neuronal extensions from the 
nucleus basalis of Meynert innervate the neocortex and amygdala and the neurones 
extending from the medial septal nucleus innervate mainly the hippocampus and the 
cingulate cortex (see Figure 3). The basal forebrain cholinergic system regulates limbic 
and cortical functioning. These cholinergic neurones degenerate and die in AD. This has 
led to the “cholinergic hypothesis”, which states that a deficit of the neurotransmitter, 
acetylcholine, underlies the primary and earliest symptoms of memory loss in AD (Bartus, 















Figure 3: Projections of the cholinergic system. Neuronal extensions from the nucleus 
basalis of Meynert innervate the neocortex and amygdala and the neurones extending from 
the medial septal nucleus innervate mainly the hippocampus and the cingulate cortex. 
 
There is no specific treatment for AD. Centrally acting acetylcholinesterase inhibitors, 
aimed at improving the acetylcholine deficit by inhibiting the enzyme that breaks it down, 
are often prescribed for symptomatic improvement in the early stages. Other drugs are in 
the clinical phases of development, with many of these being disease-modifying 
medications that are aimed at reducing the Aβ deposition (Mangialasche, Solomon, 
Winblad, Mecocci & Kivipelto, 2010). 
 
NEUROINFLAMATION AND ALZHEIMER’S DISEASE 
 
Another important and now widely accepted neuropathological feature of AD is 
neuroinflammation. Neuroinflammation may be defined as the presence of activated 
microglia and reactive astrocytes, as well as inflammatory mediators, in the central nervous 
system (CNS) (Minghetti, 2005).  
 
Celsus (30 BC – 38 AD) was the first to describe the 4 classical signs of inflammation, 














(loss of function) was added to form the 5 cardinal signs of inflammation. This classic 
innate response to infection in the periphery is caused by blood borne elements (e.g. 
cytokines, prostaglandins, histamines and nitric oxide) that are released at the site of injury. 
In 1892 Metchnikoff was the first to investigate the localised nature of inflammation by 
impaling starfish larvae with rose thorns. He observed mesenchymal cells around the site 
of injury and named these cells phagocytes (see McGeer & McGeer, 2003). In 1919 Del 
Rio Hortega identified the brains equivalent of phagocytes, microglia. In the 1980s there 
was a significant increase in research into neuroinflammation and neurodegenerative 
disorders. This research lead to the hypothesis that neuroinflammation may drive or 
contribute in part to neurodegenerative disease processes (Rozenmuller, Eikelenboom, & 
Stam, 1986; McGeer, Itagaki, & McGeer, 1988).  
 
AD does not demonstrate the cardinal signs of calor, rubor, dolor and tumor and therefore 
the inflammatory response in the brain is sometimes termed “clinically silent” (Kandel, 
2006). The inflammatory response in AD includes complement activation, chemokine 
alterations, elevated pentraxins, microglial and astrocyte activation, as well as biochemical 
features of oxidative stress and the release of neurotoxins (Rosenberg, 2005). Although 
neuroinflammation is largely considered a downstream consequence of Aβ and tau 
pathology, it may be an exacerbating factor in the pathological and clinical progression of 
the disease (Vehmas, Kawas, Stewart, & Troncoso, 2003). The rest of this section will 
describe some of the evidence implicating neuroinflammation in the pathogenesis of AD.  
 
The presence of activated microglial and astrocytes in AD 
Microglial cells and astrocytes form part of the CNS’s innate immune system. In the sense 
of inflammation, these inflammatory cells are down-regulated and inactive in normal 
healthy brains. In AD, microglia become activated in areas of the brain associated with Aβ 
plaques and tau pathology. Activation is probably in response to the pathology and may 
represent an attempt to clear Aβ plaques by phagocytosis (Braak & Braak, 1995; see 
Figure 4). When microglia are activated, they change morphologically, developing into 
















Activated microglial cells have been found in mouse models of AD and post-mortem brain 
samples. In a transgenic mouse model using the mutant human APP gene, Aβ deposition 
was associated with immune responses. Matsuoka et al. (2001) found that these mice had 
activated microglia and astrocytes that increased synchronously with the increase in 
amyloid burden. In post-mortem studies, activated microglia surround plaques and 
neurofibrillary tangles in AD brains (Akiyama et al., 2000), see Figure 4. More recently, 
Gorlovoy, Larionov, Pham, & Neumann (2009) demonstrated that activated microglia may 
also lead to the aggregation of tau in vivo, further driving AD pathology. Gorlovoy et al. 
(2009) did this experiment by co-culturing activated microglial cells from mouse 
hippocampal tissue with neurones that had been exposed to the human tau gene. Neuronal 
cultures exposed to activated microglial cells had an increase in the life-time fluorescence 
resonance energy transfer signal, indicating that activated microglia producing 
inflammatory mediators stimulated the aggregation of tau in neurites.  
 
 
Figure 4: A schematic representation of activated microglial cells engulfing a β amyloid 
plaque.  
From: M. Combrinck & J. Joska, 2008, Current Allergy & Clinical Immunology, 21, 
p.133. 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
Indirect evidence for the detrimental effect of inflammation in AD is derived from 
population-based longitudinal studies, which found that the long-term use of some 














Kowall & Felson, 2008; Côte et al., 2012). The risk of developing AD is further reduced 
with a longer duration of NSAIDs use (In’T Veld et al., 2001). NSAIDs inhibit 
cyclooxygenase (COX), the enzyme which catalyses the first step in the synthesis of 
prostaglandins and thromboxanes. The latter two chemicals are important mediators of 
inflammation (Minghetti, 2005). There are two major isoforms of COX, COX-1 and COX-
2. COX-1 is constitutively expressed while COX-2 is inducible. COX-2 has been shown to 
be increased in the brain in early stage AD (Hoozemans et al., 2005). Chronic NSAID use 
may therefore protect against AD by suppressing neuroinflammation. 
 
However, Weggen et al. (2001) demonstrated that the mechanisms by which NSAIDs 
protected against AD might be unrelated to their anti-inflammatory effects. Some NSAIDs, 
for example ibuprofen, have been found to alter the site of cleavage of the APP, thereby 
altering the Aβ fragment produced from the insoluble, amyloidogenic Aβ1-42 to the soluble 
non-amyloidogenic Aβ1-38 protein (Weggen et al., 2001). Therefore, NSAIDs may, in fact, 
reduce the Aβ burden in AD brains. Most clinical trials of NSAIDs in established AD have 
failed to show any benefit or slowing in the progression of AD (McGeer & McGeer, 2007). 
Some trials have shown that the administration of NSAIDs in the early stages of AD may 
actually be detrimental. The latter may be due to the inhibition of an early protective 
inflammatory response (Gasparini, Ongini, & Wenk, 2004). 
 
Cytokine toxicity in AD 
The activation of microglia has been shown to cause a disturbance in neuronal homeostasis 
and alterations to synapses (McGeer & McGeer, 2003). Neurotoxicity occurs as a result of 
the sustained secretion of high levels of cytokines and chemokines that damage neurones 
and perturb neuronal functions. Neurones are especially sensitive to cytokine signalling 
(Hoozemans, Veerhuis, Rozemuller, & Eikelenboom, 2006). One argument is that the 
propagation of microglial and astrocytes around the plaques drives a toxic cycle. 
Microglial and astrocytes cause neuronal damage, further APP cleavage and therefore 
increased Aβ deposition, neuronal injury, apoptosis and increased microglia activation 
(Gasparini et al., 2004). Schwartz and Schechter (2010) proposed that if microglia are 
intensely activated beyond a certain threshold and remain activated past a certain time 
















Low levels of inflammation and high Aβ load 
Cognitively healthy individuals with a high Aβ load, significant neurofibrillary tangle 
pathology but low levels of inflammation provide evidence that neuroinflammation may 
play a role in the clinical manifestation of AD (Parachikova et al., 2007). Parachikova and 
colleagues (2007) compared mild/moderate AD patients with cognitively healthy controls. 
Of the 14 cognitively healthy controls in this study (MMSE scores ranging from 25-30), 10 
had AD pathology (high plaque and/or tangle pathology), 4 of whom had a significant Aβ 
load (6.15 – 13.5%). They found that mild/moderate AD patients had significantly higher 
levels of the inflammatory markers, major histocompatibility complex (MHC) class II 
mRNA and MHC II protein load, in the hippocampus compared with controls. 
Furthermore, MHC II protein levels correlated negatively with the MMSE. These findings 
show that despite the presence of significant plaque pathology, controls had lower 
inflammatory markers. The results support the notion that inflammation may correlate with 
the clinical dementia component of the disease. Thus, the presence of neuroinflammation 
may determine whether clinical signs result from the pathology of AD. 
 
Systemic inflammation and cognition  
The role of inflammation in cognitive decline is further validated by studies examining the 
effects of systemic inflammation on cognition. 
 
High levels of systemic inflammatory markers and cognition: 
Studies investigating the relationship between levels of systemic inflammation and decline 
in cognition contribute indirectly to evidence that neuroinflammation has a role in the 
pathogenesis of AD. Higher levels of inflammatory markers in the blood have been shown 
to predict cognitive decline. Inflammation may therefore be one reason for the cognitive 
decline seen in normal ageing (Schmidt, Schmidt, Curb, Masaki, White, & Launer, 2002a; 
Eikelenboom, van Exel, Hoozemans, Veerhuis, Rozemuller, & van Gool, 2010). Ageing 
has been shown to be accompanied by a mild, controlled, chronic increase in certain 
systemic pro-inflammatory cytokines. Franceschi, Bonafè, Valensin, & Benedictis (2000) 
coined the term “inflammaging” to describe this phenomenon. Some elderly individuals 














diseased state. Inflammaging may serve as a prodrome or exacerbating factor for the 
development of AD, and may even be a risk factor (Giunta et al., 2008). The Honolulu-
Asia Aging Study showed that cognitively healthy men with high levels of highly sensitive 
C-reactive protein (CRP) had a 3-fold increased risk for dementia compared to men with 
lower levels (Schmidt et al., 2002a). The shift from age-appropriate cognitive decline to a 
disease state falls on a continuum, suggesting a gradual shift from normal ageing to 
preclinical dementia (Burns & Iliffe, 2009).  
 
The relationship between inflammation and cognition is also seen in cognitively impaired 
patients where high levels of peripheral or systemic inflammatory markers are significantly 
correlated with cognitive impairment (Holmes & Lovestone, 2003; Guerreiro, Santa, Brás, 
Santiago, Paiva, & Oliveira, 2007; Holmes et al., 2009). Guerreiro et al. (2007) found that 
levels of pro-inflammatory cytokines such as IL-1β and tumor necrosis factor alpha (TNF-
α) in the blood were highest in AD patients when compared with cognitively healthy 
controls and participants with MCI. Holmes and colleagues (2009) found that increased 
baseline levels of serum TNF-α were associated with a fourfold increase in the rate of 
cognitive decline in AD patients over a 6 month period compared to AD patients with low 
baseline levels. A high baseline level of TNF-α was also associated with the degree of 
baseline cognitive impairment. High levels of systemic inflammatory markers in older 
adults may be due to multiple recurrent or chronic systemic infections throughout life. The 
mechanisms by which systemic infection may affect cognition are discussed below.  
 
Peripheral infection and cognitive decline in AD: 
Systemic infection and other inflammatory events in the periphery are a common cause of 
delirium in the elderly. Delirium is an acute, fluctuating condition affecting multiple 
cortical functions (American Psychiatric Association DSM-IV, 2000). Delirium has been 
associated with a significant increased risk of developing dementia (McCucker, Cole, 
Dendukuri, Belzile, & Primeau, 2001). Peripheral infection has been shown to accelerate 
cognitive decline and neurodegeneration in AD patients. In a 6-month follow-up study, AD 
patients who suffered a systemic inflammatory event had a two-fold increase in the rate of 
cognitive decline when compared with patients who had not suffered a systemic 















The effect of systemic inflammation depends on the state of activation of the microglia. 
AD pathology partially activates microglia. These microglia become “primed”. The 
systemic inflammatory response is thought to further activate primed microglia in the brain 
via neuro-immune signalling from the periphery to the CNS, leading to an exaggerated 
neuro-immune response (Perry, 2004). The increase in CNS inflammation is thought to 
increase neuronal damage, apoptosis and Aβ deposition, all of which drive the decline in 
cognitive functioning. The hypothesis that peripheral infection leads to increased CNS 
inflammation is well documented in animal studies where a systemic infection, mimicked 
by lipopolysaccharide (LPS), leads to activation of microglia in the CNS (Combrinck, 
Perry, & Cunningham, 2002). The mechanisms by which this occurs are further discussed 
in this chapter (The Link between Peripheral and Central Immune Systems, page 36).  
 
The evidence summarised so far suggests that systemic inflammation can accelerate 
degeneration of neurones which, in-turn, leads to a decline in cognition. However, there 
has been much debate as to whether or not enhanced neuroinflammation is beneficial or 
detrimental to the process of neuronal stability and survival (Weninger & Yanker, 2001; 
Crutcher et al., 2006). One could argue that in the initial stages of AD, neuroinflammation 
is beneficial and that the primary mode of microglia during these stages is protective. 
Microglia and macrophages may attempt to reduce plaque formation by engulfing Aβ. 
Thus, the immune response improves neuronal survival. An early immune response may 
also repair damaged neurones (Crutcher et al., 2006). Combrinck et al. (2006) showed that 
high initial levels of prostaglandin E2 (PGE2), an anti-inflammatory-associated chemical 
mediator of inflammation, were associated with a longer survival of AD patients compared 
with AD patients with initial low levels of PGE2.  
 
Inflammation, an Early Event in AD  
 
Inflammation in AD has been studied at length. However, few studies have investigated 
inflammation at the different stages of AD. Motta, Imbesi, Di Rosa, Stivala, & 
Malaguarnera (2007) investigated cytokines in serum in mild AD patients (patients with 
MMSE scores ranging from 18 – 20.2), and moderate AD patients (patients with MMSE 
scores ranging from 14.6 – 16.3). They showed that interleukin 12 (IL-12), IL-16, IL-18 














progressively declining in moderate AD patients (Motta et al., 2007). Some CNS studies 
have shown similar results. As previously described, Braak and Braak (1995) devised a 
staging system of AD, which rates progression of the disease on a scale ranging from 1 to 6 
according to the neurofibrillary tangle pathology. A lower Braak stage indicates lower 
quantities of neurofibrillary deposits. A post-mortem study showed an increase in the 
activation of COX-2 in response to an increase in neurofibrillary tangles from Braak stages 
1 to 4 (Hoozemans et al., 2005). However, they also found that COX-2 expression subsides 
after Braak stage 4 (see Figure 5).  
 
Parachikova et al. (2007) also demonstrated that microglia activation was an early event in 
the pathogenesis of AD. They showed that the gene expression of MHC II, a marker of 
activated microglia, was increased in prefrontal cortex tissue and hippocampal tissue from 
participants with mild to moderate AD when compared with post-mortem brain samples 
from non-demented participants. Combrinck et al. (2006) confirmed that inflammation 
subsides in moderate and advanced AD patients. In this study, CSF PGE2 levels were 
higher in mild-moderate AD participants when compared with advanced AD participants. 
Therefore, the inflammatory response in MCI/early AD seems to change in nature, with 
high levels of the inflammatory markers COX-2, PGE2 and MHC II found in the early 
stages of the disease process and lower levels at later stages (see Figure 5). 
 
Many studies have not shown that inflammation subsides with the progression of AD. 
Bermejo et al. (2008) showed that IL-6, TNF-α and IFN-α were significantly raised in AD 
participants when compared with MCI participants and controls. Another study showed 
increased levels of TNF-α in sera of severe stage AD patients compared with controls; 
whereas mild/moderate AD patients did not have elevated TNF-α levels compared with 
















Figure 5: β-Amyloid and neurofibrillary tau pathology in the different stages, defined by 
Braak pathology, of Alzheimer’s disease and their relationship to an inflammatory marker, 
cyclooxygenase 2 (COX-2). 
From: J.J.M. Hoozemans, R.Veerhuis, J.M. Rozemuller, P. Eikelenboom, 2006, 
International Journal of Developmental Neuroscience, 24, p.158. 
 
Interim Summary 
The pathological features of AD include Aβ accumulation, neurofibrillary tangles, cerebral 
atrophy and neuroinflammation. Although neuroinflammation is largely considered a 
downstream consequence of Aβ and tau pathology, it may be an important factor in the 
pathogenesis and clinical progression of the disease (Vehmas et al., 2003).  
 
Quiescent microglia are activated in response to AD pathology (Braak & Braak, 1995). 
Activated microglial surround plaques in an attempt to engulf them (Akiyama et al., 2000; 
Matsuoka et al., 2001). Activated microglial also secrete cytokines and other inflammatory 
molecules. These inflammatory molecules may drive the neurotoxic cycle, leading to 
neurodegeneration. Higher levels of inflammation have also been associated with an 
increase in the rate of cognitive decline in both cognitively healthy and AD participants 
(Schmidt et al., 2002a; Guerreiro et al., 2007; Holmes et al., 2009).  
 
The inflammatory response in AD has been shown to occur early in the disease process 














may subside with the progression of the disease (Combrinck et al., 2006; Hoozemans et al., 
2006).  
 
Markers of Inflammation  
 
In both sporadic and familial forms of AD, inflammatory cells are present (McGeer et al., 
1988; McGeer & McGeer, 2003; Wyss-Coray & Rogers, 2012). Researchers have used 
different inflammatory markers to quantity inflammation. The rest of this section will 
outline some of the inflammatory markers studied in AD.  
 
Cellular Markers 
Activated microglial cells and astrocytes appear early in AD and microglia appear to 
surround plaques. Microglia are observed by immunohistochemical staining using 
antibodies against proteins displayed by the monocyte-phagocytic system. One of these 
proteins includes the MHC class II glycoproteins which are up-regulated in activated 
microglial cells (McGeer et al., 1988). Astrocytes, which provide supportive functions for 
neurones, have been found to be concentrated around Aβ plaques. Astrocytes migrate in 
response to monocyte chemoattractant protein-1 (MCP-1), a chemokine, and other chemo-
attractants present in brain lesions. Astrocytes then adhere to Aβ1-42, a process mediated by 
integrin. Adherence allows astrocytes to bind to Aβ enabling them to take up and degrade 
these plaques (Wyss-Coray et al., 2003).  
 
Complement Proteins and Pentraxins 
Pentraxins are important protein activators of the complement system. C- reactive protein 
(CRP), a pentraxin, is a protein in the blood. Originally it was believed that CRP was only 
produced in the liver and then secreted into the blood. However, genetic techniques have 
demonstrated that it is also produced locally in the brain. CRP is thought to assist in the 
process of phagocytosis by macrophages (Guyton & Hall, 2006). CRP has been shown to 
be up-regulated in AD (McGeer & McGeer, 2003).  
 
The complement system is activated by pentraxins. The function of the complement 














direct killing through the membrane attack complement” (McGeer & McGeer, 2003). 
Recognition occurs through Complement Component 1, Q Subcomponent (C1q). Briefly, 
amplification then takes place through a cascade of 30 proteins in the complement 
pathway. This attracts and activates immune cells. Tangle and plaque aggregates have been 
shown to bind to C1q and to activate the classical complement cascade. C4d and C3d are 
some of the complement fragments that have been shown to be activated in AD and not 
cognitively healthy controls (Akiyama et al., 2000).  
 
Other peripheral blood markers 
The erythrocyte sedimentation rate (ESR) is the rate at which red blood cells precipitate 
over a period of 1 hour. It is a common haematological test that is performed by placing 
anti-coagulated blood in an upright capillary tube and measuring the rate (mm/hour) at 
which the red blood cells precipitate with gravity. When fibrinogen is present in high 
concentration it causes red blood cells to stick together, thus increasing the sedimentation 
rate. High levels of fibrinogen are present in the blood in inflammatory conditions (Guyton 
& Hall, 2006). 
 
White blood cells form part of the innate immune system. They are produced particularly 
in bone marrow and partly in lymph tissue. After formation, white blood cells are 
transported to parts of the body where they are needed. An increase in the white cell count 
in peripheral blood usually indicates infection and/or inflammation (Guyton & Hall, 2006). 
 
There are six types of white blood cells present in the blood, each with a distinct form and 
function. These include monocytes, neutrophils, eosinophils, basophils and lymphocytes. 
Monocytes make up 5-10% of the total white blood cell count. Monocytes have many roles 
in the immune system; one such role is to engulf, divide and differentiate into macrophages 
therefore replenishing the macrophage population in tissues. They also migrate from the 
bloodstream to other tissues where they engulf foreign matter by phagocytosis (Guyton & 
Hall, 2006). Microglial cells (the brain’s immune defence) are most similar to monocytes. 
Microglia originate from monocytes present in the CNS. Peripheral monocytes produce the 
















Osteopontin (OPN) is an extracellular phosphoprotein expressed by macrophages. OPN is 
involved in differentiation and immune cell activation as well as cell attachment and 
migration. OPN is thought to have a pro-inflammatory role as it acts as a cytokine in 
regulating macrophage function (Scatena, Liaw, & Giachelli, 2007). OPN in the blood has 
been found to be increased in AD patients and is associated with Aβ deposition (Wung et 
al., 2007). Comi et al. (2010) showed that OPN was increased in the early phases of AD. 
OPN levels in CSF were positively correlated with MMSE scores from AD patients and 
negatively correlated with disease duration. The increase in OPN was specific to AD and 
not found in age matched controls or patients with fronto-temporal dementia (Comi et al., 
2010).  
 
Cytokines – a double edged sword 
Neuroinflammatory cytokines appear to have a dual role, with both beneficial and 
detrimental effects. Cytokines have therefore often been referred to as the double-edged 
sword of inflammation. When an immune response is triggered and microglia are 
activated, they release pro- and anti-inflammatory cytokines and chemokines. Cytokines 
are soluble communicating factors between cells. Cytokines encompass several subfamilies 
that include interleukins (ILs), interferons (IFNs), tumor necrosis factor (TNF), growth 
factors (GF) and chemokines (McGeer & McGeer, 2003; Wyss-Coray & Rogers, 2012).  
 
Anti-inflammatory cytokines, such as transforming growth factor beta (TGF-β) and PGE2, 
play a role in homeostasis and suppression of the inflammatory response. They down-
regulate the pro-inflammatory cytokines and are involved in the resolution of inflammation 
(Boche, Cunningham, Docagne, Scott, & Perry, 2006). Higher TGF-β levels in transgenic 
mice expressing the human APP gene resulted in a 50% overall reduction in the Aβ load on 
the hippocampus and neocortex (Wyss-Coray et al., 2001). Parachikova et al. (2007) 
showed that the anti-inflammatory gene sequence for the TGF-β and IL-10 receptor were 
















In contrast, pro-inflammatory cytokines such as TNF-α and IL-1β may induce 
inflammation, phagocytosis, and cell death. Elevated blood levels of TNF-α and IL-1β 
have been found in MCI and AD patients compared with controls. Animal models have 
shown similar results. Mice expressing the mutant human APP gene had significantly 
higher levels of IL-1β and TNF-α in the cortex than control mice (Sly et al., 2001). 
Activation of these pro-inflammatory cytokines may be a common mechanism that 
contributes to neurodegenerative disease processes (González-Scaran & Baltuch, 1999).  
 
Some cytokines have both anti and pro-inflammatory properties at different stages of the 
inflammatory process. Therefore, separating cytokines into anti- and pro-categories is 
problematic. 
 
In summary, activated microglia release both pro-and anti-inflammatory cytokines. 
Microglia are in a quiescent state in a normal healthy brain and are activated in AD 
pathology. The pro-inflammatory cytokines may be neurotoxic and therefore cause 
neuronal damage. Anti-inflammatory cytokines counteract the pro-inflammatory effect and 
dampen the immune response.  
 
The Link between Peripheral and Central Immune Systems 
 
The CNS was previously believed to be an immunologically privileged site that was 
protected and isolated by the BBB from the peripheral immune system. However, new 
evidence suggests that there is communication between the peripheral and central immune 
systems (Guerreiro et al., 2007; Sonnen, Montine, Quinn, Kaye, Breitner, & Montine, 
2008).  
 
The BBB generally prevents cytokines moving from the CNS to the periphery and vice 
versa. However, it does allow for signalling between the two (Guerreiro et al., 2007; 
Sonnen et al., 2008; see Figure 6). There are 3 major routes of communication between the 















Firstly, communication between the periphery and the CNS occurs via the BBB. Evidence 
for the BBB as a route of communication comes from studies showing that systemic 
infection may activate neuroinflammation (see Figure 6). Secretions of pro-inflammatory 
mediators or microbial products in the periphery are able to directly signal to the CNS. 
Peripheral cytokines and inflammatory mediators from the periphery signal to the 
endothelium of the BBB, which in turn signals to the perivascular macrophages located 
adjacent to the endothelial cells. The perivascular macrophages then signal to the resident 
microglia within the brain, which are then activated (Perry, 2004). The activated microglial 
cells are then capable of secreting cytokines and other toxic substances that damage 
neurones. In AD, primed microglia are further activated, enhancing the inflammatory 
response (Perry, 2004). In a demonstration of such interaction between the peripheral and 
central immune systems, Combrinck et al. (2002) showed that peripheral infection causes 
activation of microglia primed by prion disease, increasing pro-inflammatory cytokines in 
the diseased brains of prion-infected animals. 
 
The central immune system may also influence the peripheral circulating system (see 
Figure 6). De Simoni, De Luigi, and colleagues (1995; 1998) showed that intra-cerebral 
administration of a LPS, an endotoxin from Gram-negative bacteria, induces peripheral 
systemic inflammation. Rats that were administered LPS centrally showed an increase in 
IL-1β, IL-6 and TNF-α cytokines in the serum. These authors have also suggested that the 
sympathetic nervous system exerts a tonic inhibitory control over the peripheral synthesis 
and secretion of inflammatory cytokines. The latter were enhanced by sympathetic nervous 
system denervation. 
 
The second route of communication is by blood cytokines communicating directly with 
macrophages and other cells in the circumventricular organs of the brain that lack a BBB 
(Banks, Kastin, & Broadwell, 1995). Schwartz and Schechter (2010) also proposed that 
during neurodegeneration, monocytes might also infiltrate a leaky brain parenchyma from 
the circulatory system. These monocytes differentiate to form monocyte-derived 
macrophages. These cells are thought to regulate microglia by terminating their 















The third route of communication between the peripheral and the central immune systems 
is via the vagal nerve sensory afferents from the thoracic abdominal cavity (see Figure 6). 
The vagus nerve is the 10
th
 cranial nerve that conveys sensory information from the viscera 
to the CNS. The vagus nerve is activated by endotoxins and cytokines in the periphery, 
relaying the signal to the CNS. In-turn, vagus efferent fibres might have an anti-
inflammatory effect through acetylcholine secretion. It is through this pathway that the 
vagus nerve is thought to modulate the systemic inflammatory response to pathogenic 
invasion (Tracey, 2002). Other evidence demonstrating the vagus nerve’s function in 
peripheral and CNS communication comes from rat vagotomy studies. Vagotomised rats 
failed to display the behavioural depression in social exploration that the sham operated 
rats showed after a peripheral injection of IL-1β (Bluthé, Michaud, Kelley, & Dantzer, 
1996). 
 
Further evidence for the communication between the systemic immune system and the 
CNS is provided by the effect of an acute systemic illness on the CNS. A systemic 
infection causes an altered temperature, increased lethargy, decreased body weight, apathy, 
social withdrawal and depression. Collectively these behavioural changes are referred to as 
“sickness behaviour” and are mediated by the hypothalamus. These conditions are adaptive 
protective mechanisms aimed at creating suboptimal conditions for microbial replication 
and conservation of energy (Hart, 1988; Combrinck et al., 2002; Dantzer & Kelley, 2007; 



















Figure 6: The link between the periphery and the central nervous system (CNS) 
1: Resting microglia are activated by β-amyloid deposits. 2: Resting microglia are also 
“primed” or partially activated by β-amyloid deposits. 3: Activated microglial secrete 
cytokines. 4: Cytokines and other inflammatory molecules cause neuronal damage, 
increased apoptosis, neuronal cell loss and cognitive decline. 5: Inflammatory molecules or 
microbial products in the blood signal to the brain endothelium across the blood-brain 
barrier (BBB); the endothelial cells, in turn, signal to the perivascular macrophages leading 
to 6. 6: Primed microglia are further activated, exacerbating inflammation. 7: The vagus 
nerve senses inflammatory molecules in the viscera and signals to the CNS, activating 
CNS microglia. 8: There is some evidence that CNS inflammatory molecules are able to 
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The BBB is generally thought of as a mechanism that protects the microenvironment of the 
brain/CNS from that of the periphery or systemic circulation. It does, however, allow for 
signalling between the two. There are 3 routes of communication. First, systemic cytokines 
or microbial products in the periphery signal to the brain endothelium across the BBB; the 
latter cells, in turn, signal to the perivascular macrophages and microglia of the CNS. The 
second route of communication is via circumventricular organs that lack a BBB (Banks, 
Kastin, & Broadwell, 1995). Lastly, inflammatory events in the periphery may be sensed in 
the abdominal cavity by the vagus nerve. The vagus nerve transmits these signals to the 
CNS. The vagus nerve might then modulate the systemic inflammatory response through 
its cholinergic innervation and acetylcholine secretion (Tracey, 2002). 
 
During acute illness, inflammatory markers and microbial products in the periphery signal 
to the CNS. The hypothalamus causes an altered body temperature, apathy, social 
withdrawal, depression, lethargy and decreased body weight. This pathophysiological 
response is referred to as “sickness behaviour”.  
 
MAGNETIC RESONANCE IMAGING 
 
Magnetic resonance spectroscopy (MRS) is a rapidly developing field of neuroimaging 
that provides a non-invasive, in vivo analysis of neurochemicals (Hajek & Dezortova, 
2008). MRS permits identification of and changes in neurometabolites that reflect neuronal 
dysfunction, glial reaction, and energy metabolism. Identifying and being able to detect 
changes in neurometabolites has been used clinically in patients with a range of 
neurological and psychiatric disorders, which may contribute to the understanding of a 
variety of neurological diseases (Ross & Sachdev, 2004). PET scanning may also be used 
to detect neurometabolites. MRS has advantages over PET in that MRS is an easily 
repeatable and harmless examination whereas PET scans expose the person to radio-active 

















How MRS works 
 
Electromagnetic energy of a certain wavelength is emitted from the scanner and directed at 
the tissue under examination. This tissue either absorbs or re-emits the energy, which can 
then be measured. From the distribution and the various intensities of the measured energy, 
called a spectrum, information about the chemical properties of the tissue sample can be 
obtained (Cousins, 1995). Each neurochemical is sensitive to the pulse sequence (the series 
of radio frequency pulses applied to the tissue) and echo time (TE; the time between the 
radio frequency pulses) and therefore these parameters need to be carefully selected 




H-MRS) utilizes the nuclear magnetic resonance of protons. The 
protons spin in response to electromagnetic energy. Spinning of the neurometabolites 
protons, that are present in the tissue, produces a spectrum that is characteristic of that 
neurometabolite. The spectrum emitted from neurometabolites is detected from a 3 
dimensional volume of tissue called a voxel. Metabolites are present in low concentrations 
in the brain, therefore one needs to examine a homogenous voxel of brain tissue ranging 
from 1 to 27cm
3
 in order to detect different signals. Water is present in high concentrations 
in the brain; therefore the water resonance within the voxel needs to be suppressed to 
detect the millimolar concentrations of neurometabolites (Cousins, 1995).  
 
Besides water, the volume of interest contains other types of compounds: macromolecules 
such as lipids, metabolites greater than 1millimolar (mM) and metabolites less than 1mM 
in concentration. In human tissue the most important of these are the metabolites greater 
than 1mM. These metabolites include: lipids, lactate, N-acetylaspartate, glutamate-
glutamine, creatine, choline and myo-inositol (Hajek & Dezortova, 2008). They are 
identified by their peaks at specific frequencies at which they resonate; this is usually 
depicted in a spectrum (see Figure 7). The peaks of the spectrum measure the intensity of 
the emitted energy from the metabolite in the voxel during 
1
H-MRS: a higher peak 
indicates a higher concentration of the metabolite. Interpretation of these metabolites is 
















Interpretation of Metabolites 
 
Lipids 
The broad peak of lipids occur at 0.9 and 1.2 parts per million (ppm). An increased lipid 
peak usually indicates necrosis in brain tumours (Lin, Ross, Harris, & Wong, 2005).  
 
Lactate 
Lactate generally has a double peak occurring close together at a frequency of 1.33 ppm. 
The presence of lactate is indicative of anaerobic glycolysis, which is detected in areas of 
the brain associated with hypoxia, mitochondrial dysfunction, encephalopathy, 
lactacidosis, or brain injury (Lin et al., 2005). An increase in lactate levels has also been 
linked to inflammation. Increased lactate levels were shown to decline with the resolution 




The peak produced by glutamate-glutamine (Glu/Gln) is a mixture of closely related amino 
acids, amines and derivatives that are involved in the excitation and inhibition of 
neurotransmission. The glutamate-glutamine peak lies between 2.1 and 2.4 ppm, and has 
been used as a marker of stroke, lymphoma, hypoxia and other metabolic brain disorders 
(Lin et al., 2005). Moats, Ernst, Shonk, & Ross (1994) found a small but significant 
decrease in the glutamate-glutamine peak in AD compared with controls. Antuono and 
colleagues (2001) also found a reduction in the glutamate-glutamine peak in AD patients. 
In this study glutamate-glutamine positively correlated with the MMSE and the 
Instrumental Activities of Daily Living in AD participants.  
 
Creatine (Cr) 
The Cr peak refers to the sum of creatine and phosphocreatine, with the Cr peak lying at 
3.0 ppm. Cr acts as a central energy marker of neurones and astrocytes. Cr is considered 
relatively “constant” in most of the areas of the brain and is therefore used as an internal 
reference, with the metabolite/Cr ratio commonly used (Lin et al., 2005). The Cr 














in mind when placing voxels anatomically and when comparing metabolite/Cr ratio 
between different brain regions (Ross & Sachdev, 2004). 
 
Choline (Cho) 
Cho or trimethylamine is an umbrella term used for several soluble components of the 
brain myelin and fluid-cell membranes that resonate at 3.2 ppm in the spectrum (Lin et al., 
2005). Cho is used as a marker for membranes, with an alteration in the signal indicating 
rapid membrane turnover (e.g. presence of a tumour) or demyelination in inflammatory 
disease processes such as multiple sclerosis (Lin et al., 2005; Mader, Rauer, Gall, & Klose, 
2008). An increase in Cho and the Cho/Cr has been reported in AD patients compared with 
controls (Lazeyras et al., 1998; Wang et al., 2012). Wang et al. (2012) also reported an 
inverse correlation between the Cho/Cr ratio and the global Pittsburgh compound B (PiB) 
retention in cognitively healthy adults. As discussed previously, PiB is used to quantify Aβ 
load. In this study, Cho/Cr was the only metabolic ratio that was correlated with measures 
of cognition. It is hypothesised that there is a cholinergic deficiency in AD patients. One 
explanation for the increase in the Cho peak in AD is thought to relate to the membrane 
phosphatidylcholine catabolism. Catabolism of the membrane phosphatidylcholine may be 
an attempt to provide free choline for this deficient cholinergic system. Another 
explanation is that there is an increase in membrane turnover due to neurodegeneration 
(Wang et al., 2012). However, Dixon and colleagues (2002) reported a decrease in Cho 
with cognitive impairment. Studies investigating Cho in AD are limited and further 
research needs to be done to clarify the conflicting results from the above studies.  
 
N-acetylaspartate (NAA) 
NAA is considered a neuronal marker, resonating at 2.00 ppm, and is the predominant 
signal produced in the human brain on 
1
H-MRS (Hajek & Dezortova, 2008). NAA is 
located almost exclusively in neurones and altered (usually decreased) NAA levels indicate 
either temporary neuronal dysfunction or permanent neuronal loss (Mader et al., 2008). 
NAA has been correlated with brain maturity and is thought to be more concentrated in 
grey matter than in white matter. Thus, depletion of NAA has been found to be greater in 
the grey matter (Valenzuela & Sachdev, 2001; Hajek & Dezortova, 2008). This is 















Due to NAA’s excellent signal characteristics on 
1
H-MRS, many studies have found 
reproducible changes in the NAA/Cr ratio in AD (Kantarci et al., 2000; Dixon et al., 2002). 
Wang et al. (2012) found that in the posterior cingulate gyrus and the hippocampus, AD 
participants had lower NAA/Cr ratios compared with MCI and control participants. MCI 
participants also had a lower NAA/Cr ratio compared with controls.  
 
Dixon et al. (2002) reported a relationship between NAA and cognitive functioning: the 
NAA concentration in the hippocampus was positively correlated with MMSE scores and 
CAMCOG scores of controls and AD patients. They suggested that NAA might be useful 
in assessing the functional status of the hippocampus as it may reflect the viability of 
neurones in this region.  
 
Myo-inositol (MI) 
MI is a simple sugar alcohol that acts as an organic osmolyte in the brain and is involved in 
the functioning of the second messenger system. The MI peak resonates at 3.6 ppm on 
MRS and is composed primarily of myo-inositol and, to a lesser proportion, inositol-
1phosphate and glycine (Ross & Sachdev, 2004). An elevation of the MI is thought to be 
related to microglial cell and astrocyte activation. MI has been shown to be increased in 
inflammatory conditions such as multiple sclerosis (Lin et al., 2005; Mader et al., 2008).  
 
The MI/Cr ratio has repeatedly been found to be increased in AD patients when compared 
with MCI participants and controls (Kantarci et al., 2000; Wang et al., 2009). Kantarci et 
al. (2000) reported a significant increase in the MI/Cr ratio in MCI patients compared with 
healthy controls. A further increase in the MI/Cr ratio was found in probable AD 
participants compared to MCI participants. Similar results were found by Wang et al. 
(2009) who reported an increase in the MI/Cr ratio in AD patients when compared with 
controls and MCI participants. A pathological study by Kantarci et al. (2011) used the 
retention of PiB to show the extent of amyloid burden in cognitively healthy individuals. 
They found that global retention of PiB and PiB retention in the posterior cingulate gyrus 















Due to the decrease in NAA and the increase in MI commonly found in AD, many studies 
use the NAA/MI or MI/NAA ratios when analysing and interpreting data. These ratios are 
robust in discriminating AD from controls, with a positive predictive value of 98%, thus 
potentially making it a good diagnostic discriminant (Shonk et al., 1995). Regional 
differences in the MI/NAA have also been shown in AD patients. Wang et al. (2009) found 
an increase in MI/NAA ratio in the hippocampus compared with the posterior cingulate 
area (Wang et al., 2009). Parietal MI/NAA ratios were also inversely correlated with 




Figure 7: Spectrum acquired using proton spectroscopy (
1
H-MRS) at 3 Tesla (3T) from the 
posterior cingulate gyrus in a healthy adult. The image depicts the peaks of: creatine and 
phosphocreatine (Cr) at 3 parts per million (ppm), glutamate (Glu) and glutamine (Gln) lies 
between 2.1 and 2.4 ppm (not labelled), myo-inositol (MI) at 3.6ppm, choline (Cho) at 
3.2ppm, N-acetylaspartate (NAA) at 2ppm. 






















Brain Regions in Imaging 
 
Imaging studies have mostly concentrated on volumetric analysis of the medial temporal 
structures such as the hippocampus and the entorhinal cortex. The hippocampus forms part 
of the limbic system and is buried in the depths of the temporal lobes. The entorhinal 
cortex region is located between the hippocampus and the transhippocampus spreading 
over the anterior borders of the parahippocampal gyrus (see Figure 8a). It is not surprising 
that research has focussed on these areas as this is where the neuronal loss is thought to 
typically start in AD (Rosenberg, 2005). Newer evidence suggests that the metabolism, 
perfusion and neuronal integrity of the posterior cingulate cortex are also affected in MCI 
and the early stages of AD (see Figure 8b; Nestor et al., 2003; Kantarci et al., 2011; Wang 
et al., 2012).  
 
 
Figure 8: The anatomical location of the limbic system. a) The hippocampus forms part of 
the limbic system and is buried deep within the temporal lobes. b) A sagittal section of the 
brain depicting the anatomical location of the posterior cingulate (highlighted in blue). 
Figure 8a from: http://www.ahaf.org/alzheimers/about/understanding/anatomy-of-the-
brain.html. 
 
Pengas, Hodges, Watson, & Nestor (2010) investigated the role of the posterior cingulate 
region in MCI using volumetric magnetic resonance imaging (MRI). Their results show 
that when compared with controls, MCI participants had significant atrophy of the 
hippocampus and two posterior cingulate regions (Brodmann areas 29/30 and 23). Both the 















the posterior cingulate was not just a consequence of generalised atrophy as no significant 
difference in atrophy was found in the anterior cingulate between MCI and matched 
control participants. This study therefore supports the hypothesis for early pathological in 
the posterior cingulate in AD.   
 
In a study by Choo et al. (2010), MCI and AD patients showed significantly reduced 
bilateral posterior cingulate cortex volumes in comparison to controls. AD patients had the 
lowest posterior cingulate cortex volumes. Anatomically, this study also showed that 
cingulum fibre disruption begins near the medial temporal structures, progressing to the 
posterior cingulate cortex. The progression of the disruption in cingulum fibres to the 
posterior cingulate cortex disruption coincides with the clinical progression of AD, from 
the preclinical to clinical stages. These results show that the posterior cingulate cortex is 
involved both directly and indirectly in AD: the direct involvement is the atrophy of the 
posterior cingulate cortex and the indirect involvement is the effect of the cingulum fibre 
degeneration due to the hippocampal atrophy (Choo et al., 2010).  
 
Involvement of the posterior cingulate gyrus in early AD is further supported by a 
metabolic study. Nestor et al. (2003) calculated the metabolic rate of glucose using PET 
scanning. Metabolism was reduced in patients with mild AD throughout the limbic 
network and the posterior cingulate gyrus.  
 
The hippocampus is relatively small and is anatomically in close proximity to areas of air 
and bone within the cranium, thus making it technically challenging to study using 
1
H-
MRS. Both bone and air distort the magnetic field homogeneity (Dixon et al., 2002). In 
AD research, distortion due to bone and air is exaggerated by the substantial quantity of 
CSF within the 
1
H-MRS voxel. The presence of CSF is thought to be due to the large 
degree of atrophy of the medial temporal lobes causing an increase in the volume of the 
temporal horn of the lateral ventricles. All these factors lead to limiting spectra resolution, 
low signal-to-noise ratios and difficulty suppressing water signals (Dixon et al. 2002). The 
posterior cingulate is more homogenous than the hippocampus and therefore ideal in AD 

















H-MRS uses electromagnetic energy to identify changes in neurometabolites that reflect 
neuronal dysfunction, glial reaction, and energy metabolism therefore making it possible to 
identify these metabolites in a non-invasive way (Hajek & Dezortova, 2008). Two 
important metabolites in AD research are MI and NAA. MI is considered to be an astrocyte 
and glial marker and has been shown to be increased in inflammatory conditions (Lin et 
al., 2005; Mader et al., 2008). Many studies report an increase in MI in AD and MCI 
(Kantarci et al., 2000; Wang et al., 2009). NAA is a prominent marker of neuronal 
dysfunction and viability and has been shown to be significantly decreased in AD. The 
ratio between NAA and MI is robust in discriminating AD from controls and it is therefore 
frequently used in the literature (Shonk et al., 1995; Wang et al., 2009).  
 
The hippocampus is technically a difficult area to examine with 
1
H-MRS. The posterior 
cingulate is a more homogenous and has been shown to have early metabolic, perfusion 
and structural changes in MCI and AD. Thus, the posterior cingulate is an ideal region to 
examine using 
1
H-MRS (Kantarci et al., 2000; Nestor et al., 2003; Kantarci et al., 2011; 




The apolipoprotein E (APOE) gene codes for the 34 kilodalton (kDa) apolipoprotein E 
(ApoE) protein. The ApoE protein is produced in the CNS mainly by astrocytes, to a lesser 
extent by microglia and under certain conditions by neurones (Kim, Basak, & Holtzman, 
2009). ApoE is mainly involved cholesterol transport and metabolism (Mahley, 1988).  
 
As previously discussed, the APOE gene is encoded by a gene on chromosome 19 and has 
three main alleles: ε2, ε3 and ε4 (Utermann, Langenback, Beisiegel, & Weber, 1980). The 
ε3 allele has been shown to be the most common allele in Caucasian populations with an 
average frequency of 75%; the ε2 and ε4 allele frequencies are 8% and 15% respectively 
(Zannis, Kardassis, & Zannis, 1993). The ε4 allele has also been shown to be highest in 














showed that in the South African Khoi San population the presence of the homozygous ε4 
allele (ε4/ ε4) was 3-5 fold more frequent when compared with a European population. 
 
The presence of the APOE ε4 allele has been shown to increase the risk of developing AD. 
In a meta-analysis by Farrer et al. (1997), the odds ratio for developing AD was 2.6 for the 
ε2/ε4 genotype, 3.2 for the ε3/ε4 genotype and 14.9 for the ε4/ε4 genotype. Thus the risk is 
also dose-dependent. Homozygous (ε4/ε4) participants also have an earlier age of onset of 
AD than heterozygous participants (Farrer et al, 1997). However, the relationship between 
the risk of AD and the ε4 allele is thought to weaken with age, with some studies showing 
that the ε4 exerts it maximal effect before the age of 70 (Corder et al., 1994; Farrer et al., 
1997; see Figure 9). Unlike the ε4 allele, the ε2 allele seems to have a protective effect, 
with the presence of the ε2 allele predicting a later age of onset of AD (Corder et al., 1994; 
Farrer et al., 1997). The odds ratio of developing AD with the ε2/ε2 or ε2/ε3 genotype is 




Figure 9: Relative odds of developing Alzheimer’s disease according to apolipoprotein E 
(APOE) genotype and age among Caucasians. The odds ratio for the allelic variants ε2/ε4, 
ε3/ε4, ε4/ε4, and ε2/ε2 or ε2/ε3 are depicted according to the symbols in the box. 
From: Farrer et al., 1997, Journal of the American Medical Association, 278, p.1353.  
 
The relationship between the ε4 allelic variant and the risk of developing AD in Africa is 
still unclear. A study comparing African-Americans residing in Indianapolis versus people 
in Nigeria found that the APOE ε4 allele was not as strongly related to AD in the Nigerian 














This was also shown in a study in East Africa (Kenya and Tanzania) where non-demented 
elderly participants over the age of 65 had the same ε4 allele frequency as age-matched 
demented patients. In both groups, 25% of individuals had at least one ε4 allele (Sayi et al., 
1997). These results suggest that, in Africa, the APOE ε4 genotype may not be as strongly 
related to AD in comparison to Western countries where there is a strong association. The 
lack of association suggests that both genetic and environmental factors may be 
responsible for increased risk of AD. Environmental factors, such as a high lipid and 
cholesterol intake typically seen in Western industrialized countries, together with the 
presence of the ε4 allele may strengthen the genetic association of ε4 and the risk of 
developing AD (Osuntokun et al., 1995; Gureje et al., 2006). 
 
As well as its association with AD, the APOE ε4 allele has also been associated with 
poorer prognosis in multiple sclerosis (Schmidt et al., 2002b); poor recovery in traumatic 
brain injuries (Sorbi et al., 1995) and an increase in inflammation in patients following a 
cardiopulmonary bypass (Grocott et al., 2001). The increase in inflammation after bypass 
probably relates to, aside from APOE’s role in cholesterol metabolism and transport, 
APOEs role in mediating the systemic and CNS’s inflammatory responses (this is 
discussed later in this section). This response may be isoform specific (Lynch et al., 2003). 
 
In summary, the APOE gene codes for the ApoE protein that is involved in lipid transport. 
In the CNS ApoE is secreted mainly by astrocytes. The gene has 3 allelic variants: ε2, ε3 
and ε4. The ε4 allele has been shown to increase the risk of developing AD. Despite the 
apparent high frequency of the ε4 allele in Africa, little known about the risk of AD and 
the ε4 allele in this environment. 
 
APOE and the Pathology of AD 
 
The role of ApoE in the pathological processes of AD is not yet fully understood. It is 
thought that the APOE allele might differentially modulate the clearance and 
accumulation of Aβ plaques. The release of ApoE is increased in neurodegenerative 
diseases such as AD (Diedrich et al., 1991). ApoE binds to extracellular Aβ deposits, 














Otomo, & Ikeda, 1991; Strittmatter et al., 1993). LaDu et al. (1994) found that ApoE3-Aβ 
binding was 20 fold greater than that of ApoE4-Aβ binding. Authors argue that the 
increase ApoE3 binding increases the clearance of Aβ plaques compared to the low 
ApoE4-Aβ binding. ApoE also affects the vascular drainage of Aβ through peripheral 
channels resulting in the accumulation of Aβ in the brain (Thal et al., 2007). Post-mortem 
studies provide evidence for the hypothesis that ε4 modulates the accumulation and 
clearance. AD homozygous ε4 brain tissue was shown to have greater Aβ plaques and 
neurofibrillary tangles when compared with AD patients with the APOE ε3 /ε3 genotype or 
the ε3/ε4 genotype (Tiraboschi et al., 2004). The ε4 isoform has been shown to increase the 
ratio of Aβ1-40 to Aβ1-42 in cerebral vessels, resulting in an accumulation of Aβ deposits and 
amyloid angiopathy (Fryer et al., 2005). The ε2 allele however, has been shown to provide 
some protection against the accumulation of plaques and tangles. The protective effect of 
the ε2 allele was also dominant in the case where there was an ε4/ε2 genotype (Nagy et al., 
1995).  
 
More recently the use of the PiB allowed researchers to investigate the accumulation of Aβ 
in vivo. Kantarci et al. (2012) showed that global retention of the PiB compound in 
cognitively healthy individuals progressively increased from ε2 to ε3 to ε4 carriers.  
 
APOE and Cognition 
 
The relationship between cognition and the ε4 allele is controversial. Henderson and 
colleagues (1995) showed that non-demented ε4 positive participants had a faster cognitive 
decline compared with non-demented participants with no ε4 allele. However, Small and 
colleagues (2000) found little evidence for an alteration in cognitive performance when 
comparing ε4 non-demented carriers with non-carriers (ε3 and ε2 allelic variants). All 
participants in the study performed similarly across all domains of cognition (Small et al., 
2000). The relationship between APOE genotype and cognitive decline after the onset of 
AD is also controversial. Most studies, however, show that AD ε4 carriers have a greater 
rate of decline compared with AD participants with other alleles (Petersen et al., 1995). 
Martins and colleagues (2005) showed that the rate of cognitive decline in AD participants 
had a dose-dependent relationship with the ε4 allele, with homozygous patients declining 















Kantarci et al. (2012) were the first to examine the relationship between amyloid burden 
(using PiB retention), cognition and the APOE genotype in a cognitively healthy 
population. They found that the association between lower cognitive scores and higher 
retention of PiB was strongest in ε4 carriers. They suggested that APOE ε4, together with 
other factors such as cognitive reserve, mediates the relationship between Aβ load and 
cognitive function. 
 
In summary, the ε4 allele is also thought to modulate the accumulation and clearance of Aβ 
plaques (Tiraboschi et al., 2004; Fryer et al., 2005; Thal et al., 2007). Studies have shown 
that ε4 carriers had a greater Aβ load (Tiraboschi et al., 2004; Kantarci et al., 2012). The ε4 
allele mediates the relationship between Aβ load and decline in cognition. AD ε4 carriers 
have been shown to have a faster rate of cognitive decline (Kantarci et al., 2012).  
 
Mechanism of APOE 
 
The mechanisms by which the ε4 allele exerts its harmful effects over the ε2 and ε3 alleles 
are unclear. One hypothesis is that APOE may affect synaptic plasticity during 
regeneration and repair. ApoE is thought to be released in response to neuronal injury and 
may be needed for repair of the nervous system (Slezak & Pfrieger, 2003). Klunk, 
Panchalingam, Clure, Stanley, & Pettegrew (1998) showed that AD post-mortem brain 
samples with the ε4 allele had significantly higher phospholipid metabolites, 
glycerophosphocholine (GPC) and glycerophosphoethanolamine (GPE), compared with 
post-mortem brain samples from controls as well as AD ε4 negative samples. Both GPC 
and GPE are products of the breakdown of membrane phospholipids. The authors therefore 
argue that if the APOE alleles have different efficiencies for membrane repair then the 
higher levels of GCP and GPE may be a reflection of inefficient membrane repair 
mechanisms in ε4 carriers.  
 
Evidence supporting this hypothesis is found in a study showing that cultured cortical 
neurones from an adult mouse that were incubated with human ApoE3 had greater 
neuronal outgrowths in comparison to neurones incubated with ApoE4. This relationship 














more effective in blocking the endogenous protective ApoE production by activated 
microglia. This results in a decreased release of the ApoE which may impair neuronal 
repair processes (Guo et al., 2004).  
 
APOE and Inflammation 
 
ApoE is thought to have an immune modulating function (Mahley & Rall, 2000). ApoE 
has been shown by van den Elzen et al. (2005) to bind to antigens and then transport the 
antigens to antigen presenting cells. ApoE is also thought to be released from antigen 
presenting cells to survey the local environment for serum-borne lipid antigens (van den 
Elzen et al., 2005). ApoE has been shown to decrease T cell proliferation. The mechanism 
by which ApoE reduces T cell proliferation is thought to be due to ApoEs effect on IL-2. 
Kelly, Clay, Mistry, Hsieh-Li, & Harmony (1994) demonstrated that the addition of ApoE 
to mitogen-stimulated T-cells decreased the production of IL-2 by 50-65% when compared 
with non-ApoE exposed cells. The binding site or cell surface receptor that functions as the 
ApoE immunosuppressive receptor is, however, unknown (Mahley & Rall, 2000). 
 
The immune modulatory role of ApoE is also thought to be isoform specific. The APOE ε4 
allele has been shown to contribute to, or to exacerbate the inflammatory process and 
increase activation of microglia in AD. The ε4 allele is thought to be less effective at 
suppressing the activation of microglia than the other allelic variants. Support for this 
argument comes from post-mortem examination of the brains of individuals diagnosed 
with AD. Egensperger and colleagues (1998) showed an increase in the activation of 
microglia as well as the tissue area occupied by these cells, in the presence of the ε4 allele 
in post-mortem AD brains. The increase is dependent on the ε4 gene dose, with ε4/ε4 
brains showing the greatest increase in microglia. 
 
The ε4 allele may have a more robust pro-inflammatory effect than ε3 allele therefore 
exacerbating the detrimental effects of these cytokines (Guo et al., 2004). Lynch et al. 
(2003) found that transgenic mice carrying the human ε4 allele had higher levels of pro-
inflammatory cytokines (TNF-α and IL-6) than those carrying the human ε3 allele. An in 














inflammatory cytokine) when stimulated with ApoE4 compared to stimulation with 
ApoE3. The release of IL-1β increased in a concentration-dependent manner (Guo et al., 
2004). 
 
Evidence for the pro-inflammatory effect of ε4 is also seen in other medical conditions. In 
patients who underwent a cardiopulmonary bypass, those with the APOE ε4 genotype had 
higher pro-inflammatory molecules IL-8 and TNF-α within 48 hours after surgery (Drabe 
et al., 2001). 
 
In summary, the ε4 allele is thought to exacerbate the inflammatory process in AD. It may 
do so by increasing pro-inflammatory cytokines or by decreasing anti-inflammatory 
cytokines thereby leading to an unopposed pro-inflammatory effect.  
 
In conclusion, the APOE ε4 allele may have properties that increase inflammatory 
responses that lead to a further increase in cognitive decline. Understanding the role of 
APOE in the progression of AD and APOE’s relationship with neuroinflammation is 
important as it adds insight into the pathological process of AD. Drugs may be designed to 
interact with the APOE genotype and therefore mechanisms in which the isoforms interact 




AD is an age-related neurodegenerative disorder (Burns & Iliffe, 2009). Little is known 
about the prevalence of AD in South Africa. However, anecdotal evidence from our local 
clinics suggests that it is not uncommon. The strongest risk factor for AD is age and South 
Africa’s population over the age of 50 years is projected to rise dramatically in the next 
few years (Hebert et al., 1995; US Census Bureau, 2012).  
 
The neuropathological features of AD include accumulation of Aβ plaques, neurofibrillary 
tangles, neuronal loss and cerebral atrophy (Rossor, 1993; Braak & Braak, 1995; see 














hence the early and pronounced memory impairments (Braak & Braak, 1995). Another 
important pathological feature of AD is neuroinflammation.  
 
Evidence that inflammation is involved in the pathological process of AD comes from 
studies showing the presence of activated microglia deposition in the regions of Aβ and 
neurofibrillary tangles. Microglia are normally in a down-regulated, inactive state (see 
Figure 10). In AD the microglia become activated and release neurotoxic cytokines and 
other inflammatory molecules (Braak & Braak, 1995). The AD pathology itself also 
partially activates or “primes” microglial cells. Primed microglia are further activated 
during systemic infection resulting in an enhanced inflammatory condition leading to 
further cognitive decline (Perry, 2004). Other evidence that inflammation is involved in the 
pathological process of AD comes from large population-based longitudinal studies 
showing that long-term use of NSAIDs was associated with a reduced risk of developing 
AD. Parachikova et al. (2007) also showed that some cognitively healthy individuals with 
high Aβ loads had low levels of inflammation. This suggests that inflammation may be 
important in the clinical manifestation of AD.  
 
Activation of microglia and subsequent cytokine release has been shown to occur early in 
the disease process in some studies. This initial inflammatory response may however 
subside with the progression of the disease (Hoozemans et al., 2005; Combrinck et al., 
2006).  
 
The BBB generally prevents cytokines and other inflammatory molecules from moving 
between the periphery and the CNS. It does, however, allow for signalling between the 
two. There are 3 routes of communication. First, systemic cytokines or microbial products 
in the periphery are able to signal to the brain endothelium across the BBB. The 
endothelium, in turn, signals to the perivascular macrophages and can further activate 
primed microglia in the brain parenchyma. The second route of communication is via 
circumventricular organs that lack a BBB (Banks, Kastin & Broadwell, 1995). Lastly, 
inflammatory events in the periphery are sensed in the abdominal cavity by the vagus 
nerve. The vagus nerve relays these signals to the CNS. The vagus nerve might then even 
















High levels of systemic inflammatory markers have been shown to be associated with a 
faster rate of cognitive decline in both cognitively healthy controls and AD patients 
(Schmidt et al., 2002a; Guerreiro et al., 2007; Holmes et al., 2009). Systemic inflammatory 
or infective events are also a major cause of delirium or acute transient cerebral 
dysfunction in the elderly (McCusker et al., 2001). Systemic infection may further activate 
primed microglia in the brain and so drive neurotoxic inflammatory damage. The latter 
could lead to accelerated neuronal loss and worsening cognitive functioning (Holmes et al., 
2009).  
 
Proton magnetic resonance spectroscopy (
1
H-MRS) permits identification of, and changes 
in, metabolites that reflect neuronal dysfunction, glial reaction and energy metabolism 
(Ross & Sachdev, 2004). NAA is commonly investigated chemical in AD research using 
1
H-MRS. NAA is a neuronal marker. A decrease in the NAA signal on 
1
H-MRS indicates 
temporary neuronal dysfunction or permanent neuronal loss (Mader et al., 2008). MI is 
another metabolite that is often been studied. An increase in the MI peak on 
1
H-MRS is 
related to microglial and astrocyte activation (Mader et al., 2008). The NAA/MI ratio is 
potentially a good diagnostic discriminate in AD (Shonk et al., 2005). 
 
The APOE gene has 3 main alleles, ε2, ε3 and ε4. The presence of the ε4 allele has been 
shown to increase the risk of developing AD (Farrer et al., 1997). The ε4 allele has been 
shown to differentially modulate the accumulation and clearance of Aβ plaques leading to 
increased plaque density in AD (Fryer et al., 2005; Thal et al., 2007; Kantarci et al., 2012). 
AD ε4 carriers have also been shown to have a greater rate of cognitive decline compared 
with AD participants with other alleles (Petersen et al., 1995; Martins et al., 2005).  
 
ApoE is also thought to have an immune modulating function (Mahley & Rall, 2000). 
Egensperger et al. (1998) showed increased activation of microglia in ε4 post-mortem AD 
brains compared with post-mortem brains of patients with other alleles.  
 
In South Africa we have a rapidly increasing older population, high rates of systemic 














Delport, Vermaak, & Utermann, 1995; Lawn, Bekker, Middelkoop, Myer, & Wood, 2006). 
For these reasons the current study aimed at investigating the relationships between 
systemic inflammation, CNS inflammation, APOE genotype, neuronal integrity and 

















Figure 10: Summary of the Introduction. The figure depicts the pathological changes occurring in the CNS 
and inflammation in the systemic circulation, from a healthy individual to advanced or late stage 
Alzheimer’s disease (AD). The presence of the ε4 allele (+ε4) accelerates the progression. 










NORMAL HEALTHY BRAIN: 
* intact neuronal structure  
* quiescent microglia 
* no CNS inflammation 
* no systemic inflammation 
* no tangles or plaques 
THE AGEING BRAIN: 
“inflammaging”   priming of microglia  
some microglial activation   systemic and 
CNS inflammation 
EARLY AD: 
* + ε4 allele accelerates progression from healthy 
ageing to AD 
 
*  Tangle pathology, Aβ production &/or  
Aβ clearance  priming of microglia   
activation of microglial   secretion of 
cytokines ( when ε4 present)   neuronal 
damage   neuronal loss 
 
* systemic infection/inflammation  signalling 
to CNS   CNS inflammation  further 
neuronal damage  
 
*  CNS inflammation   systemic 
inflammation  
MODERATE AD: 
* + ε4 accelerates progression from early to 
moderate AD 
 
*  Aβ deposits & tangles   neuronal 
damage   neuronal loss  
 
* dampening of inflammation 
LATE AD: 
* + ε4 accelerates progression from moderate to 
late AD 
 
*  Aβ deposits & tangles   neuronal 
damage   neuronal loss  
 








CNS inflammatory cells 
















RATIONALE FOR THE PROPOSED RESEARCH 
 
WHY IS RESEARCH ON OLDER ADULTS IMPORTANT? 
 
Ageing is regarded as a triumph of development and is one of humanity’s greatest 
achievements. As countries provide better nutrition, sanitation, health care systems and 
medical advances, their population ages (Osotimehin, 2012). Therefore, an ageing 
population has been widely perceived as being a problem only of high-income countries. 
Kinsella & He (2008) predict that the speed at which low- to middle-income countries age 
will however, outpace that of high-income countries. This is largely due to already high 
numbers of older adults and decreased fertility rates in the developed world. In South 
Africa the number of people over the age of 50 is expected to rise from 8 million in 2010 
to 13.5 million in 2050 (U.S. Census Bureau, 2012).  
 
As our population ages, individuals, families, communities and governments are faced 
with social, economic, demographic and cultural challenges. How we deal with these 
challenges will determine whether we reap the rewards of an ageing population. 
Understanding the health and disease status of the ageing population will allow 
governments to prepare their health care services, social support systems and design health 
care policies that cater for the specific needs of their population (He, Muenchrath, & 
Kowal, 2012).  
 
The risk of non-communicable diseases increases with advancing age. As the number of 
people over the age of 50 increases, the rate of dementia prevalence can be expected to 
rise. A Delphi consensus study (Ferri et al., 2005) estimated that in 2001, 60% of the 24.3 
million people with dementia came from developing countries. These numbers are 
expected to rise dramatically with an estimated 300% rate of increase from 2001 to 2040. 
This is compared to a 100% rate of increase in dementia cases in the developed world 
(Ferri et al., 2005). The prevalence of AD in South Africa is unknown. However, anecdotal 
















WHY STUDY AD IN SOUTH AFRICA? 
 
It is important that AD be studied in an African context as the rate of dementia prevalence 
is expected to rise. There is a dearth of knowledge and research in this area and most risk 
factors for AD have been identified in Europe and North America. As mentioned in the 
Introduction, a study found that risk factors associated with AD, such as the APOE ε4 
allele, were not as strongly related to AD in a Nigerian cohort as in an African- American 
cohort. These results suggest that additional environmental factors such as high cholesterol 
and lipid intake may, together with the ε4 allele, contribute to AD prevalence (Osuntokun 
et al., 1995; Gureje et al., 2006). The homozygous ε4 allelic frequency in indigenous 
populations of southern Africa has been shown to be 3-5 times higher when compared to 
European populations (Sandholzer et al., 1995). Therefore, research on the effects of the ε4 
allele in our population will be very informative.  
 
High levels of poverty, overcrowding and inadequate sanitation and nutrition have 
contributed to high levels of systemic infection in the Western Cape (de Swardt, Puoane, 
Chopra, & du Toit, 2005; Lawn et al., 2006). South Africa has one of the highest rates of 
tuberculosis and HIV/AIDS infections globally (Lawn et al., 2006). As discussed in the 
Introduction, Aβ and tau pathology prime microglia. During acute infection, microglia are 
further activated leading to an exaggerated inflammatory response. Holmes and colleagues 
(2003; 2009; 2011) have also showed that AD patients who acquire a systemic infection 
have a faster rate of cognitive decline than AD patients who remain healthy (Holmes et al., 
2003; 2009; 2011). These studies were conducted in an industrialized country with a low 
prevalence of systemic infection; rates of systemic infection are much higher in South 
Africa.  
 
The cost of dementia care is expected to increase more rapidly than the prevalence (WHO, 
2012). Of the US$315 billion worldwide dementia care cost in 2005, it was estimated that 
one third of that was informal care. Therefore, informal care constitutes a major cost 
component, particularly in less developed regions (Wimo, Winblad, & Jönsson, 2007). It is 
essential that South Africa prepares for the financial implications of the rising cost of 















THE USE OF BIOMARKERS 
 
The use of biomarkers is helpful in understanding the disease process. A biomarker, as 
defined by the Biomarker Definition Working Group (Atkinson et al., 2001), is “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacological response to a therapeutic 
intervention”. Biomarkers help identify the disease process and may be used in the 
predicting or monitoring the course of the illness. Inflammation is a pathological hallmark 
of AD. The use of inflammatory markers as biomarkers may be helpful in understanding 
the pathological process of the disease. Few biomarker studies have been performed in a 
developing world context where there is a high prevalence of systemic inflammatory 
conditions together with a high ε4 allelic frequency.  
 
The Western Cape offers a unique setting for biomarker research. Although South Africa is 
largely regarded as a developing country, the University of Cape Town does have access to 
some sophisticated neuro-imaging equipment. There are only few places in Africa that 
have a 3 Tesla (3T) MRI scanner and experienced radiographers to perform the scans. The 
Cape Universities Brain Imaging Centre (CUBIC) is a research unit that allows us to 
perform MRS scans on our participants using a 3T scanner. Lumbar punctures were not 
permitted by the ethics committee in this study as there were no clinical/ diagnostic reason 
or beneficial therapeutic intervention for performing one. MRS is useful as it allows one to 
quantify metabolic changes in AD brains in vivo. 
 
In summary, the identification of risk factors for AD such as APOE genotype is important 
in a population and environment-specific context. Identifying different patterns or markers 
of inflammation may also be important in developing reliable biomarkers, with special 
reference to our context. Understanding the relationships between these different factors is 
important as it may lead to a better understanding of the mechanisms underlying disease 
prevalence in this country. Research on the different stages of disease process and 
identifying biomarkers for these different stages may also be important in drug 
















In conclusion, dementia is a devastating condition that imposes a huge burden of care on 
families, caregivers, as well as the health care system. There are few dementia services 
available to South African communities to provide support and relieve some of the burden 
of disease on caregivers. Medical conditions of the elderly also tend to be ignored due to a 
lack of resources in the South African health care settings. Cholinesterase inhibitors are 
currently not available in the state / public health service.  
 
Understanding the association between systemic inflammation, CNS inflammation, 
neuronal loss, APOE genotype and cognitive functioning may lead to better preventative 
public health interventions and education on AD in a context specific to a South African 
population. Research provides knowledge that will lead to increased public awareness. 














AIMS AND HYPOTHESES 
 
The overall aim of this study is to investigate the relationship between systemic 
inflammation, CNS inflammation, neuronal loss and the APOE genotype in a population of 
elderly South Africans in the Cape Town region. Furthermore, the aim is to identify how 
these inflammatory and genetic factors influenced cognition over a period of one year. A 
diagrammatic framework is represented in Figure 11. 
 
To assess systemic inflammation, pro-inflammatory (TNF-α, IL-1β) and anti-inflammatory 
(TGF-β1, TGF-β2, TGF-β3, IL-10) cytokines, the total white cell count, monocyte count 
and the ESR in peripheral blood will be measured. 
1
H-MRS imaging for the MI and N-
acetylaspartate and N- acetylaspartylglutamate (NAA+NAAG) peaks will be examined as 




A number of hypotheses will be tested in a cross-section study, longitudinal study and a 
MRS study: 
 
Cross-Sectional and Longitudinal Studies: 
 
Hypothesis 1: Systemic inflammatory markers will be highest in the early stages of AD, 
declining with the progression of the disease. Participants with moderate AD and 
cognitively healthy controls will have comparable levels of inflammatory markers, 
whereas participants with severe AD will have lower levels of inflammatory markers when 
compared with the controls. 
 
Hypothesis 2: AD and control participants, either homozygous or heterozygous for the 
















Hypothesis 3: Participants, either homozygous or heterozygous for the APOE ε4 allele, 
will have higher baseline levels of systemic inflammatory markers compared with 
participants with no ε4 allele.  
 
Hypothesis 4: High levels of baseline systemic inflammatory markers will predict a faster 
rate of cognitive decline over a one-year period.  
 
Hypothesis 5: The presence of the ε4 allele (either homozygous or heterozygous) in 
participants will exacerbate their rate of cognitive decline when compared with participants 




Hypothesis 6: MI, a central nervous system inflammatory marker, will be highest in the 
early stages of AD, declining with the progression of the disease.  
 
Hypothesis 7: There will be a direct relationship between the NAA+NAAG peak on MRS 
in the posterior cingulate gyrus and the hippocampus, and cognitive functioning; i.e. the 
better the cognitive functioning, the higher the NAA+NAAG peak.  
 
Hypothesis 8: The ratio between MI and NAA+NAAG will be negatively correlated with 
cognition.  
 
Hypothesis 9: Participants, either homozygous or heterozygous for the APOE ε4 allele, 
will have higher baseline levels of MI and lower levels of NAA+NAAG compared with 
participants with no ε4 allele. 
  
Hypothesis 10: There is a direct association between systemic inflammation and CNS 
inflammation and neuronal loss. MI, a marker of CNS inflammation in the posterior 
cingulate and hippocampus, will be positively correlated with systemic measures of 














correlated with NAA+NAAG. NAA+NAAG will also be negatively correlated with 
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Figure 11: A diagrammatic representation of the study's underlying framework. The diagram shows the progression from cognitively healthy (left) 
to moderate Alzheimer’s disease (AD) (right). It is hypothesised that the progression from cognitively healthy to early or mild AD is accompanied 
by an increase in systemic and CNS inflammation and a decrease in neuronal integrity. The progression from early AD to moderate AD is then 
accompanied by a further decrease in neuronal integrity and a dampening of inflammation. The hypotheses predict that the presence of the ε4 
allele a) increases the rate of cognitive decline b) increases systemic and CNS inflammatory markers c) decreases neuronal integrity.  
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RESEARCH DESIGN AND SETTING 
 
The study consisted of three sections:  
(1) A cross-sectional component that investigated the relationship between peripheral 
inflammatory markers, APOE genotype and cognition.  
(2) Another cross-sectional component that investigated the relationship between 
neurometabolites on MRS, the APOE genotype, peripheral inflammatory markers and 
cognition. 
(3) A longitudinal component that investigated the relationship between peripheral 
inflammatory markers at baseline, APOE genotype and cognitive decline over a 1-year 
period. 
 
This study formed part of a larger observational study investigating risk factors for 
cognitive impairment in a sample of older adults from the Cape Town area. All study 
procedures were conducted at the Research Unit in the Neurology Ward at Groote Schuur 
Hospital or at the participants’ places of residence. The MRS component was conducted at 
the Cape Universities Brain Imaging Centre (CUBIC) at the Medical Campus of 




The Cross-sectional and Longitudinal Studies 
 
Participants were recruited from the Cape Town metropolitan region between the year 
2009 and 2012. Older adults with mild to moderate AD were recruited from community 
Old Age Homes in Cape Town and the Geriatric Medicine and Memory Clinics of the 
Groote Schuur Hospital, Cape Town. Participants were also recruited via referrals from 
local general practitioners and neurologists. Pamphlets outlining the objective of the study 














encouraged to speak to their doctor about participation. Cognitively healthy, community-
dwelling older adults were also recruited from community Old Age Homes and via word of 
mouth advertising. In some cases, spouses or relatives of enrolled AD participants were 
interested in participating in the study and if suitable, these participants were enrolled.  
 
The MRS Study 
 
Participants enrolled in the study were contacted and screened for contra-indications to 
MRI. Due to the large cost of MRI scans, a limited number of controls were invited to 
participate in this section of the study. Controls were selected based on age; older controls 
were invited to take part. This was done to try match the AD and control groups as far as 
possible. AD and control participants with no contra-indications to MRI scanning were 
invited to undergo MRI and MRS scanning after signing additional consent.  
 
Inclusion and Exclusion Criteria 
 
Individuals who were 55 years of age or older, who had basic literacy (i.e., the ability to 
speak, read and write in English or Afrikaans), and who had an MMSE score of more than 
12 were eligible for the study. The inclusion and exclusion criteria for the cross-sectional 
and longitudinal studies are summarized in Table 2. 
 
Participants with clinically overt systemic inflammatory conditions or infections were 
excluded. Participants who had an ESR above 40mm per hour were also excluded.  
 
For the MRS study, participants were excluded if they had any of the following: 
pacemaker, aneurism clips, artificial heart value, vena cava filters, prosthesis, shrapnel in 
their eye or body, neurostimulator, cochlear implant (ear) or hearing aid (Appendix A). 
Participants who had an ESR above 40mm per hour at the time of their MRS scan were 















Table 2  
Inclusion and Exclusion Criteria for the Current Study 
 
Sample Size Estimation 
 
A sample size calculation (power = 0.8) was done. ESRs for some participants that had 
been recruited in the larger study were available. Therefore the use of the ESR for a priori 
power calculations was a practical choice. A sample size of 15 participants in each group 
(mild AD, moderate AD, severe AD and controls) in the cross-sectional analysis was 
Inclusion criteria Exclusion criteria 
Age 55 years old and older Medical history 
  Diagnosis of: 
Basic literacy   HIV/AIDS 
 Basic ability to speak, read, and   Uncontrolled hypertension 
      write in English or Afrikaans  Uncontrolled diabetes mellitus 
  Any other medical condition that, 
Cognition (controls)   in the opinion of the investigator, 
 Reported normal cognition   precluded the patient 
   from participation 
Cognition (patients)  
 Possible or probable AD by 
NINCDS/ADRDA criteria 
Presence of infection 
 Clinical features of infection at the  
 MMSE score > 12              time of assessment and blood- 
  taking 
Informant  ESR > 40mm per hour 
 Availability of close relative/   
friend or caregiver who could  Psychiatric history 
provide information about   Presence of any major disorder  
cognitive change and functional            (e.g. depression: GDS>8) 
abilities  
 Neurological history 
  Presence of any other neurological 
             disorder e.g. Parkinson’s disease, 
        Huntington’s disease 
  Stroke within the last 6 months 
  Significant head injury within the 















needed. A significant difference in the frequency of the APOE ε4 allele was seen in a case-
control study of 33 AD patients and 35 controls (Combrinck et al., 2006). 
 
Post-hoc power calculations for differences in inflammatory markers at the different stages 
of AD were done. Ideal power (1 - β) was set at .80 and α = .05, two-tailed:  
IL-10: when the mild AD and moderate AD groups were compared, an actual 
power of 0.06 was achieved with an effect size of 0.08. When the mild AD and severe AD 
groups were compared, an actual power of 0.34 was achieved with an effect size of 0.58. 
When the mild AD and control groups were compared, an actual power of 0.20 was 
achieved with an effect size of 0.35. 
TNF-α: when the mild AD and moderate AD groups were compared, an actual 
power of 0.28 was achieved with an effect size of 0.53. When the mild AD and severe AD 
groups were compared, an actual power of 0.16 was achieved with an effect size of 0.36. 
When the mild AD and control groups were compared, an actual power of 0.32 was 
achieved with an effect size of 0.49. 
TGFβ1: when the mild AD and moderate AD groups were compared, an actual 
power of 0.05 was achieved with an effect size of 0.002. When the mild AD and severe 
AD groups were compared, an actual power of 0.05 was achieved with an effect size of 
0.008. When the mild AD and control groups were compared, an actual power of 0.06 was 
achieved with an effect size of 0.109. 
TGFβ2: when the mild AD and moderate AD groups were compared, an actual 
power of 0.05 was achieved with an effect size of 0.07. When the mild AD and severe AD 
groups were compared, an actual power of 0.05 was achieved with an effect size of 0.03. 
When the mild AD and control groups were compared, an actual power of 0.05 was 
achieved with an effect size of 0.03. 
MI: when the AD and control groups were compared, an actual power of 0.06 was 






















Ethical approval for all study procedures was obtained from the Research Ethics 
Committee of the University of Cape Town, Faculty of Health Sciences and Groote Schuur 
Hospital (Approval #: 346/2008). All procedures were conducted according to the ethical 
guidelines and principles of the International Declaration of Helsinki (2002) and the South 
African Guidelines for Good Clinical Practice (Department of Health, 2006). 
 
All participants were required to sign informed consent (Appendix B). Informed consent 
was obtained before the participant was enrolled in the study and before the participant had 
their scan. In the case of those with cognitive impairment, a close relative, friend or 
caregiver was also required to sign the consent forms. The consent form emphasized that 
participants were free to withdraw from the study at any point without this affecting their 
general medical care.  
 
Anonymity with regards to laboratory tests, data storage and publications was ensured. On 
enrolment all participants were assigned a study number. The first participant in the study 
was assigned the number 001 and each subsequent participant was assigned a study 
number in numerical order. All samples, including those sent to the laboratory for tests, 
were labelled with the participants’ study number and not their name. Files with the 
participants’ study observations were stored in a locked room. Only researchers involved 
in the study had access to this room. 
 
Participants were reimbursed for transport costs to and from either Groote Schuur Hospital 















PROCEDURE FOR STUDY 
 
The Cross-Sectional and Longitudinal Study 
 
Participants that were interested in taking part in the study were contacted. Participants 
were briefly screened to see if they were suitable for the study. Arrangements were then 
made for the participants’ first baseline visit. See Figure 12 for a summary of the study 
procedures. 
 
The majority of participants were assessed at the Research Clinic in the Neurology Unit, 
Groote Schuur Hospital. Exceptions were made in some instances where the participant 
was unable to attend. In these cases they were assessed in their place of residence. The 
study was explained to the participant and, if he/she was interested in participating, 
informed consent was obtained (see Appendix B). All participants included in the study 
had an informant – usually a spouse or another close relative - who was required to be in 
regular contact with the participant. The informant completed the Deterioration de 
Cognition Observee (DECO) and the Bristol Activities of Daily Living (BADLS 
questionnaires - see Information Gathering and Measures for details). Socio-demographic 
information, including data about age, handedness, gender, and level of education achieved 
was collected from the participant and informant. The participant also completed the 
Geriatric Depression Scale (GDS - see Information Gathering and Measures for details).  
 
All participants underwent cognitive testing (see Information Gathering and Measures for 
details). Tests were conducted in English. English was the second language of 33 
participants. However, all participants were all able to speak English fluently. Cognitive 
testing took approximately 90 minutes to complete.  
 
A medical doctor performed a comprehensive clinical assessment that included a full 
medical history, a general physical examination and a detailed examination of the nervous 
system. Blood tests for electrolytes, glucose, cholesterol, syphilis serology, liver function, 
renal function, serum vitamin B12, folate levels and thyroid function (thyroid stimulating 














disorders that might contribute to cognitive impairment. Additional blood was taken for 
inflammatory markers and apolipoprotein (APOE) genotyping. Blood samples were sent to 
The National Health Laboratory Service (NHLS) for the white cell count, monocyte count 
and ESR. Blood for cytokine analysis and APOE genotyping was stored until analysis (see 
Information Gathering and Measures for details).  
 
Seven participants underwent computerised tomography (CT) scanning for additional 
diagnostic clarification. In addition to these 7 participants, 14 participants were sent for CT 
or MRI scans by their medical doctors before they were enrolled in our study. Researchers 
excluded all participants that were not eligible for the study (see Inclusion and Exclusion 
Criteria). The remaining participants were then assigned to groups by a neurologist and 
neuropsychologist (including myself) using the NINCDS/ADRDA criteria (see Table 1) 
for the diagnosis of possible and probable AD (McKhann et al., 1984). The diagnostic 
process included a multi-step procedure. A neurologist and neuropsychologist used the 
DECO and BADLS scores in conjunction with information gleaned during the history 
taking to determine the degree of cognitive decline and level of activities of daily living for 
each participant. The neurologist rechecked the medical history notes, blood tests and 
clinical examination notes to make sure that these investigations did not reveal any other 
systemic or brain disease that could account for cognitive impairment. The neurologist also 
examined the MRI or CT scans of the 21 participants who had undergone scanning. The 
neuropsychologists calculated the participants’ cognitive scores to determine the level of 
functioning on the different cognitive domains. Once all the information was bought 
together a diagnosis was made.  
 
All participants were invited to participate in a follow-up assessment 12 months after their 
baseline visit. All participants were contacted and arrangements were made for their 
follow-up assessment. At this follow-up visit the CAMCOG cognitive test battery (which 
















Participants enrolled into the study 
Participant contacted and screened 
cognitive assessment (II) 
CAMCOG, learning subscale 
& MMSE) 
ONE-YEAR FOLLOW-UP 
participant contacted and follow-up visit 
arranged 
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consensus meeting on diagnosis of participants 
informant questionnaires 
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DECO and BADLS 
CAMCOG, learning subscale & 
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full blood count, cytokine 
measurements, APOE genotyping 
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THE MRS STUDY 
 
The MRS imaging study was performed as a separate cross-sectional study within the 
larger study. It involved participants for whom there were no contra-indications to 
performing MRI scans (see Appendix A for a list of contra-indications). Participants were 
contacted and screened and if suitable, arrangements were made for them to go to CUBIC. 
 
AD participants were accompanied to CUBIC by a caregiver. All participants were first 
administered the MMSE and learning subscale from the CAMOCG test battery on the 
morning (or day) of their scan. Cognitive testing took approximately 30 minutes. The 
radiographer then prepared the participant for the scan by making sure all metal objects 
had been removed. The scanning procedure lasted 20 minutes.  
 
To reduce the amount of stress placed on participants before scanning, blood was taken 
after the scan was complete. The NHLS of Groote Schuur Hospital analysed blood samples 
for the total white cell count, differential white cell (including monocyte) count and ESR. 
Whole blood was kept on ice prior to centrifugation at 4000 revolutions per minute (rpm) 
for 10 minutes in a standard laboratory bench top centrifuge machine. Serum for cytokine 
analysis was then stored at – 80
0 
C until further analysis (see cytokine measurements, 
under Peripheral Inflammatory Measures).  
 
My role in this study consisted of the following categories: 
1) Recruitment of participants. 
2) Contacting and pre-screening participants referred to the study by general 
practitioners, neurologists as well as participants that had heard about the study from their 
community.  
3) Scheduling participant’s baseline and follow-up visits. 
4) Briefing the participant on the study and documentation of consent procedures. 
5) Collection of demographic information. 
6) Neuropsychological test battery administration and scoring at baseline and follow-
up. 














8) Diagnosis consensus of participants. 
9) Contacting, screening and orchestrating the participants visit to CUBIC. 
10)  Briefing participants on procedures at CUBIC as well as neuropsychological test 
administration and sample collection at CUBIC. 
11)  Processing and analysis of all MRS data. 
 
INFORMATION GATHERING AND MEASURES 
 
Sociodemographic and Lifestyle Measures 
 
A) The Deterioration de Cognition Observee (DECO) 
The DECO (Richie & Fuhrer, 1996; Appendix C) is a 19-item questionnaire in which an 
informant rates the degree of cognitive change in the participant over the past year. The 
DECO items include questions about daily activity levels, memory (semantic and visual 
memory for places and procedures), visuospatial performance and the learning of new 
skills. For example, the informant was asked: “How well does he/she manage his/her 
money?”  The informant was asked to rate each item as, compared to 1 year ago, Better or 
About the Same, Not as Well, or Much Worse. Responses were scored as 2, 1 or 0 
respectively, with a maximum score of 38 indicating no change in functioning over the 
past year. A score less than 25 is generally taken to indicate the presence of dementia. 
Studies using the DECO have shown the questionnaire to have high test-retest reliability 
and good face validity (Ritchie & Fuhrer, 1996). The DECO has previously been used in 
South African research studies (Lenger, de Villiers, & Louw, 1996; Heckmann et al., 
2004). 
 
B) The Bristol Activities of Daily Living Scale (BADLS) 
The BADLS (Bucks, Ashworth, Wilcock, & Siegfried, 1996; Appendix D) is a 20-item 
scale that was specifically designed to obtain information from caregivers about daily 
living abilities of patients with dementia. The BADLS includes items related to hygiene, 
dressing, eating and handling of finances. The BADLS has good test-retest reliability and 
good construct validity (Burns, Lawlor, & Craig, 2004). This test has previously been used 















C) The Geriatric Depression Scale (GDS) 
The GDS (Yesavage et al., 1983; Appendix E) is a 15-item self-reported questionnaire that 
requires participants to respond by answering yes or no to items enquiring about how they 
felt over the past week. The GDS is often used in geriatric clinical assessments and was 
developed as a measure for depression in the elderly. Both the original and shortened 
versions of the GDS display high internal consistency, test-retest reliability and validity in 
American studies (Yesavage et al. 1983). A cut-off score of 8 was used to indicate the 
presence of depression in the current study. The GDS has previously been used in a South 
African study examining depression and social support in elderly people (Rodriguez, 




A) The Cambridge Cognitive Examination for Mental Disorders of the Elderly – Revised 
(CAMCOG-R; Huppert et al., 1995) is a section of a larger instrument, the Cambridge 
Mental Disorders of the Elderly Examination - Revised (CAMDEX- R; Roth, Huppert, 
Mountjoy, & Tym, 1988). The CAMCOG-R investigates eight aspects of cognition: 
orientation, language, memory, calculation, concentration and attention, praxis, abstract 
thinking and visuospatial perception. Sub-scores for each of these cognitive domains were 
calculated. The CAMCOG-R consists of 67 items. If the participant gets the item right, one 
point is awarded. Some items require the participant to give more than one answer, for 
these items one point for each answer is given. For example, one of the 67 items requires 
the participant to recall three items. For this item, a maximum of 3 points is awarded. The 
participant can achieve a maximum possible score of 105. Lower scores indicate cognitive 
impairment. The CAMCOG-R (which will now be referred to as the CAMCOG) can be 
used to rate the severity of cognitive impairment/dementia.  
 
A few of the CAMCOG items were altered in order to suit the South African population. 
These items included questions relating to historical events and recognition of famous 
people. For example, questions like “Who was the Prime Minister of South Africa during 














leper colony, military base and prison?” were asked. The CAMCOG booklet, which 
contains pictures relating to some of the items that were changed, was reprinted with 
images that were more appropriate for administration to a South African population. The 
CAMCOG has high test-retest and inter-rater reliability (O’Connor, Pollitt, Brook, & 
Reiss, 1989), and has been used in several longitudinal and cross-sectional studies of the 
neuropsychology of dementia (Walker, Allen, Shergill, & Katona, 1997; Nielsen, Lolk, 
Andersen, Andersen, & Kragh-Sørensen, 1999; Martins, Oulhaj, de Jager, & Williams, 
2005).  
 
B) The Learning Subscale 
The CAMCOG learning subscale (scored out of 17) tests both visual and verbal memory 
recall. The learning subscale score is therefore a marker of episodic memory impairment, 
the first cognitive domain to decline in most AD patients (Mickes et al., 2007). The 
learning subscale score in this study was used as a proxy of disease severity and 
progression (Combrinck et al., 2006).  
 
C) The Mini-Mental State Examination (MMSE) 
The MMSE (Folstein et al., 1975), which is incorporated within the CAMCOG, is a 
common tool used in the assessment of dementia. The test consists of 19 questions that 
cover various cognitive functions including orientation, language, memory, attention, 
naming of objects, following of verbal and written commands, sentence production and the 
ability to copy a complex figure. A maximum score of 30 can be obtained on the MMSE, 
with lower scores indicating cognitive impairment. The MMSE has been used in many 
studies to examine the relationship between cognitive function and neuroinflammation 
(see, e.g., Guerreiro et al., 2007). This measure has previously been used in an AD study 
by Heckmann et al. (2004) in South Africa, and is commonly used in South African 




















Peripheral Inflammatory Measures 
 
A) White cell count, ESR, and monocyte count 
Systemic markers of inflammation viz. the ESR, total white cell count and differential 
white cell (including monocyte) count were measured at the participants first visit (baseline 
visit) and at the time of the MRS study. At baseline, blood was taken from each 
participant. Samples were collected between 12h00 and 13h00 on the day of the 
participant’s clinical and cognitive assessment. For the MRS study, blood was taken after 
the participant had their scan. All blood samples for the total white cell count, monocyte 
count and ESR were analysed at the Groote Schuur Hospital NHLS. 
 
B) Cytokine Measurements 
Blood samples from participants were collected at baseline and after neuroimaging for 
cytokine analysis. Blood was taken from each participant, placed on ice and centrifuged 
within one hour at 4000 rpm for 10 minutes in a standard bench top laboratory centrifuge 
machine. Serum supernatants were pipetted into cryotubes and stored in a -80°C freezer 
until they were analysed.  
 
Due to the number of wells per plate, some controls were excluded from the cytokine 
analysis. The youngest controls were excluded in an attempt to match the groups on age. 
Cytokines included in the analysis were anti-inflammatory cytokines (TGF-β1, TGF-β2, 
TGF-β3 and IL-10) and pro-inflammatory cytokines (TNF-α and IL-1β). The serum 
samples were transported on ice to the Centre for Proteomic & Genomic Research (CPGR) 
at the University of Cape Town for analysis. All procedures were conducted according to 
manufacturers’ instructions that were included in the kit (Appendix F - H). All buffers, 
diluents, standards and controls were supplied with the kits. 
 
Cytokines (TNF-α, IL-1β and IL-10) were measured using a Bio-Plex Pro Assay (Bio-Rad 
Laboratories; Appendix F) according to the manufacturer’s instructions. Bio-Plex assays 
use xMAP technology. xMAP technology employs tiny colour-coded beads called 
microspheres or microbeads to detect molecules of interest. These colour-coded 














interest. In the current study’s assay, the beads were coated with antibodies for the 
cytokines under investigation. The microbeads were first diluted in buffer   following 
which 50µl of the microbead solution was added into each well of a 96 well plate. 50µl of 
diluted serum from each participant (diluted with standard diluent in a ratio of 1:4, i.e. 
10ml neat serum from each participant), 50µl of each standard
1
 (provided by the 
manufacturer) and 50µl of each of the two controls (samples of known concentration 
provided by the manufacturer) were then pipetted in duplicate into the wells of the plate 
and incubated according to the manufacturer’s instructions. This process allows for the 
immobilized antibodies to bind to each cytokine. 
 
The wells were then washed to remove any unbound protein. 50µl of biotinylated 
antibodies were then added to each well. Biotinylated antibodies detect the cytokine of 
interest (see Figure 13). Following incubation at room temperature and washing, 50µl of 
the streptavidin-phycoerythrin conjugate was added. Streptavidin-phycoerythrin binds to 
the biotinylated detection antibodies. Phycoerythrin serves as a fluorescent indicator. After 
30 minutes of incubation the plates were washed and the micro-particles re-suspended with 
wash buffer. 
 
Bio-Plex sandwich immunoassay 
 
                                                 
1
 Standards (samples with standard concentrations) were used to generate a standard curve 
for each assay. A best-fit curve was then be plotted and the cytokine concentration 
calculated from the best-fit curves equation. 
1) Microsphere with capture antibody              2) Capture antibody binds cytokine  
3) Biotinylated detection antibody binds to cytokine     4) Streptavidin-phycoerythrin conjugate binds to the biotinylated antibody.  
  Phycoerythrin serves as a fluorescent indicator 
Figure 13: xMAP assay principle. 














The 96 well plates were then placed into the Bio-Plex machine for analysis. In the Bio-Plex 
machine, each micro particle was passed through 2 lasers. The first laser excites the 
internal dye of the microsphere and the label on the detection antibody compound. This 
allows for the Bio-Plex Manager software to detect which particular microsphere is passing 
through, i.e. the microsphere, with the known capture antibody, is identified therefore 
allowing for the identification of the cytokine. The second laser determines the magnitude 
of the detection antibody signal. This signal is directly proportional to the amount of 
cytokine bound to the microsphere-capture antibody complex. Multiple readings were 
made on each bead set and an average of the multiple readings is calculated by the 
computer software and reported. Multiple readings on the microbeads validate the results. 
The classification and quantification of each microbead readings were made on each 
individual particle using the Bio-Plex Manager software. The software calculates the 
standard curve for the assay, the type of microsphere detected and the concentration of the 
cytokine of interest in each of the wells. 
 
TGF-β1, TGF-β2 and TGF-β3 were analysed using the Fluorokine MAP TGF-β Multiplex 
Kit according to manufactures instructions (R&D Systems, cat# LKT001; Appendix G). 
The Multiplex Kit simultaneously assessed the levels of all 3 TGF-β molecules in a single 
sample. Again, the Multiplex kit uses xMAP technology as described above. Latent TGF-β 
first needs to be activated to become immuno-reactive. To activate TGF-β, 100µl of serum 
was added to 20µl of 1N hydrochloric acid. The mixture was incubated for 10 minutes at 
room temperature and neutralized by adding 20µl of NaOH/0.5M HEPES (prepared 
according to manufacturer’s instructions). The serum was then diluted with Calibrator 
Diluent RD5-49 in a ratio of 1:10.71 thus making a final dilution factor of 1:15. 50µl of the 
diluted serum samples, standards (provided by the manufacturer) and controls (provided by 
the manufacturer) were added to the 96 well plate in duplicate. The xMAP technology–
based procedures described above were then performed for quantification of each TGF-β 
cytokine.  
 
C) Osteopontin (OPN) 
The MILLIPLEX MAP Human Bone Panel 1 (Millipore, cat # HBN1A-51K), a multiplex 
assay kit, was used to analyse OPN. Procedures were carried out according to the 














Buffer provided in the kit. 25µl of diluted serum, standards and controls were added to 
each well in duplicate as described above. Quantification of OPN was then carried out 
using xMAP technology, as described above.  
 
Proton Magnetic Resonance Spectroscopy (
1
H-MRS) and Neurometabolite Analyses 
 
A small pilot project took place before the commencement of participant scanning. Three 
young, healthy adults volunteered to undergo 
1
H-MRS scanning. Consent from these 
volunteers was obtained. During this pilot phase a radiologist, neurologist, physicist and 
myself made sure that all parameters outlined below were programmed and correct on the 
scanner. Voxel sizes from previous literature were used and the neuroradiologist ensured 
that the radiographer at CUBIC knew the exact anatomical location of the voxel placement.  
 
In order to gain some insight to the mechanism of measuring neurometabolites, the 
explanation in this section is of necessity highly technical. 
 
All scans were performed using a 3T Siemens Allegra (Siemens Medical Systems, 
Erlangen, Germany) scanner. Scans were performed by an experienced radiographer at 
CUBIC. Sagittal multi-echo magnetization-prepared rapid acquisition with gradient echo 
(MPRAGE) images were acquired with the following parameters: resolution = 1x1x1mm
3
, 
slices = 160, repetition time (TR) = 2530ms, four echo times (TE): TE 1 = 1.53ms, TE 2 = 
3.21ms, TE 3 = 4.89ms, TE 4 = 6.57ms, T1 = 1100ms, flip angle = 7 degrees, base 
resolution = 256, phase resolution = 75%, bandwidth = 651 Hz/pixel. Structural images 
were acquired for the placement of the single voxels over the region of interest. 
1
H-MRS 
was performed using voxels placed on the hippocampus and posterior cingulate. 
1
H-MRS 
data were obtained using an echo-planar imaging (EPI) volumetric navigated point-
resolved spectroscopy (PRESS) sequence (Hess, Tindall, Andronesi, Meintjes, & van der 
Kouwe, 2011a), with real-time shim and motion correction. The following parameters were 
used: TR= 2000ms, TE= 30ms. Water signal were suppressed. In addition, water 
unsuppressed spectra were acquired in the voxel using 7 different TE’s: TE =30ms, 50ms, 
75ms, 100ms, 144ms, 500ms, 1000ms; TR=4000 and two averages were acquired for each 














CSF in the voxels of interest. This allows for more reliable metabolite levels (Ernst, Kreis, 




 (20 × 20 × 20mm) voxel, prescribed on a mid-sagittal T1 weighted image, 
over the midline of the right and left posterior cingulate gyri was placed. The anterior 
border of the splenium, the superior border of corpus callosum and the cingulate sulcus 
were the anatomical landmarks used to define the anterior inferior and the anterior superior 
border of the 8000mm
3
 voxel (see Figure 14a). The voxel placement and size were used 




 (30 x 12 x 12mm) voxel was placed over the left temporal region and included 
the entorhinal cortex, subiculum, hippocampal proper and dentate gyrus (see Figure 14b).  
 
Pre-processing of the water-suppressed data was done according to the method of Hess, 
van der Kouwe, & Meintjes (2011b). Pre-processing of the data using the technique 
outlined by Hess et al. (2011b) ensures narrower line widths and higher signal to noise 
ratios. This makes the results more reliable. The corrected water-suppressed spectra were 
quantified using the software package LC model (Provencher, 2003). The water signal 
from the water-unsuppressed spectra of each TE measurement were also quantified using 
the LC Model and then modelled as a function of TE using a tri-exponential function 
(SigmaPlot; version 11). This estimates the fraction of grey matter, white matter and CSF 
in the voxel of interest. Because metabolites are found in different concentrations in white 
matter, grey matter and CSF, these fractions are then used to obtain absolute quantification 

















Figure 14: Location of the a) 4320mm
3
 left hippocampal voxel b) 8000mm
3
 posterior 
cingulate voxel. Both were acquired on a T1 weighted localizing image. 
Note: This image is taken from a pilot participant within this study.  
 
Absolute metabolite concentrations are reported as unsuppressed data were acquired. 
Reporting the absolute concentrations is considered the gold standard as it takes into 
account the different tissue fractions and is therefore more reliable (Valenzuela & Sachdev, 
2001). In the results section the N-acetylaspartate and N- acetylaspartylglutamate 


















At the participants first, baseline visit peripheral blood was collected in 
ethylenediaminetetraacetic acid (EDTA) tubes. These were kept on ice and centrifuged at 
4000 rpm for 10 minutes. The buffy coat layer containing the white blood cells was 
pipetted into cryotubes and stored in a -80°C freezer until analysis. 
 
The buffy coat layer was thawed on ice. DNA was then extracted from the buffy coat. 
QIAamp DNA Blood Mini kits were used for purification of total DNA. The QIAamp 
DNA purification procedure was carried according to manufacturer’s instructions. All 
buffers and washers were supplied with the kits. A QIAamp spin columns were provided in 
the kits. The spin columns have silica membranes that DNA binds to. The spin columns are 
removed and placed in new microcentrifuge tubes throughout the process. 
 
20μl QIAGEN Protease was pipetted into a microcentrifuge tube together with 200μl of the 
buffy coat sample from the participant. 200μl of Buffer AL was added. Microcentrifuge 
tube was mixed by pulse vortex for 15 seconds.  
 
The sample was incubated for one hour at 56 °C. 200μl of 96% - 100% ethanol was added 
to the sample and mixed for 15 seconds. The QIAamp spin column was removed and 
placed into a QIAamp spin column tube. 200μl of Buffer AL was added to the 
microcentrifuge tube and centrifuged again at 8000 rpm for 1 minute. 500μl of Buffer 
AW1 was added and centrifuged at 8000 rpm for one minute. 500μl of Buffer AW2 was 
added and centrifuged at 14000 rpm for 3 minutes. The QIAamp spin column was placed 
in a clean microcentrifuge tube and 200μl of Buffer AE was added. The microcentrifuge 
tube was incubated at room temperature for 1 minute and then centrifuged at 8000 rpm for 
1 minute.  
 
DNA restriction isotyping for rapid genotyping of the three common APOE alleles was 
then performed. Procedures were carried out according to Hixson and Vernier (1990). In 
the first step, restriction digestion involved amplification, using oligonucleotides, of a 228 














112 and 158. The 228 base pair sequence was amplified to a 237 base pair sequence. The 
amplification products were then digested using the HhaI restriction enzyme. HhaI cleaves 
the GCGC encoding 112arg and 158arg but does not cleave the GTGC encoding 112cys 
and 158cys. Thus it distinguishes the ε2, ε3 and ε4 alleles. The fragments were then 
separated by electrophoresis on a 10% acrylamide gel. The ε2, ε3 and ε4 fragments 
resulted in several bands. Fragment sizes of a DNA standard were used to identify the 




Data were collected and checked for missing information. Statistical tests were performed 
at the 0.05 level. All statistical analyses were completed using a computer software 
package, Statistica 11 (Borovikov & Borovikov, 1998) and the Statistical Package for the 
Social Science (SPSS) version 21.0 (Kirkpatrick & Feeney, 2008). Graphs were plotted 
using Graph Pad Prism 5, SPSS 21.00 and Statistica 11.  
 
Unless otherwise stated, all assumptions for the specific statistical analyses were upheld. 
The level for statistical significance was set at α = 0.05. Where data were not normally 
distributed, log-transformations were done. In all cases where data were still skewed after 
such transformations, non-parametric statistical measures were used. For between-group 
comparisons Mann-Whitney U tests were performed. Non-parametric correlations were 
performed using Spearman’s ranked correlations. In the case where data was normally 
distributed, ANOVA analysis and Student’s t-test were used for between-group 
comparisons. Pearson’s correlation analysis was used for correlations of normally 
distributed data. Regression models were used in cases where there were small sample 
sizes within the groups. Chi-squared analysis was used for between-group categorical 

















THE CROSS-SECTIONAL STUDY 
 
Final Sample Composition 
 
One hundred and fifty-one participants were initially enrolled in the study. Four 
participants withdrew before their first visit. Nineteen participants were excluded from the 
study according to the exclusion criteria. Details of these exclusions are summarised in the 
figure below (see Figure 15). 
 
Exclusion after visit 1: At the end of the cognitive testing and completion of the self-rated 
questionnaires, 4 participants were excluded due to the presence of moderate to severe 
depressive symptoms (a GDS score greater than 8). A further 8 participants were excluded 
after their medical examination: 2 because they had parkinsonian signs, 2 were excluded 
due to the presence of significant psychiatric symptoms other than depression, 3 were 
thought to have dementia not due to Alzheimer’s disease and 1 participant had epilepsy.  
Exclusion on blood results: Seven participants were excluded because their ESRs were 
above 40 mm per hour. 
 
At a diagnostic consensus meeting (consisting of a neurologist and neuropsychologist) 
each of the 128 participants were assigned to either the control group (n = 68) or the 
possible/probable AD group (n = 60) according to the NINCDS/ ADRDA criteria (see 















































Figure 15: Flow diagram of participant enrolment and attrition. 
  
Enrolled (n = 151) 
Withdrew before first visit (n= 4) 
Neurological Examination 
Excluded:  
Depression (n = 4) 
Excluded: 
Parkinsonian signs (n = 2) 
Psychiatric symptoms (n= 2) 
Dementia not of the Alzheimer’s type (n=3) 
Epilepsy (n=1) 
Cognitive testing and self-rated questionnaires 
Blood taken 
Excluded: 
ESR > 40 (n = 7) 
Diagnosis Meeting 














Final Sample: Demographic Characteristics and Cognitive Scores 
 
Demographic data were collected from all participants at their baseline visit. Table 3 
describes the demographic characteristics of the study population (n = 128).  
Age: The participants’ ages ranged from 58 to 100 years (M = 73.9, SD = 9). The 
age data were normally distributed and therefore a Student’s t-test was used to compare 
groups. Control participants (M = 71.3) were significantly younger than AD participants 
(M = 76.8; p < 0.001).  
Sex: There were 37 males and 91 females in the final sample. Pearson’s Chi-
Squared analysis of these data showed that there were no significant between-group 
differences with regard to sex distribution. 
Level of education: This variable was defined as the total number of years of 
successfully completed education. If the person repeated a year at school, the two years 
were counted as one. The number of years of education ranged from 3 to 25 in the sample 
population (M = 11.8, SD = 4.6). Control participants (M = 13.8) had significantly more 
years of education when compared with AD participants (M = 9.5; p < 0.001). 
 
Table 3 
Demographic Data for the Cross-Sectional Study’s Participants 
 
Note: For age and level of education, means are presented with standard deviations in 
parentheses. The mean ± 1 standard deviation was used. Level of education was measured 
as the number of years of successfully completed education. ESE = effect size estimate; for 
continuous variables (age, level of education) the ESE is Cohen’s d; for sex the ESE is Phi. 
See Appendix I: Table A - E for raw data. 
*Control and AD groups differed significantly, p < .001.  
 
 
 Group     
 Control AD     
 (n = 68) (n = 60) t / χ
2
 df p ESE 
age 71.3 (8.8) 76.8 (8.3) 3.64 126 < .001* 0.61 
sex (M:F) 16:52 21:39 2.04 1  .153 -0.13 














Cholinesterase inhibitor use: None of the AD participants in this study were on 
cholinesterase inhibitors at baseline or at follow-up. 
 
Cognitive Testing 
All participants underwent cognitive testing at their first, baseline visit. Cognitive tests 
included the CAMCOG, which incorporated the MMSE and learning subscale. Details of 
the cognitive tests scores are given in Table 4. Cognitive scores were not normally 
distributed, therefore Mann-Whitney U tests were used for between-group comparisons. 
Cognitive scores, together with the DECO, BADLS and clinical history, formed part of the 
diagnostic criteria. Therefore cognitive scores were, as expected, significantly different 
between the controls and AD participants.  
CAMCOG: Total CAMCOG scores for both groups ranged from 38 to 101 out of 
a total of 105 (for the entire sample, Median = 85, IQR = 68 – 94.5). Control participants 
(Median = 94) predictably performed better than the AD participants (Median = 67.5) on 
the total CAMCOG score (p < .001). 
MMSE: The participants’ MMSE scores ranged from to 12 to 30 out of a total of 
30 (for the entire sample, Median = 27, IQR = 22 – 29). Control participants (Median = 29) 
had higher scores on the MMSE compared with AD participants (Median = 21.5; p < 
.001). 
Learning subscale: Learning subscale scores for all participants ranged from 1 to 
17 out of a total of 17 (Median = 12.5, IQR = 7 – 14). Control participants (Median = 14) 


















Between-Group Comparisons of Neuropsychological Test Scores at Baseline 
 Group     
 Control AD     
Cognitive test (n = 68) (n = 60) U df p r 
CAMCOG total 94 (89 – 96) 67.5 (52 – 76) 25 126 <.001* -0.85 
MMSE 29 (28 – 30) 21.5 (16 – 24) 105 126 <.001* -0.82 
Learning subscale 14 (13 – 15) 7 (4 – 10) 208 126 <.001* -0.77 
 
Note: For the total CAMCOG, the Mini-Mental State Examination (MMSE) and the 
learning subscale the median is presented with the interquartile range in parentheses. 
Mann-Whitney U, the degrees of freedom (df) and the effect size r, are presented. See 
Appendix I: Table A - E for raw data. 
*Control and AD groups differed significantly, p < .001.  
 
The Relationship Between Systemic Inflammatory Markers and Cognition 
 
Blood samples from all participants (68 controls, 60 AD participants) were compared with 
respect to ESR, white cell count and monocyte count. Two AD participant did not have a 
serum sample. Cytokine and OPN analysis was done on a smaller sample because of 
restrictions on the number of wells per plate. The youngest 9 control participants were 
excluded. Table 5 displays the demographic data for the participants that were included in 
the cytokine and OPN analysis. For the cytokine and OPN analysis the final groups 
consisted of 58 AD and 59 control participants. 
 
The AD participants were still older (p = .009) and had fewer years of education (p < .001) 

















Demographic Data for the Cross-Sectional Sample Included in the Cytokine and OPN 
Analysis  
 
Note: For age and level of education, means are presented with standard deviations in 
parentheses. The mean ± 1 standard deviation was used. Level of education was measured 
as the number of years of successfully completed education. ESE = effect size estimate; for 
continuous variables (age, level of education) the ESE is Cohen’s d; for sex the ESE is Phi. 
See Appendix I: Table A - E for raw data. 
Control and AD groups differed significantly, *p < .01, **p < .001.  
 
Mann-Whitney U tests were used to compare the inflammatory markers in all AD 
participants and the controls. No significant differences in any of the inflammatory 
markers were found (see Table 7).  
 
Hypothesis 1 predicted that peripheral inflammatory markers in the early stages of AD 
would be highest. Systemic inflammatory markers would then decline, below that of 
control participants, as participants reached more advanced stages of AD. In other words, 
there would be a biphasic relationship between systemic inflammatory markers and the 
stage of AD.  
 
In order to test hypothesis one, AD participants were divided into 3 subgroups based on 
their learning subscale scores. The learning subscale is a test of episodic memory, which is 
usually the first cognitive domain to decline in AD. It is also the most severely affected 
aspect of cognitive function in AD. The first group formed the early/mild AD (n = 13) 
subgroup. Participants with learning subscale scores greater and equal to 11/17 were 
assigned to this group. The second group, the moderate AD group (n = 22), consisted of 
AD participants with learning subscale scores of 7/17 to 10/17. Participants who fell into 
the more severe AD group (n = 25) had learning subscale scores equal to or below 6/17. 
 Group     
 Control AD     
 (n = 59) (n = 58) t / χ
2
 df p ESE 
age 72.9 (8.3) 77.0 (8.4) 2.65 115 .009* 0.49 
sex (M:F) 15:44 20:38 1.14 1  .284 -0.10 














Note that participants who fell into the severe AD group were severe in terms of their 
learning subscale score. As previously mentioned, all participants in the study were 
mild/moderate stage AD and were able to provide consent at the start of the study. They 
were also able to complete cognitive testing. 
 
One-way ANOVA analysis and Tukey HSD post-hoc test showed that controls (M = 71.3, 
SD = 8.8) were younger than mild AD participants [(M = 78.9, SD = 9.2), F(3,124) = 5.68, 
p =.0017, partial ηp
2 
= 0.12], and severe AD participants [(M = 78.2, SD = 7.8), F(3,124) 
= 5.68, p =.003, partial ηp
2 
= 0.12].  
 
There were no detectable levels of TGFβ3 in any of the participants, therefore TGFβ1 and 
TGFβ2 levels are only reported.  
 
In all participants, Spearman’s ranked correlation analysis showed no correlation between 
age and ESR, white cell count, monocyte count, OPN or any of the cytokines, see Table 6. 






















Note: The test statistic is Spearman’s rho.  See Appendix I: Table A - E for raw data. 
 
Inflammatory Marker r p 
ESR 0.17 .062 
White cell count 0.07 .429 
Monocyte count 0.1 .288 
IL-1β 0.06 .556 
IL-10 0.09 .357 
TNF-α -0.12 .185 
TGF-β1 -0.05 .618 
TGF-β2 -0.12 .186 














The systemic inflammatory markers were not normally distributed. Non-parametric Mann-
Whitney U tests were therefore used for between-group comparisons. Table 7 details the 
median and interquartile range for each group. 
 
The mild AD group (Median = 20) had significantly higher ESRs compared with controls 
(Median = 8), U = 254, p = .018, r = -0.26, and moderate AD participants (Median = 6), U 
= 75, p = .031, r = 0.37 (Table 7, Figure 16). The moderate AD, severe AD and control 
groups did not significantly differ with respect to their ESRs. The mild AD group (Median 
= 2.5) also had a significantly higher IL-1β level compared with controls (Median = 2), U 
= 253, p = .05, r = -0.21, moderate AD participants (Median = 2), U = 75, p = .031, r = 
0.37, and severe AD participants (Median = 2), U = 94, p = .047, r = 0.32 (Table 7; Figure 
17). Again, the moderate AD, severe AD and control groups did not significantly differ 
from one other with respect to their IL-1β levels. OPN was highest in mild AD group 
compared with the controls, moderate and severe AD groups. his however did not reach 
significance. 
 
The severe AD group had significantly higher total white cell count (Median = 7.41) 
compared with the moderate AD group (Median = 6.09), U = 165, p = .047, r = -0.29. 
There were no between-group differences with respect to the monocyte count, TGF-β1, 











































Figure 16: Median erythrocyte sedimentation rates (ESRs) for the control (n = 68), mild 
AD (n = 13), moderate AD (n = 22) and severe AD groups (n = 25). Error bars represent 
the upper interquartile range.  
* The mild AD group differed significantly from the moderate AD group and the controls, 

























Figure 17: Median interleukin 1 beta (IL-1β) for the control (n = 59), mild AD (n = 13), 
moderate AD (n = 21) and severe AD (n = 24) groups. Error bars represent the upper 
interquartile range.  
* The mild AD group differed significantly from the control, moderate and severe AD 

















Peripheral Inflammatory Marker Concentrations for the AD Subgroups and the Control Participants 
 
Note. Inflammatory markers medians are presented with the interquartile range in parentheses. The erythrocyte sedimentation rate (ESR) was expressed 
as mm in 1 hour; the total white cell and monocyte counts are represented as cells x109/l. Interleukin 1 beta (IL-1β), interleukin 10 (IL-10), tumor 
necrosis factor alpha (TNF-α), transforming growth factor beta 1 and 2 (TGF-β1 and TGF-β2) and osteopontin (OPN) concentrations are expressed in 
picograms per millilitre (pg/mL). See Appendix I: Table A - E for raw data. 
* Significantly different from the mild AD group, p < .05. † Significantly different from the moderate AD group, p < .05.  
 
  Group 
Outcome variable 
Control 
(n = 68) 
AD 
(n = 60) 
Mild AD 
(n = 13) 
Moderate AD 
(n = 22) 
Severe AD 
(n = 25) 
ESR 8 (3 – 17)* 11 (5 – 22) 20 (12 – 30) 6 (4 – 13)* 10 (7 – 22) 
White cell count 6.64 (5.55 – 7.68) 6.98 (5.46 – 7.78) 5.66 (4.94 – 9.67) 6.09 (5.41 – 7.54) 7.41 (6.18 – 8.48)† 
Monocyte count 0.39 (0.32 – 0.48) 0.40 (0.3 – 0.53) 0.37 (0.29 – 0.43) 0.36 (0.29 – 0.51) 0.42 (0.34 – 0.53) 
 
Control 
(n = 59) 
AD 
(n = 58) 
Mild AD 
(n = 13) 
Moderate AD 
(n = 21) 
Severe AD 
(n = 24) 
IL-1β 2 (1.5 – 2.5)* 2 (1.5 – 2.5) 2.5 (2 – 3.5) 2 (1.5 – 2)* 2 (1.5 – 2.4)* 
IL-10 4.5 (3.5 – 5.5) 4.5 (3.5 – 5.5) 5 (3.8 – 7) 4.5 (4 – 5.5) 4 (3.3 – 5.4) 
TNF-α 3.5 (3 – 4) 3.5 (3 – 4) 3.5 (3.3 – 5) 3.5 (3 – 4) 3.5 (3 – 3.8) 
TGF-β1 999 (178.3 – 1476.5) 899.9 (186.5 – 1533.5) 914 (138.3 – 1430.8) 933 (218.3 – 1612.5) 816.9 (189.4 – 1411.4) 
TGF-β2 5.5 (3.5 – 8) 5.4 (3.5 – 7) 5 (3.3 – 7) 5.5 (4.5 – 6.8) 6.55 (3.25 – 7.75) 














The Relationship Between APOE Genotype and Cognition 
 
APOE demographics 
APOE genotyping was available for 123 participants (64 controls, 59 AD participants). 
Table 8 shows the allelic frequency (ε2, ε3 and ε4) in all participants as well as the control 
and AD groups. The allelic frequency was calculated by dividing the number of each allele 
by the total number of alleles in all participants, in controls or in AD participants. The 
most common allele in both the control and AD groups was the APOE ε3 allele, with 
allelic frequencies of 0.703 and 0.551 respectively. Pearson’s Chi-Squared analysis 
showed that the control group (0.703) tended to have a higher ε3 allelic frequency when 
compared with the AD group (0.551; p = .074). The allelic frequency of ε4 was 
significantly higher in the AD group (0.356) compared with the control group (0.203; p = 
.025. In both the control and AD group, the ε2 allelic frequency was the lowest.  
 
Table 8 
Allelic Frequency of the APOE ε2, ε3 and ε4 Alleles  




(n = 123) 
Control 
(n = 64) 
AD 
(n = 59) χ
2
 df p r 
ε2 0.093 0.094 0.093 0.68 1 .795 -0.23 
ε3 0.630 0.703 0.551 3.18 1 .074 -0.16 
ε4 0.276 0.203 0.356 5.00 1 .025* 0.20 
 
Note: The test statistic is Pearson’s Chi-Squared (χ
2
). The degrees of freedom (df) and the 
effect size estimator r are given. See Appendix I: Table A - E for raw data. 
* Control and AD groups differed significantly, p < .05.  
 
Table 9 and Figure 18 to 20 show the distribution of the different APOE genotypes among 
the control and AD participants. The most frequent APOE genotype in all the participants 
was ε3/ε3, 39% of participants had this APOE genotype. When the groups were examined 
separately, the most frequent genotype in the controls remained the ε3/ε3 combination. 
Pearson’s Chi-squared analysis showed that significantly more controls had the ε3/ε3 
combination when compared with the AD group (p = .026). Forty-eight percent of controls 















The ε2/ε2 genotype was the least common genotype frequency in all participants (1%). 
Only one AD participant had the ε2/ε2 genotype (2%). There were no controls with this 
genotype. In the control group, the ε2/ε4 genotype was the 3rd least common genotype 
after ε2/ε2 (0%) and ε4/ε4 (3%). Five percent of controls had the ε2/ε4 genotype. Three 
percent of AD participants in the AD group had the ε2/ε4 genotype.  
 
Forty-seven percent of all participants had at least one ε4 allele, 8% were homozygous. 
Thirty-eight percent of controls had at least one ε4 allele; 3% were homozygous. In the AD 
group, the most common APOE genotype was ε3/ε4. Forty-one percent of AD participants 
had the ε3/ε4 allele and 14% had the ε4/ε4 genotype. Chi-Squared analysis showed that the 
AD group had a significantly higher number of participants who were homozygous for the 
ε4 (ε4/ ε4) genotype compared with the control group (p = .034). In total, 58% of AD 
participants had at least one ε4 allele.  
 
When adjusted for age, the odds ratio (95% CI = 0.965 – 4.954) for AD was 2.2 fold 
higher in participants with one ε4 allele compared with participants with no ε4 allele. 
Homozygous ε4 participants had a 9 times higher odds (95% CI = 1.619 – 48.721) of 
















The Distribution of the APOE Genotype  
 




(n = 123) 
Control 
(n = 64) 
AD 
(n = 59) χ
2
 df p ESE 
ε2 / ε2 1 0 1 1.09 1 .296 0.09 
ε2 / ε3 16 9 7 0.13 1 .717 -0.03 
ε3 / ε3 48 31 17 4.97 1 .026* -0.20 
ε2 / ε4 5 3 2 0.13 1 .716 -0.03 
ε3 / ε4 43 19 24 1.63 1 .202 0.12 
ε4 / ε4 10 2 8 4.47 1 .034* 0.19 
 
Note: The test statistic is Pearson Chi-Squared (χ
2
) for between-group differences with 
respect to the control and AD group. The degrees of freedom (df) and the effect size 
estimator (ESE) r are given. See Appendix I: Table A - E for raw data. 
































Figure 19: The percentage distribution of the APOE genotypes in the control participants.  
 
 







































APOE and cognitive functioning 
The control and AD groups were divided into subgroups based on their genotype. APOE 
ε4 carriers formed the ε4 carrier subgroup and participants who had the APOE ε2 and/or 
APOE ε3 alleles formed the ε4 non-carrier subgroup. The ε4 carrier subgroup included ε4 
homozygous (ε4/ε4) and heterozygous participants (ε2/ε4 and ε3/ε4). Table 10 outlines the 
details of the between group comparison.  
 
AD participants with at least one ε4 allele tended to have lower MMSE scores (Median = 
21) when compared with ε4 non-carrier participants (Median = 24; p = .053). However, 
there was no significant difference on CAMCOG scores between AD ε4 carriers and non-
carriers. Similarly, there was no significant difference on the learning subscale between 
AD ε4 carriers and non-carriers.  
 
When the control group was divided according to presence/absence of the ε4 allele, there 
were no significant differences in scores on the CAMCOG, MMSE and learning subscale 
















Cognitive Scores for the APOE ε4 Carrier and APOE ε4 Non-Carrier Subgroups  
 
Note: For the total CAMCOG, the Mini-Mental State Examination (MMSE) and the 
learning subscale the median is presented with the interquartile range in parentheses. 
Mann-Whitney U, the degrees of freedom (df) and the effect size r, are presented. 




 Control     
Cognitive 
APOE ε4  
Non-Carrier 
APOE ε4  
Carrier     
Measure (n = 40) (n = 24) U df p r 
CAMCOG 95 (89.5 – 97) 93.5 (88.5 – 95.5) 381.5 62 .174 -0.17 
MMSE 29 (28 – 29) 29 (28 – 30) 437.5 62 .560 0.07 
Learning subscale 14 (13 – 15) 14 (13 – 15) 415.0 62 .371 0.11 
 AD      
 
APOE ε4  
Non-Carrier 
APOE ε4  
Carrier     
 (n = 34) (n = 25) U df p r 
CAMCOG 68 (56 – 76) 66.5 (52 – 76) 419.5 57 .939 -0.01 
MMSE 24 (17 – 26)  21 (16 – 23)  298.5 57 .053 -0.25 














The Relationship Between APOE Genotype and Systemic Inflammation 
 
Hypothesis 3 stated that participants, either homozygous or heterozygous for the APOE ε4 
allele, would have higher baseline levels of systemic inflammatory markers compared with 
the non-ε4 carriers. In order to investigate the relationship between the ε4 allele and 
inflammation, between-group comparisons were done using the Mann-Whitney U test as 
well as linear regression analysis.  
 
The control and AD groups were divided into an APOE ε4 carrier subgroup and APOE ε4 
non-carrier subgroup. The APOE ε4 carrier subgroup included ε4 homozygous and 
heterozygous participants whereas the APOE ε4 non-carrier subgroup included participants 
that did not have any ε4 alleles. Forty control participants had ESR, total white cell count 
and monocyte count data. Thirty-five control participants had cytokine and OPN data. 
Twenty-four AD participants had ESR, total white cell count and monocyte count data. 
Twenty-two AD participants had cytokine and OPN data. Table 11 and Table 12 outline 
the details of the Mann-Whitney U tests, for between-group comparison, for the control 
and AD group respectively.  
 
There were no significant differences in any of the inflammatory markers when the control 
APOE ε4 carrier and non-carrier groups were compared.  
 
Likewise, there were no significant differences in any of the inflammatory markers when 






































Note. Inflammatory markers medians are presented with the interquartile range in parentheses. The test statistic is the Mann-Whitney U. The 
degrees of freedom (df) and estimated effect size, r, are displayed. The erythrocyte sedimentation rate (ESR) was expressed as mm in 1 hour; the 
total white cell and monocyte counts are represented as cells x10
9
/l. Interleukin 1 beta (IL-1β), interleukin 10 (IL-10), tumor necrosis factor alpha 
(TNF-α), transforming growth factor beta 1 and 2 (TGF-β1 and TGF-β2) and osteopontin (OPN) concentrations are expressed in picograms per 
millilitre (pg/mL). See Appendix I: Table A - E for raw data. 
 
 Control     
Inflammatory APOE ε4 Non-carrier APOE ε4 Carriers     
marker (n = 40) (n = 24) U df p r 
ESR 9 (3 – 16) 8.00 (5.5 – 18) 441.5 62 .598 0.07 
White cell count 6.58 (5.66 – 7.80) 6.64 (5.33 – 7.4) 474.5 62 .945 -0.01 
Monocyte count  0.38 (0.33 – 0.49) 0.41 (0.29 – 0.44) 442.0 62 .603 -0.07 
 APOE ε4 Non-carrier APOE ε4 Carriers     
 (n = 35) (n = 22)     
IL-1β 2 (1.5 – 2.5) 2 (1.5 – 2) 384.0 55 .993 < -0.01 
IL-10 4.5 (3.5 – 5.5) 4.9 (3.3 – 5.5) 360.5 55 .694 0.05 
TNF-α 3.5 (3 – 4.3) 3.5 (2.8 – 4) 319.5 55 .287 -0.14 
TGF-β1 999 (244 – 1436.5) 1003.75 (108.8 – 1738.5) 384.5 55 .486 0 
TGF-β2 5.5 (3.5 – 8) 5.5 (4 – 8.5) 362.0 55 .999 0.05 





































Note. Inflammatory markers medians are presented with the interquartile range in parentheses. The test statistic is the Mann-Whitney U. The 
degrees of freedom (df) and estimated effect size, r, are displayed. The erythrocyte sedimentation rate (ESR) was expressed as mm in 1 hour; the 
total white cell and monocyte counts are represented as cells x10
9
/l. Interleukin 1 beta (IL-1β), interleukin 10 (IL-10), tumor necrosis factor alpha 
(TNF-α), transforming growth factor beta 1 and 2 (TGF-β1 and TGF-β2) and osteopontin (OPN) concentrations are expressed in pictograms per 
millilitre (pg/mL). See Appendix I: Table A - E for raw data. 
 AD      
Inflammatory APOE ε4 Non-carrier APOE ε4 Carriers     
marker (n = 24) (n = 34) U df p r 
ESR 18.5 (5 – 25) 10 (5 – 16) 342.5 56 .392 -0.11 
White cell count 7.31 (4.98 –9.08) 6.35 (5.66 – 7.59) 398.0 56 .881 -0.02 
Monocyte count  0.45 (0.30 – 0.54) 0.36 (0.3 – 0.47) 324.0 56 .325 -0.31 
 APOE ε4 Non-carrier APOE ε4 Carriers     
 (n = 25) (n = 33)     
IL-1β 2 (1.5 – 2.5) 2 (1.5 – 2.5) 409.5 56 .969 0.01 
IL-10 4.5 (3.5 – 6.3) 4.5 (3.8 – 5.5) 411.0 56 .987 <0.01 
TNF-α 3.5 (3 – 4) 3.5 (3 – 4) 402.5 56 .881 -0.02 
TGF-β1 577.8 (160 – 1533.5) 1069.0 (192.3 – 1458.8) 366.0 56 .470 0.09 
TGF-β2 5.25 (3 – 7) 5.5 (3.5 – 8) 379.0 56 .604 0.06 














For linear regression analysis, the presence or absence of the ε4 allele was the independent 
variable. Dummy variables were created for the presence (1) and absence (0) of the ε4 
allele. The individual systemic inflammatory markers were the dependent variables. Table 
13 details the results from the linear regression analysis for each inflammatory marker. The 
control and AD group were analysed together and as individual groups.  
 
Linear regression analysis showed that across both groups, the presence of one ε4 allele 
was not significantly associated with any of the systemic inflammatory markers. In the 
control group, the ε4 allele tended to be positively associated with IL-10 (p = .099). In 
other words, controls with the ε4 tended to have higher baseline levels of IL-10. In the AD 
group, ε4 tended to be negatively associated with IL-10 (p = .078). But neither reached 



















The Association between Inflammation and APOE ε4 in all Participants and in the Control and AD Groups 
 
Note. β = standardized coefficients for beta. Std Error = standard error. The erythrocyte sedimentation rate (ESR) was expressed as mm in 1 
hour; the total white cell and monocyte counts are represented as cells x10
9
/l. Interleukin 1 beta (IL-1β), interleukin 10 (IL-10), tumor necrosis 
factor alpha (TNF-α), transforming growth factor beta 1 and 2 (TGF-β1 and TGF-β2) and osteopontin (OPN) are represented as picograms per 






(n = 123) 
Control 
(n = 64) 
AD 
(n = 59) 
β Std Error R
2
 p β Std Error R
2
 p β Std Error R
2
 p 
ESR -.008 1.820 <.001 .933 .067 2.356 .004 .600 -.139 2.875 .019 .304 
White cell count -0.17 .341 <.001 .849 -.032 .449 .001 .803 -.032 .546 .001 .814 
Monocyte count -.121 .021 .015 .189 -.080 .028 .006 .529 -.179 .034 .032 .186 
IL-1β -.071 .218 .005 .454 -.039 .216 .002 .771 -.110 .385 .012 .410 
IL-10 -.045 3.807 .002 .635 .220 4.256 .049 .099 -.233 6.243 .054 .078 
TNF-α -.150 .355 .022 .110 -.142 .221 .020 .292 -.210 .673 .044 .113 
TGF-β1 .038 135.072 .001 .690 .021 196.541 <.001 .876 .064 192.129 .004 .634 
TGF-β2 .057 .588 .003 .544 .035 .836 .001 .798 .073 .869 .005 .584 














Summary of the Cross-Sectional Results 
 
The final sample number for the cross-sectional analysis was 128, and consisted of 68 
controls and 60 AD participants. Control participants had significantly more years of 
education and were younger when compared with the AD group. Age was not correlated 
with any of the systemic inflammatory markers; therefore age was not controlled for in the 
analyses.  
 
Systemic Inflammation and Cognition 
Hypothesis one stated that in AD, systemic inflammatory markers would be highest in the 
early stages. The AD group was divided into mild, moderate and more severe subgroups 
based on their learning subscale scores. The mild AD group had a significantly higher ESR 
compared with controls (p = .018) and moderate AD participants (p = .031). There were no 
significant differences between the moderate AD, severe AD and control groups.  
 
Mild AD participants also had a significantly higher IL-1β levels compared with the 
control group (p = .05), moderate AD group (p = .031) and severe AD group (p = .047). 
Again, there were no significant differences between the moderate AD, severe AD and 
control groups.  
 
APOE genotype and Cognition 
APOE genotyping was available for 123 participants, which included 64 controls and 59 
AD participants. The most frequent allele in both groups was ε3. The allelic frequency for 
the ε3 allele in the control group was 0.703 and 0.551 in the AD group. The controls 
tended to have a higher ε3 frequency compared with the AD group (p =. 074). AD 
participants had a significantly higher frequency of the ε4 allele when compared with 
controls (p = .025). The most common genotype in the controls was the ε3/ε3 genotype 
whereas the ε3/ε4 genotype was the most common in the AD group. The AD group had 
significantly more ε4 homozygous participants than the control group (p = .034). The ε2 
allele was the least common allele. The ε2 allelic frequency in controls was 0.094 and 















The AD and control groups were divided up into APOE ε4 carriers and non-carriers. 
Mann-Whitney U test was used to compare between-group differences with respect to 
cognitive measures (CAMCOG, MMSE and learning subscale). In the controls, there was 
no significant difference between the APOE ε4 carriers and non-carriers on any of the 
cognitive measures. In the AD group, the APOE ε4 carriers tended to have poorer scores 
on the MMSE when compared with the APOE ε4 non-carriers (p = .053). There were no 
between-group differences on the learning subscale and the CAMCOG when AD APOE ε4 
carriers and non-carriers were compared.  
 
APOE genotype and Inflammation 
When the subgroups were compared using Mann-Whitney U tests, the control APOE ε4 
carrier and non-carrier subgroups did not differ on any of the inflammatory measures. This 
was true for the AD APOE ε4 carrier and non-carrier subgroups too. Linear regression 
showed a tendency for APOE ε4 to be positively associated with IL-10 in the control group 














THE LONGITUDINAL STUDY 
 
Final Sample Composition 
 
Figure 21 depicts the participant attrition at follow-up. One hundred and six participants 
(59 controls, 47 AD participants) were contacted after one year for follow-up. The 
remaining 22 participants (9 Controls, 13 AD participants) from the cross-sectional study 
were not contacted as they had been recruited in the final year of the study. Twenty-six 
participants were not followed-up for the following reasons:  
Withdrew from the study: Five Control and 8 AD participants withdrew from the study 
after the first year. Reasons for withdrawal were increased frailty or simply no further 
interest in participating in the study. 
Deceased: One Control and 3 AD participants died after their first visit. 
Relocated: Three Control participants and 1 AD participant relocated to different parts of 
South Africa. 
Advanced disease: Two AD participants had progressed to advanced dementia and 
therefore were unable to consent to further testing.  
Loss to follow-up: 1 AD participant was no longer contactable.  
Conversions: 2 Control participants converted to MCI after their baseline visit.  
 





























Figure 21: Participant attrition at one-year follow-up.  
  
AD Group  
(n = 60) 
Control Group  
(n = 68) 
Baseline (n = 128) 
Recruited in last year: n = 9 
Withdrew from the study: n = 5 
Deceased: n = 1 
Relocated:  n = 3 
Lost to follow-up: n = 2 
Converted to MCI: n = 2 
Participants followed-up: 
AD Group  
(n = 32) 
Participants followed-up: 
Control Group  
(n = 48) 
Recruited in last year: n = 13 
Withdrew from the study: n = 8 
Deceased: n = 3 
Relocated:  n = 1 
Lost to follow-up: n = 1 














Final Sample: Demographic Characteristics and Cognitive Scores 
 
Demographic data were obtained from all participants at their baseline visit. Table 14 
describes the demographic characteristics of the participants that were followed-up (n = 
80).  
Age: At baseline, follow-up participants’ ages ranged from 58 to 91 years (M = 
72.5, SD = 8.6). The age data were normally distributed and therefore a Student’s t-test 
was used to compare groups. There was no significant difference between the control 
participants and the AD participants that were followed-up (p = .115).  
Sex: There were 23 males and 57 females in the final follow-up sample. Pearson’s 
Chi-Squared analysis of these data showed that there were no significant between-group 
differences with regard to sex distribution. 
Level of education:  Level of education was defined as the total number of years 
of successfully completed education. The number of years of education ranged from 3 to 
25 in the sample population (M = 12.1, SD = 4.6). Control participants (M = 13.9) had 




Demographic Data for the Longitudinal Study’s Participants  
 
Note: For age and level of education, means are presented with ±1 standard deviations in 
parentheses. Level of education was measured as the number of years of successfully 
completed education. ESE = effect size estimate; for continuous variables (age, level of 
education) the ESE is Cohen’s d; for sex the ESE is Phi. See Appendix I: Table A - E for 
raw data. 
*Control and AD groups differed significantly, p < .001.  
 
 
 Group     
 Control AD     
 (n = 48) (n = 32) t / χ
2
 df p ESE 
age 71.2 (8.2) 74.3 (9.1) 1.59 78 .115 0.36 
sex (M:F) 11:37 12:20 1.99 1  .158 -0.16 














All participants had cognitive testing at their 12-month follow-up. The cognitive test 
battery included the CAMCOG, the learning subscale of the CAMCOG, and the MMSE. 
Table 15 and Figure 22 to 24 depict the baseline scores of the participants who were 
followed-up and the follow-up scores of the two groups. Cognitive decline was measured 
by subtracting the participant’s raw baseline score from their follow-up score. Therefore, a 
negative number indicates a decline in cognitive functioning; whereas a positive number 
indicates improvement in cognition. The median and interquartile range for cognitive 
decline was calculated from each participant’s raw scores.  
 
CAMCOG: The median change in CAMCOG scores are presented in Table 15. 
AD participants had lower CAMCOG scores at baseline and at the one-year follow-up 
compared with controls. The AD group declined, on average, by 7 points on the CAMOCG 
over 12 months whereas the control group improved by 1 point. The change in CAMCOG 
scores was significantly different between the AD and control groups (p < .001).  
MMSE: At baseline and at follow-up the AD group had significantly lower MMSE 
scores when compared with controls. The AD group declined by 2 points on the MMSE 
over 12 months. There was no change in the median scores on the MMSE in the control 
group. The AD groups MMSE score declined more over 12 months than the control group 
(p = .049). 
Learning Subscale: AD participants had significantly lower learning subscale 
scores at baseline and at their follow-up. The median change in the learning subscale over 
12 months was -1.5 in the AD group and 0 in the control group. The change in the learning 
subscale score in one year was greater in the AD group compared with the control group (p 
















Cognitive Test Scores at Baseline and One-Year Follow-up  
 Group     
Cognitive test 
Control AD     
(n = 48) (n = 32) U df p r 
CAMCOG 1 94 (89 – 96) 64.5 (52 – 75.5) 7.0 78 < .001* -0.84 
CAMCOG 2 94 (31.5 – 97) 57 (46.5 – 70) 8.5 78 < .001* -0.83 
CAMCOG 2 –1 1 (-1 – 2) -7 (-11 – -2.5) 272.5 78 < .001* -0.54 
MMSE 1 29 (28 – 29) 21.5 (17 – 24) 21.0 78 < .001* -0.82 
MMSE 2 29 (27 – 30) 19 (16.5 – 22.5) 22.5 78 < .001* -0.82 
MMSE 2 – 1 0 (-1 – 1) -2 (-4 – 1.5) 566.5 78 .048** -0.22 
LS 1 14 (13 – 15) 7 (4 – 10) 57.5 78 < .001* -0.78 
LS 2 14.5 (14 – 15.5) 5.5 (2.5 – 7.5) 18.0 78 < .001* -0.83 
LS 2 – 1 0 (-0.5 – 2) -1.5 (-3 – 0) 360.5 78 < .001* -0.45 
 
Note. Medians are presented with interquartile ranges in parentheses. The CAMCOG 1, 
Mini Mental State Examination (MMSE) 1 and learning subscale (LS) 1 represent baseline 
cognitive scores. The CAMCOG 2, MMSE 2 and LS 2 represent 1 year follow-up scores. 
Cognitive decline was measured by subtracting the baseline score (1) from the follow-up 
score (2). See Appendix I: Table A - E for raw data. 




















Figure 22: Baseline and follow-up CAMCOG scores for AD (n = 32) and control (n = 48) 





































Figure 23: Baseline and follow-up Mini-Mental State Examination (MMSE) scores for AD 
(n = 32) and control (n = 48) groups. M1 represents the baseline MMSE score. M2 





















Figure 24: Baseline and follow-up learning subscale scores for AD (n = 32) and control (n 















When both groups were analysed together, Spearman’s ranked correlation showed that age 
was not correlated with cognitive decline on the CAMCOG (r = -0.139, p = .650), MMSE 
(r = -0.104, p = .235), or learning subscale (r = -0.08, p = .515). Similarly, when the 
control and AD groups were analysed separately, age was not correlated with cognitive 
decline on the CAMCOG (r = -0.190, p = .364), MMSE (r = 0.112, p = .476), or learning 
subscale (r = -0.019, p = .937) in the control group or in the AD group; CAMCOG (r = 
0.014, p = .483), MMSE (r = -0.213, p = .246), or learning subscale (r = 0.011, p = .824). 
Therefore the following analyses did not control for age.  
 
Education was also not significantly related to cognitive decline on the CAMCOG (r = 
0.149, p = .197), MMSE (r = -0.022, p = .843) or the learning subscale (r = 0.054, p = 
.632).  
 
The Effect of Systemic Inflammation on Cognitive Decline 
 
Hypothesis 4 stated that high levels of baseline systemic inflammation would predict a 
faster rate of cognitive decline over a one-year period.  
 
Linear regression analysis was used to examine the independent effect of inflammation on 
cognitive decline. APOE ε4 was added to the model as an independent variable to account 
for the APOE ε4 related decline in cognition. The dependent variable in the regression 
analysis was cognitive decline on the CAMCOG (CAMCOG 2 – CAMCOG 1), MMSE 
(MMSE 2 – MMSE 1) and learning subscale (learning subscale 2 – learning subscale 1). 
The independent variables were the presence or absence of the APOE ε4 allele and the 
systemic inflammatory markers (ESR, white cell count, monocyte count, IL-10, TGF-β1, 
TGF-β2, TNF-α, IL-1β and OPN). Linear regression analyses were performed by adding 
the APOE ε4 status (present or absent) as an independent variable together with each 



















Table 16 depicts the results from the linear regression analysis for the CAMCOG. The p 
value is the independent effect of the inflammatory marker. As previously mentioned, ε4 
was added to the model to account for the effect of the ε4 allele on cognitive decline. A 
positive association indicates that a high level of the baseline systemic inflammatory 
marker was associated with a smaller decline on the cognitive score. A negative 
association indicates that a high level of the baseline systemic inflammatory marker was 
associated with a greater or faster decline on the cognitive score.  
 
When the two groups were analysed together, the total white cell count (p = .050) and 
TNF-α (p = .019) were independently negatively associated with cognitive decline on the 
CAMCOG (Figure 25 and 26 respectively). In other words, high levels of baseline TNF-α 
and total white cell count were associated with greater decline on the CAMCOG. IL-10 
was positively associated with a decline on the CAMCOG (p = .032), i.e. the higher the 
baseline level of IL-10 the greater decline on the CAMCOG, see Figure 27. 
 
Similarly in the AD group, high baseline levels of white cell count and TNF-α  predicted 
greater cognitive decline on the CAMCOG, p = .023 and p = .049 respectively (Figure 25 
& 26). The monocyte count also tended to be negatively associated with cognitive decline 
on the CAMCOG (p = .082). High baseline levels of IL-10 tended to predict a slower rate 
of cognitive decline on the CAMCOG (p = .068; Figure 27), but this did not reach 
significance.  
 
In the control group, there were no significant associations between decline on the 
















Figure 25: The relationship between the white cell count and decline on the CAMCOG 
(CAMCOG 2 – CAMCOG 1). The black line represents the association when all 




Figure 26: The relationship between tumor necrosis alpha (TNF-α) and decline on the 
CAMCOG (CAMCOG 2 – CAMCOG 1). The black line represents the association when 

















Figure 27: The relationship between interleukin 10 (IL-10) and decline on the CAMCOG 
(CAMCOG 2 – CAMCOG 1). The black line represents the association when all 




















The Association Between Cognitive Decline on the CAMCOG and Systemic Inflammatory Markers 
 
Note. β = standardized coefficients for beta, Std Error presents the standard error. Abbreviations for the inflammatory markers are as follows: 
erythrocyte sedimentation rate (ESR), interleukin 1 beta (IL-1β), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-α), transforming 
growth factor beta 1 and 2 (TGF-β1 and TGF-β2), osteopontin (OPN). See Appendix I: Table A - E for raw data. 





All participants Control AD 
β Std Error R
2
 p β Std Error R
2
 p β Std Error R
2
 p 
ESR -.045 .078 .025 .697 -.042 .048 .133 .768 -.078 .147 .086 .687 
White cell count -.223 .379 .076 .050* .093 .233 .140 .511 -.407 .664 .245 .023* 
Monocyte count -.125 6.435 .038 .281 .119 3.811 .145 .401 -.325 11.798 .183 .082 
IL-1β .110 1.026 .048 .352 -.022 .565 .145 .885 .288 2.010 .213 .104 
IL-10 .249 .032 .098 .032* .003 .026 .144 .986 .377 .051 .232 .068 
TNF-α -.273 .538 .109 .019* .006 .538 .144 .968 -.354 .756 .248 .049* 
TGF-β1 .037 .001 .038 .752 .214 .001 .190 .142 .030 .002 .131 .871 
TGF-β2 .002 .268 .036 .989 .085 .146 .152 .563 -.035 .544 .131 .847 















Table 17 depicts the results from the linear regression analysis for the MMSE. When the 
groups were analysed together, IL-10 tended to be positively associated with decline on the 
MMSE (p = .077), i.e. the higher the baseline level of IL-10, the smaller the decline on the 
MMSE in all participants (see Figure 28). TNF-α was negatively associated with decline 
on the MMSE (p = .027), i.e. the higher the baseline level of TNF- α, the greater the 
decline on the MMSE (see Figure 29). There were no significant associations between 
decline on the MMSE and the systemic inflammatory markers in the control group (Table 
17).  
 
In the AD group, IL-10 tended to be positively associated with decline on the MMSE (p = 
.082), the higher the baseline level of IL-10 the smaller the decline on the MMSE (see 


















Figure 28: The relationship between interleukin 10 (IL-10) and decline on the Mini Mental 
State Examination (MMSE) (MMSE 2 – MMSE 1). The black line represents the 




Figure 29: The relationship between tumor necrosis alpha (TNF-α) and decline on the 




































Note. β = standardized coefficients for beta, Std Error presents the standard error. Abbreviations for the inflammatory markers are as follows: 
erythrocyte sedimentation rate (ESR), interleukin 1 beta (IL-1β), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-α), transforming 
growth factor beta 1 and 2 (TGF-β1 and TGF-β2), osteopontin (OPN). See Appendix I: Table A - E for raw data. 










 p β Std Error R
2
 p β Std Error R
2
 p 
ESR -.063 .034 .013 .593 -.028 .025 .019 .852 -.063 .074 .005 .756 
White cell count .082 .168 .014 .475 .048 .121 .021 .751 .136 .370 .022 .483 
Monocyte count .082 2.76 .016 .485 .166 1.953 .046 .266 .070 6.274 .006 .725 
IL-1β .083 .445 .027 .486 .113 .298 .032 .477 .110 1.024 .017 .569 
IL-10 .208 .014 .063 .077 .018 .014 .020 .912 .345 .025 .112 .082 
TNF-α -.261 .233 .087 .027* .011 .286 .020 .942 -.304 .379 .092 .119 
TGF-β1 .088 <.001 .028 .461 .032 <.001 .021 .839 .173 .001 .035 .370 
TGF-β2 .113 .115 .033 .340 -.075 .078 .025 .634 .246 .258 .065 .200 














Learning Subscale  
Table 18 depicts the results from the linear regression analysis for the learning subscale. 
When the AD and control groups were analysed together the ESR (p = .025) and TNF-α (p 
= .029) measures were negatively associated with decline on the learning subscale (see 
Figure 30 and 31 respectively). I.e. the higher the level of ESR and TNF-α at baseline, the 
greater the decline on the learning subscale. When the control group was analysed 
separately, high levels of ESR at baseline predicted greater decline on the learning 
subscale score, p = .028 (see Figure 30). There were no other significant associations 
between systemic inflammatory markers and decline on the learning subscale in the control 
group. In the AD group, the monocyte count and TGF-β2 levels were negatively associated 
with decline on the learning subscale, p = .032 (Figure 32) and p = .034 (Figure 33) 
respectively. High baseline levels of OPN also tended to predict greater decline on the 
learning subscale over one-year, p = .061. No other significant associations were found in 
















Figure 30: The relationship between the erythrocyte sedimentation rate (ESR) and decline 
on the learning subscale in all the participants. The black line represents the effect of ESR 




Figure 31: The relationship between tumor necrosis alpha (TNF-α) and decline on the 
learning subscale in all the participants. The black line represents the effect of TNF-α 
















Figure 32: The relationship between the monocyte count and decline on the learning 




Figure 33: The relationship between transforming growth factor beta 2 (TGF-β2) and 


















The Association Between Cognitive Decline on the Learning Subscale and Systemic Inflammatory Markers 
 
Note. β = standardized coefficients for beta, Std Error presents the standard error. Abbreviations for the inflammatory markers are as follows: 
erythrocyte sedimentation rate (ESR), interleukin 1 beta (IL-1β), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-α), transforming 
growth factor beta 1 and 2 (TGF-β1 and TGF-β2), osteopontin (OPN). See Appendix I: Table A - E for raw data. 
* Significant effect on learning subscale, p < .05.  
 
Learning Subscale  
Inflammatory 
marker 
All participants Control AD 
β Std Error R
2
 p β Std Error R
2
 p β Std Error R
2
 p 
ESR -.257 .028 .078 .025* -.324 .030 .105 .028* -.215 .046 .044 .282 
White cell count -.162 .148 .045 .158 -.031 .156 .001 .841 -.293 .235 .087 .125 
Monocyte count -.140 2.398 .032 .232 .075 2.546 .006 .622 -.412 3.644 .166 .032* 
IL-1β -.012 .361 .030 .921 -.137 .351 .027 .388 .169 .640 .033 .381 
IL-10 .142 .011 .050 .227 .087 .016 .015 .591 .317 .016 .095 .112 
TNF-α -.256 .189 .094 .029* -.084 .336 .015 .599 -.288 .240 .082 .141 
TGF-β1 -.039 <.001 .031 .741 .238 <.001 .065 .128 -.237 .001 .060 .216 
TGF-β2 -.095 .093 .039 .422 .152 .091 .031 .334 -.397 .154 .160 .034* 














The Effect of the APOE ε4 on Cognitive Decline 
 
Table 19 displays the decline in cognition over 12 months in APOE ε4 carriers and ε4 non-
carriers. Again, a negative number indicates a decline in cognitive functioning; whereas a 
positive number indicates improvement in cognition. 
 
Table 19 
Changes in Cognitive Test Scores Over One-Year in APOE ε4 Carriers and Non-Carriers  
 
Note. Medians are presented with interquartile ranges in parentheses. Cognitive decline is 
measured by subtracting the baseline score (1) from the follow-up score (2) for the 
CAMCOG, Mini Mental State Examination (MMSE) and learning subscale (LS).  
See Appendix I: Table A - E for raw data. 
 
Hypothesis 5 stated that the presence of the ε4 allele (either homozygous or heterozygous) 
in participants would exacerbate their rate of cognitive decline when compared to 
participants with the ε3 or ε2 allele.  
 
To test the above hypothesis, linear regression analysis was used. The presence or absence 
of the APOE ε4 allele was the independent variable. Each inflammatory marker was also 
added to the model as an independent variable to examined if the APOE ε4 allele was 
independently associated with cognitive decline, and that the decline was not associated 
  Control Group 
Cognitive test 
APOE ε4 Non-carriers APOE ε4 Carriers 
(n = 28) (n = 19) 
CAMCOG 2 – CAMCOG 1  0.5 (-2 – 1) 2 (1 – 4) 
MMSE 2 – MMSE 1 0 (-1 – 1) 0 (-1 – 1) 
LS 2 – LS 1 0 (-0.5 – 2) 1 (-1 – 2) 
  AD Group 
 
APOE ε4 Non-carriers APOE ε4 Carriers 
(n = 11) (n = 20) 
CAMCOG 2 – CAMCOG 1  -6 (-11 – 10) -7.5 (-11 – -4) 
MMSE 2 – MMSE 1 0 (-6 – 3) -2.5 (-4 – 1.5) 














with inflammation. The dependent variable was decline in cognition on the CAMCOG, 
MMSE and learning subscale.  
 
Across both groups, the APOE ε4 allele (either homozygous or heterozygous) was not 
associated with cognitive decline on the MMSE, β = -0.113, R
2
 = 0.013, p = .343, or the 
learning subscale, β = -0.138, R
2
 = .019, p = .229. On the CAMCOG, the presence of the 
ε4 allele tended to be associated with greater cognitive decline, β = -0.188, R
2
 = 0.035, p = 
.099; i.e. the ε4 allele predicted greater decline on the CAMCOG in all participants in one-
year. 
 
When the groups were analysed separately, the presence of the ε4 allele was positively 
associated with decline on the CAMCOG, β = 0.362, R
2 
= 0.131, p = .012 in the control 
group (see Figure 34). Controls with the ε4 allele tended to decline less than the controls 
without the ε4 allele. The presence of ε4 was not associated with decline on the MMSE, β 
= -0.136, R
2
 = 0.018, p = .362, or the learning subscale score, β = 0.011, R
2
 <0.001, p = 
.942, in the controls. 
 
In the AD group, the ε4 allele was negatively associated with decline on the CAMCOG, β 
= -0.359, R
2
 = 0.187, p = .047 (see Figure 35). AD participants with the ε4 allele had a 
greater decline on the CAMCOG compared with AD participants with no ε4 allele. There 
was no significant association between the presence or absence of the ε4 allele and the 
MMSE, β = -0.037, R
2
 = 0.001, p = .843 or the learning subscale score, β = -0.077, R
2
 = 
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Figure 34: The relationship between the presence and absence of the APOE ε4 allele and 
cognitive decline on the CAMCOG in control participants (ε4 Present n = 19; ε4 Absent n 
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Figure 35: The relationship between the presence and absence of the APOE ε4 allele and 
cognitive decline on the CAMCOG in AD participants (ε4 Present n = 20; ε4 Absent n = 
















Longitudinal Study Summary 
 
Eighty participants were followed-up after 12 months. As expected, AD participants 
declined faster than controls on the CAMCOG, MMSE and learning subscale. The AD 
participants had a median change of -7 on the CAMCOG, -2 on the MMSE and -1.5 on the 
learning subscale. Decline in cognition was measured as the follow-up score minus the 
baseline score.  
 
The effect of inflammation on cognition 
Linear regression analysis was used to take into account the effect of the APOE ε4 allele 
on cognitive decline. This was done to examine the independent effect of inflammation on 
cognitive decline.  
 
Across all participants, high baseline levels of TNF-α were associated with greater decline 
on the CAMCOG, MMSE and learning subscale. A high total white cell count at baseline 
was associated with a greater decline on the CAMCOG. High baseline levels of ESR were 
associated with greater decline on the learning subscale. 
 
In all participants, IL-10 was positively associated with decline on the CAMCOG. I.e. high 
levels of IL-10 were associated with smaller decline on the CAMCOG across all 
participants. Similarly, high levels of IL-10 tended to be associated with smaller decline on 
the MMSE in all participants. 
 
In the AD group, high baseline levels of TNF-α and the total white cell count were 
associated with a greater decline on the CAMCOG. The monocyte count also tended to be 
negatively associated with decline on this measure. A high monocyte count and high levels 
of TGF-β2 were associated with greater decline on the learning subscale in AD 
participants. OPN tended to be negatively associated with decline on the learning subscale, 
i.e. high levels of OPN at baseline tended to be associated with a greater decline on the 















High levels of IL-10 in the AD group tended to be associated with smaller decline on the 
CAMCOG and MMSE.  
 
In the control group, a high baseline ESR was associated with greater decline on the 
learning subscale.  
 
The effect of APOE ε4 on cognition 
Linear regression analysis was used to determine the effect of APOE ε4 on cognitive 
decline. In controls, the absence of the ε4 allele was associated with greater decline on the 
CAMCOG over one year. However, in the AD group, the presence of the ε4 allele was 
associated with a greater decline on the CAMCOG over one year. There were no 















THE MRS STUDY 
 
Final Sample Composition 
 
AD and control participants already enrolled in the study were contacted and requested to 
participate in the MRS study. As far as possible, the control and AD group were matched 
on age and education. AD participants that had been enrolled within the last two years of 
the study were asked to take part. Controls that were older and had fewer years of 
education were contacted.  
 
Fifty participants were approached to participate in the MRS study; this included 21 
controls and 29 AD participants. Four controls and 4 AD participants declined to 
participant. The mains reasons for refusal were increased frailty and claustrophobia. One 
control was excluded from the MRS study because of metal plates in her neck. One AD 
participant was excluded as he/she had a prosthetic heart value. Sixteen controls and 24 
AD participants were eligible for, and agreeable to, MRI scanning. Figure 36 summarises 
the participant attrition for the MRS study. One Control and 4 AD participants were unable 
to tolerate the 20-minute duration of the scan and their scans had to be terminated. Full 
MRS data were not obtainable from these participants. One control and 1 AD participant 
had ESRs over 40 mm in one hour. These participants MRS data were used but their 
systemic inflammatory markers were excluded. During the data analysis stage, 
neurometabolite readings from 2 AD participants could not be obtained for technical 
reasons. The final sample consisted of 33 participants: 15 Controls and 18 AD participants. 
Due to exclusion of participants with ESRs above 40 mm per hour, the final sample 
numbers for analysing the relationship between systemic inflammatory markers and 

















































Figure 36: Participant attrition for MRS study. 
  
Contacted  
n = 50 (21 control; 29 AD) 
Declined to partake in MRS study: 
 n = 8 (4 control; 4 AD) 
Excluded due to contraindication for MRI scanning:  
n = 2 (1 control; 1 AD) 
Volunteered and Eligible  
n = 40 (16 control; 24 AD) 
Unable to tolerate full duration of scan:  
n = 5 (1 control; 4 AD) 
Blood results excluded from systemic 
inflammation analysis  
n = 2 (1 control; 1 AD) 
Technical difficulties during MRS data analysis:  
n = 2 (0 control; 2 AD) 
Final sample for metabolite analysis 
n = 33 
Final sample for systemic 
inflammation analysis 
n = 31 
Control 




















Final Sample: Demographic Characteristics and Cognitive Scores 
 
Table 20 summarises the demographic characteristics of participants in the MRS study.  
Age: The participants’ (AD and controls) ages ranged from 61 to 87 years (M = 
74.35, SD = 7.46). The age data were normally distributed and therefore Student’s t-test 
was used to do between-group comparisons. There was no significant age difference 
between the control and AD group (p = .451).  
Sex: There were 16 males and 17 females in the final sample. Pearson’s Chi-
Squared analysis of these data showed that there were no significant between-group 
differences with regard to sex distribution (p = .373). 
Level of education: Again, this variable was defined as the total number of years 
of successfully completed education. The number of years of education in all participants 
ranged from 5 to 18 years (M = 11.32, SD = 3.14). Education was normally distributed and 
therefore the Student’s t-test was used to compare groups. Control participants (M = 13.2) 
had significantly more years of education when compared with AD participants (M = 10.1; 
p = .002). 
APOE ε4: Sixty-four percent of all participants who were included in this MRS 
study did not carry an APOE ε4 allele. Thirty-six percent of all participants were either 

















Demographic Data for the MRS Study’s Participants  
 
Note: For age and level of education, means are presented with standard deviations in 
parentheses. Level of education was measured as the number of years of successfully 
completed education. Apolipoprotein ε4 (APOE ε4) was given as a percentage of controls 
and AD participants with at least one ε4 allele (either homozygous or heterozygous). ESE 
= effect size estimate: for continuous variables (age and level of education) the ESE is 
Cohen’s d; for categorical variables (sex and APOE ε4) the ESE is Phi. See Appendix J: 
Table A &B for raw data. 
* Control and AD groups differed significantly, p < .005.  
 
All participants were administered the MMSE and learning subscale tests from the 
CAMCOG on the morning of, and prior to, the scan itself. Table 21 shows results of the 
two groups scores’ for the learning subscale and the MMSE. For both cognitive measures, 
scores were not normally distributed.  
MMSE: In all participants, the MMSE scores ranged from 12 to 30 (Median = 27, 
IQR =19 – 29). The MMSE is scored out of a total of 30. Controls (Median = 29) had 
significantly higher MMSE scores than AD participants (Median = 19; p < .001). 
Learning subscale: The participants’ learning subscale scores ranged from 0 to 17 
(Median = 13, IQR = 6 – 15). The maximum score on the learning subscale is 17. Controls 
(Median = 15) had significantly higher learning subscale scores than AD participants 
(Median = 6.5; p < .001). 
  
 Group     
 Control AD     
 (n = 15) (n = 18) t / χ
2
 df p ESE 
age 72.9 (6.3) 74.9 (8.1) 0.76 31 .451 0.27 
sex (M:F) 6:9 10:8 0.79 1 .373 -0.16 
level of education 13.2 (3.00) 10.1 (2.3) -3.41 31 .002* -1.22 















Between-Group Comparisons of Neuropsychological Test Scores for the MRS Study 
 
Note. Medians are presented with interquartile ranges in parentheses. Raw scores for the 
Mini-Mental State Examination (MMSE) and learning subscale are presented. See 
Appendix J: Table A &B for raw data. 
* Control and AD groups differed significantly, p < .001.  
 
As previously indicated, a total of 18 AD participants had complete MRS data. The 18 AD 
participants were divided up into two groups. AD participants with a learning subscale 
score equal to and greater than 7/17 were considered mild/moderate AD (n = 9) and those 
who scored below 7/17 were considered more advanced AD participants (n = 9). The AD 
group was not divided into three separate sub-groups: mild, moderate and severe, as was 
done previously done in the cross-sectional study because of the smaller numbers in the 
imaging study.  
 
Technical difficulties were experienced while acquiring MRS data from the hippocampal 
areas. MRS data from the hippocampal areas were therefore not obtainable. The rest of this 
section will only report results from the posterior cingulate gyrus.  
 
Inflammatory data and neurometabolites were normally distributed. Therefore, statistics 
for normally distributed data were used in this section. When the control and 
mild/moderate AD group were compared using the Student’s t-test, there was no 
significant difference in their age (t (23) = 0.60, p = .558, d = 0.25) or education (t (23) = -
1.82, p = .082, d = -0.76). When the control group was compared with the advanced AD 
group, there was no significant difference in the age of the two groups (t (23) = 0.71, p = 
.488, d = 0.30). However, the control group did have a significantly greater number of 
years of education (t (23) = -3.77, p = .001, d = -1.57). There were no significant between-
group differences with respect to age (t (17) = 0.17, p = .867, d = 0.08) or education (t (17) 
= -1.88, p = .079, d = 0.91) when the mild/moderate and advanced AD groups were 
 Group     
 Control AD     
Cognitive test (n = 15) (n = 18) U df p r 
MMSE 29 (27 – 29) 19 (17 – 24) 19 31 < .001* -0.73 














compared. Education was not correlated with any of the neurometabolites and therefore 
education was not adjusted for in the analyses.  
 
The Relationship Between CNS Inflammation in the Posterior Cingulate Gyrus and 
Cognitive Scores  
 
Hypothesis 6 predicted that myo-inositol (MI), a marker of glial cell activation in the CNS, 
would be highest in the early stages of AD, declining with the progression of the disease. 
Two different statistical tests were used to test this hypothesis: one-way ANOVA to 
compare between-group differences and Pearson’s correlation analysis. For Pearson’s 
correlation analyses all AD participants were examined together and not as separate sub-
groups. Table 22 and Table 23 detail the results from the one-way ANOVA and Pearson’s 
correlation analyses respectively.  
 
Mild/moderate AD participants (learning subscale score ≥ 7/17) did not have a 
significantly higher MI level when compared with controls or advanced AD participants. 
However, one-way ANOVA and a post-hoc Tukey test showed that more advanced AD (M 
= 5.03) participants (learning subscale score < 7/17) had a significantly higher MI level 
compared with mild/moderate AD participants (M = 4.24; p = .011; see Figure 37). 
Pearson’s correlation between MI and cognition showed that when controls were analysed, 
there was no correlation between MI and the learning subscale or the MMSE. However, 
when the AD group was analysed, the learning subscale tended to be negatively correlated 
with MI (p = .093; see Figure 38). There was no significant correlation between MI and 















Figure 37: Bar graph showing myo-inositol (MI) in the control (n = 15), mild/moderate (n 
= 9) and advanced AD (n = 9) groups. MI is measured in parts per million (ppm).  




Figure 38: The correlation between myo-inositol (MI) and decline on the learning subscale 


















The Relationship Between Neuronal Integrity in the Posterior Cingulate Gyrus and 
Cognitive Scores 
 
Hypothesis 7 stated that there would be a direct relationship between the NAA+NAAG 
peak on MRS, i.e. the better the cognitive functioning, the higher the NAA+NAAG peak. 
Again, this hypothesis was tested using one-way ANOVA and Pearson’s correlation 
analysis (see Table 22 and 23 respectively).  
 
One-way ANOVA analysis showed that the NAA+NAAG neurometabolites were 
significantly higher in the controls (M = 6.03) compared with the mild/moderate AD group 
(M = 5.64; p = .003) and the advanced AD group (M = 5.78; p = .02), see Figure 39. There 
was no significant difference between the mild/moderate AD group and the advanced AD 
group (p = .783). Pearson’s correlation analysis showed no correlations between 





























Figure 39: Bar graph showing N-acetylaspartate and N-acetylaspartylglutamate 
(NAA+NAAG) in the control (n = 15), mild/moderate (n = 9) and advanced AD (n = 9) 
groups. NAA+NAAG is measured in parts per million (ppm). 
* The mild/moderate and advanced AD groups differed significantly from the control 















The Relationship Between Neuronal Integrity, CNS Inflammation and Cognitive 
Scores  
 
Hypothesis 8 stated that the ratio between MI and NAA+NAAG would be negatively 
associated with cognition measured on the learning subscale and the MMSE. One-way 
ANOVA analysis was used to compare the three groups: mild/moderate AD, advanced AD 
and control groups (Table 22; Figure 40). One-way ANOVA analysis and a post-hoc 
Tukey test showed that advanced AD participants (M = 0.88) had a higher 
MI/(NAA+NAAG) ratio compared with controls (M = 0.73; p = .005) and the 
mild/moderate AD group (M = 0.75; p = .044). There was no significant difference 
between the control and mild/moderate AD groups for the MI/(NAA+NAAG) ratio (p = 
.806). Pearson’s correlation analysis was also used (Table 23). Pearson’s correlation 
analysis showed that the MI/(NAA+NAAG) ratio in the posterior cingulate gyrus was not 































Figure 40: Bar graph showing the ratio of MI to N-acetylaspartate and N-
acetylaspartylglutamate (NAA+NAAG) in the control (n = 15), mild/moderate (n = 9) and 
advanced AD (n = 9) groups. MI and NAA+NAAG are measured in parts per million 
(ppm).  
* The control and mild/moderate AD groups differed significantly from the advanced AD 





























Note: Means are presented with standard deviations in parenthesis. Absolute metabolite concentrations for myo-inositol (MI) and N-
acetylaspartate and N-acetylaspartylglutamate (NAA+NAAG) are given in parts per million (ppm). The mean for ratio between MI and 
NAA+NAAG is presented (MI/NAA+NAAG). See Appendix J: Table A &B for raw data. 
* The more advanced AD group and the mild/moderate AD group differed significantly, p < .05. ** Controls and mild/moderate AD participants 
differed from the more advanced AD group, p < .01.
 †
 Controls differed from the mild/moderate AD participants and the more advanced AD 
group, p < .001.  
 
  





(n = 9) 
More Advanced AD 
(n= 9) F p Partial η
2
 
MI 4.58 (0.53) 4.24 (0.54) 5.03 (0.57) 4.89 .015* 0.25 
NAA+NAAG 6.30 (4.46) 5.64 (0.33) 5.78 (0.46) 7.81 .001
†
 0.34 





























Note: The Pearson correlation statistic is r. Abbreviations are as follows: myo-inositol (MI), N-acetylaspartate and N-acetylaspartylglutamate 
(NAA+NAAG), the ratio between MI and NAA+NAAG, MI/(NAA+NAAG). The cognitive measures are the learning subscale (LS) and the 
Mini-Mental State Examination (MMSE). See Appendix J: Table A &B for raw data. 
 Controls AD 
 (n= 15) (n =18) 
 LS MMSE LS MMSE 
Neurometabolite r p r p r p r p 
MI .130 .644 -.201 .473 -.408 .093 -.233 .353 
NAA+NAAG .010 .973 -.349 .202 -.210 .402 .285 .252 














The Relationship Between CNS Inflammation, Systemic Inflammatory Markers and 
Neuronal Integrity 
 
Hypothesis 10 predicted that there would be a direct association between systemic 
inflammation, CNS inflammation and NAA+NAAG. Firstly, MI, a marker of CNS 
inflammation, in the posterior cingulate and hippocampus would be positively correlated 
with the systemic measures of inflammation (cytokines, OPN, white cell count, monocyte 
count, and ESR). Secondly, MI would be negatively correlated with NAA+NAAG. 
Thirdly, NAA+NAAG would also be negatively correlated with systemic inflammatory 
markers. 
 
The inflammatory markers were normally distributed therefore Pearson’s correlation 
analyses were used to analyse the data. Table 24 shows the correlation statistics for the 
control and AD group.  
 
In the control group, the monocyte count was positively correlated with NAA+NAAG, p = 
.004. NAA+NAAG correlated positively with the ESR and white cell count, but this did 
not reach significance. TNF-α and OPN were both negatively correlated with 
NAA+NAAG. MI had a positive correlation with the white cell count and a negative 
correlation with TNF-α. These correlations however, were not significant.  
 
In the AD group, NAA+NAAG was negatively correlated with TGF-β1 and TGF-β2, p = 
.025 and p = .023 respectively (see Figure 41 and Figure 42).  
 
When the relationship between MI and NAA+NAAG was investigated, MI and 
NAA+NAAG were not correlated in the AD group (r = -0.928, p = .714). However, in the 















Correlation Analyses between Peripheral Inflammatory Markers, MI and NAA+NAAG 
 
Note: The test statistic is Pearson’s r. MI = myo-inositol, NAA+NAAG = N-
acetylaspartate and N-acetylaspartylglutamate. Abbreviations for the inflammatory 
markers are as follows; erythrocyte sedimentation rate (ESR), interleukin 1 beta (IL-1β), 
interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-α), transforming growth factor 
beta 1 and 2 (TGF-β1 and TGF-β2), osteopontin (OPN). ). See Appendix J, Table A &B for 
raw data. See Appendix J: Table A &B for raw data. 








MI NAA+NAAG MI NAA+NAAG 
r p r p r p r p 
ESR .213 .583 .300 .434 -.335 .204 .054 .843 
White cell count .303 .428 .331 .385 -.386 .140 .049 .858 
Monocyte count .297 .437 .842 .004* -.084 .757 .178 .509 
IL-1β -.053 .893 -.110 .779 -.437 .090 -.201 .456 
IL-10 .032 .935 .146 .708 -.231 .389 -.037 .890 
TNF-α -.331 .384 -.460 .213 -.323 .222 .370 .158 
TGF-β1 .088 .822 .100 .798 .155 .566 -.558 .025* 
TGF-β2 .125 .750 .071 .856 -.033 .903 -.562 .023* 
















Figure 41: Inverse correlation between N-acetylaspartate and N-acetylaspartylglutamate 




Figure 42: Inverse correlation between N-acetylaspartate and N-acetylaspartylglutamate 














Figure 43 a, b and c depict the relationship between the decline on the learning subscale 
(indicative of disease progression) and the ESR; IL-1β and TNF-α; as well as MI and 
NAA+NAAG in all participants. From the graphs it can be seen that in the periphery, 
inflammatory markers: ESR, IL-1β and TNF-α rise when there is a 1 to 8 point loss on the 
learning subscale. Inflammatory markers then decline with a further decrease in learning 
subscale scores. In the CNS, MI rises when there is a decline on the learning subscale and 
continues to rise with further decline on the learning subscale. NAA+NAAG declines with 




















Figure 43: The relationship between a) erythrocyte sedimentation rate (ESR), b) tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-
1β) c) myo-inositol (MI) and N-acetylaspartate and N-acetylaspartylglutamate (NAA+NAAG) and decline on the learning subscale in all 
participants. The y-axis represents a) the ESR (mm/hr), b) TNF-α and IL-1β in picograms per millilitre (pg/mL), c) MI and NAA+NAAG levels 
in parts per million (ppm). 














The Relationship Between the APOE ε4 Allele, CNS Inflammation and Neuronal 
Integrity in the Posterior Cingulate Gyrus 
 
Hypothesis 9 predicted that participants, either homozygous or heterozygous for the APOE 
ε4 allele, would have higher baseline levels of MI and lower levels of NAA+NAAG 
compared with participants that did not carry an ε4 allele. Linear regression analysis was 
used to test this hypothesis. Dummy variables for the presence (1) or absence (0) of the 
APOE ε4 allele were created. The APOE ε4 allele was the independent variable. MI and 
NAA+NAAG and the MI/(NAA+NAAG) ratio were the dependent variables.  
 
Table 25 details the results from the linear regression analyses. In the control and AD 
group, MI and the MI/NAA+NAAG ratio were positively associated with the ε4 allele. 
NAA+NAAG was negatively associated with the ε4 allele. In other words participants with 
at least one ε4 allele had a lower NAA+NAAG and higher MI peak on MRS. However, the 
regression results for MI, MI/(NAA+NAAG) and NAA+NAAG did not reach significance.  
 
Table 25 
The Association between the Presence of the APOE ε4 Allele, MI and NAA+NAAG 
 
Note. β = standardized coefficients for beta, Std Error represents the standard error. Myo-
inositol (MI), N-acetyl aspartate and N-acetylaspartylglutamate (NAA+NAAG) and the 
















MI .246 .334 .060 .377 .175 .314 .031 .488 
NAA+NAAG -.123 .299 .015 .663 -.005 .195 <.001 .986 














The MRS Study Summary 
 
A total of 33 participants were included in the MRS study, 15 controls and 18 AD 
participants. To examine the relationship between neurometabolites and cognition the AD 
group was divided into a mild/moderate group and an advanced AD group based on their 
learning subscale scores. 
 
The relationship between CNS inflammation in the posterior cingulate gyrus and 
cognition.  
One-way ANOVA showed that the advanced AD group had higher MI levels compared 
with the moderate AD group. There were no differences between the control group and the 
moderate or advanced AD groups. There was no correlation between MI and the MMSE or 
the learning subscale in the control group. In the AD group, MI tended to be negatively 
correlated with cognition on the learning subscale but not the MMSE. 
 
The relationship between neuronal integrity in the posterior cingulate gyrus and cognition.  
One-way ANOVA showed the NAA+NAAG was higher in the control group compared 
with the mild/moderate AD group and the advanced AD group. There was no significant 
difference in NAA+NAAG when the moderate AD and advanced AD groups were 
compared. Pearson’s correlation analysis showed no significant correlations between 
NAA+NAAG and the MMSE or the learning subscale in the control and AD group.  
 
The relationship between the ratio of CNS inflammation to neuronal integrity and 
cognitive functioning.  
More advanced AD participants had a higher MI/(NAA+NAAG) ratio compared with 
controls and mild/moderate AD participants. There was no significant difference in the 
ratio when the control and mild/moderate groups were compared.  There was also no 
significant correlation between MI/(NAA+NAAG) and the MMSE or the learning subscale 

















The relationship between systemic inflammation, CNS inflammation and neuronal integrity 
In the control group, the monocyte count was positively correlated with NAA+NAAG. 
There was a moderate positive correlation between NAA+NAAG and the ESR as well as 
the total white cell count. NAA+NAAG also had a strong negative correlation with TNF-α 
and OPN.  
 
In the AD group TGF-β1 and TGF-β2 were negatively correlated with NAA+NAAG. MI 
had a strong negative correlation with IL-1β and a moderately negative correlation with the 
ESR, white cell count and TNF-α.  
 
The relationship between APOE ε4, neuronal integrity and CNS inflammation 
Linear regression analysis showed that although the presence of APOE ε4 allele was 
associated with a higher MI and lower NAA+NAAG in the posterior cingulate gyrus in 




The key finding from the cross-sect onal, longitudinal and MRS analyses are summarised 


















Table 26  
Summary of Key Findings 
 Systemic Inflammation CNS Inflammation and Neuronal 
Integrity 






* ESR and IL-1β raised in mild AD participants compared 
with the control, moderate AD and severe AD groups. 
* Severe AD participants had a higher white cell count 
compared with moderate AD participants.  
- * AD participants had a 
significantly higher ε4 allelic 
frequency compared with 
controls.  
* The age-adjusted odds ratio for 
AD was 2.2 in heterozygous ε4 
carriers and 9 in homozygous ε4 
carriers compared with non-ε4 
carriers.  
*AD ε4 carriers tended to have 
lower MMSE scores compared 
with non-carriers 
* Controls: ε4 carriers 
tended to have higher 
IL-10 levels compared 
with non-carriers. 
* AD: ε4 carriers 
tended to have lower 




* AD: high baseline levels of TNF-α and the white cell count 
were associated with greater decline on the CAMCOG. 
* AD: high baseline levels of the monocyte count and TGF-β2 
were associated with a greater decline on the learning 
subscale; high levels of OPN also tended to be associated with 
the learning subscale. 
* AD: high levels of IL-10 at baseline were associated with 
less of a decline on the CAMCOG and MMSE. 
* Controls: High baseline levels of ESR were associated with a 
greater decline on the learning subscale. 
- * Controls: non-ε4 carriers had a 
greater decline on the CAMCOG 
in one year compared with ε4 
carriers. 
* AD: ε4 carriers had a greater 
decline on the CAMCOG in one 
year compared with non-carriers. 
 
- 
MRS Study  * Advanced AD participants had 
higher MI levels compared with 
moderate AD participants. 
* AD: MI tended to be negatively 
correlated with the learning subscale.  
* NAA+NAAG was higher in controls 
compared with all AD participants.  
- 
 
* The presence of ε4 
allele did not have a 
significant effect on 
the MI or 
NAA+NAAG peaks. 
 
* Controls: The monocyte count was positively correlated with NAA+NAAG; TNF-α and OPN had a 
strong negative correlation with NAA+NAAG. 
* AD: TGF-β1 and TGF-β2 were negatively correlated with NAA+NAAG.  
















AD is a devastating neurodegenerative disease that affects millions of patients, families 
and caregivers worldwide. South Africa is currently on the verge of an epidemic that the 
developed world is already experiencing as the population over the age of 55 continues to 
increase at a rapid rate, despite the HIV/AIDS epidemic. High rates of infection, 
inadequate access to primary health care, poverty and low levels of education increase the 
vulnerability of our ageing population to age-related cognitive disorders. Without local 
knowledge of the disease processes, risk factors and prevalence of these conditions in 
South Africa, we shall be ill equipped to deal with this impending epidemic. Public health 
facilities currently do not provide for geriatric care in general, and dementia in particular. 
Greater public and government awareness will be required to formulate and implement 
health policies around dementia.  
 
This study investigated the relationships between cognitive functioning, the APOE 
genotype, CNS inflammation, systemic inflammation and neuronal integrity, in a sample 
population of older adults from the greater Cape Town metropolitan area. The study 
consisted of 3 sub-studies: a cross-sectional, a longitudinal and a MRS study.  
 
Firstly, participant demographics will be discussed. The findings from each hypothesis will 
then be integrated, setting each into context alongside relevant previously published 
literature. The limitations of the study and some directions for future research will also be 
discussed. 
 
THE PARTICIPANT POPULATION 
 
Age and Education 
One hundred and twenty-eight participants, 68 controls and 60 AD participants, were 
included in the cross-sectional analyses. The control group was younger and had more 
years of education than the AD group. Age is known to be the strongest risk factor for AD 
with the incidence rising from 0.6% in individuals aged 65 to 69 years to 8.4% in 














were younger than the AD participants. Similarly, lower levels of education are a risk 
factor for AD. Controls with lower levels of education are more likely to develop AD 
compared to those with a higher educational attainment (Kukull et al., 2002; Mickes et al., 
2007).  
 
The difference in education levels between the control and AD group raises the question of 
cognitive reserve. Cognitive reserve is a term used to describe the resilience of neurones to 
Aβ and tau pathology. Several studies have shown that some cognitively healthy 
individuals have significant pathological features of AD at autopsy. However, the AD 
pathology did not result in dementia (for a review see Stern, 2009). Cognitive reserve is 
thought to account for the discrepancy between the pathological features of AD and its 
clinical manifestations (Albert, 1995). A larger cognitive reserve has been shown to be 
associated with higher educational attainment, higher socio-economic status, exposure to 
occupations and participation in leisure activities (Stern, 2006). A larger cognitive reserve 
allows the person to cope better when Aβ and tau pathology begin accumulating. This is 
probably due to increased complexity of neuronal networks and higher cognitive processes 
(Stern, 2006).  
 
Cognitive reserve has several implications for the current research. Some control 
participants, although performing within the normal range on cognitive tests, may have had 
AD pathology. This may have impacted on other factors investigated, such as 
inflammation. The use of PiB to measure Aβ load might have been helpful in addressing 
Aβ accumulation in control participants.   
 
In the current study, age was not correlated with the inflammatory markers. This was 
unexpected as ageing has been shown to be accompanied by a low-grade inflammatory 
state. For a review see Vasto et al. (2007) and Franceschi et al. (2000). Sadeghi, Schnelle, 
Thomas, Nishanian, & Fahey (1999) showed that when compared with younger 
participants (age range: 20 - 47 years), older adults (age range: 72 – 100 years) had 
increased blood IL-1β and IL-6 levels. Activated microglia are thought to be the primary 
source of the age-related increase in CNS IL-6 (Ye & Johnson, 1999). One reason why 
there was not a positive correlation in the current study might be because our participants 














inflammatory markers were less. This study also investigated a disease that is associated 
with inflammation.  
 
Cholinesterase inhibitor use 
One of the strengths of the current study was that there were no participants on 
cholinesterase inhibitors at baseline or at follow-up. Although modest in their effects, 
cholinesterase inhibitors have been shown to slow or stabilize decline in cognition (Lanctôt 
et al., 2003; Hansen, Gartlehner, Webb, Morgan, & Jonas, 2008). The use of cholinesterase 
inhibitors was, therefore, not a factor when measuring cognitive decline in the current 
study. Similarly, the use of cholinesterase inhibitors did not influence inflammatory 
markers. The ‘cholinergic anti-inflammatory pathway’ provides a physiological 
mechanism that links the neurotransmitter acetylcholine with inhibition of inflammatory 
processes (Nizri, Hamra-Armitay, Sicsic, Lavon, & Brenner, 2006). Therefore, AD 
participants taking cholinesterase inhibitors might have had lower inflammatory markers 
than AD participants not using these drugs.  
 
APOE Genotype 
Of the 123 participants that were genotyped, the most common allele was APOE ε3. Sixty-
three percent of all participants carried this allele. Corbo & Scacchi (1999) showed in their 
study examining the world distribution of APOE alleles, that 75.2% of participants carried 
the ε3 allele. As expected, ε2 was the least common allele in all participants. The allelic 
frequency of ε2 was 9.3 % in AD participants and 9.4% in controls. This was similar to 
frequencies found in a Nigerian study, where the allelic frequency was 10.2% in AD 
participants and 11.1% in controls (Gureje et al., 2006). The frequency of ε2 in the current 
study was also similar to that found in an indigenous Southern African population, the 
Khoi San (7.7%; Sandholzer et al., 1999). The ε2 allele is thought to be protective and its 
presence predicts a later age of AD onset (Corder et al., 1994; Farrer et al., 1997). 
However, this protective effect of the ε2 allele has not been studied in a South African 
context.  
 
The allelic frequency of ε4 was higher in AD participants when compared with controls 














reported in a Nigerian study (21.7%). However, the AD participants in the current study 
had a higher ε4 allelic frequency compared with AD participants from Nigeria, 35% vs. 
26% respectively (Gureje et al., 2006). A study on East Africans in Kenya and Tanzania 
found no difference in the ε4 allelic frequency between AD patients and controls, 25% in 
both groups (Sayi et al., 1997). When all participants were taken together, the allelic 
frequency of ε4 in the current study was 27.6%.  
 
The frequency of the homozygous ε4 genotype was higher than that reported in a meta-
analysis that included African Americans, Hispanics and Japanese AD patients (Farrer et 
al., 1997). In this review the frequency of the homozygous ε4 genotype was highest in 
Caucasian AD participants (14.8%), which is similar to the 14% found in the current study 
(Farrer et al., 1997). The frequency of the homozygous ε4 genotype in AD participants in 
the current study was also higher than that of a Nigerian AD population (Gureje et al., 
2006).  
 
The ε4 allelic frequency in the current study was lower than the 37% frequency found in 
the indigenous Khoi San population (Sandholzer et al., 1999). A possible explanation for 
this may be the varied genetic profile of the population in the Western Cape region of 
South Africa. Cape Town is historically a colonial port city servicing trade between 
Europe, Africa and Asia. Its population is therefore genetically diverse, with European, 
African and Asian influences.  
 
The age-adjusted odds of having AD with one ε4 allele was 2.2 compared with non- ε4 
carriers. The homozygous ε4 state was associated with an odds ratio of 9 compared with 
non- ε4 carriers. These ratios were higher than those found in a Nigerian population 
(Gureje et al., 2006) but were similar to those calculated by Farrer et al. (1997) for a 
European/ North American (“Caucasian”) population. Unlike other African countries, the 
population of the Cape Metropole region live in urban (Western), industrialised 
environments. The reason there was a relationship between the ε4 allele and AD, which 
was not seen in other African studies, may be because of this lifestyle difference. Our 
participants may have had higher cholesterol levels, higher body mass index, more 
hypertension, more diabetes and their diet may contain more processed carbohydrates and 














rural African populations. All these environmental factors might have contributed to the 
association between AD and the ε4 allele being seen in this urban environment (Hendrie et 
al., 2011).  
 
The sample size in the current study was small and this was not primarily a genetic or 
prevalence study. Therefore, the figures have to be interpreted cautiously. However, they 
do indicate a high population prevalence of the ε4 allele. Furthermore, ε4 was a risk for the 
development of AD in the study population. Further larger, prevalence studies would be 
needed to verify these findings. 
 
In summary, findings from this study showed that the population sample investigated had 
similar ε2 and ε3 allelic frequencies when compared with other African studies (Sayi et al., 
1997; Gureje et al., 2006). The ε4 allelic frequency was higher compared with AD 
participants in other African studies but similar to those found in European and North 
American studies (Farrer et al., 1997; Sayi et al., 1997; Gureje et al., 2006). The ε4 allelic 
frequency was lower than that found in an indigenous South African population 
(Sandholzer et al., 1999). The most likely explanation for this is the mixed genetic 
population in the Western Cape. Further dementia prevalence studies are needed to 















THE RELATIONSHIP BETWEEN SYSTEMIC INFLAMMATION, CNS 
INFLAMMATION AND COGNITION 
 
Both CNS and systemic inflammation have been shown to be associated with 
neurodegeneration and cognitive decline. High levels of poverty, overcrowding and 
inadequate access to primary health care have led to high rates of systemic infection in 
South Africa. The Western Cape has the highest reported infection rate for tuberculosis in 
the world (Lawn et al., 2006). High levels of systemic infection may predispose our 
population to faster rates of cognitive decline. Therefore, one of the aims of this study was 
to investigate the role of systemic inflammation and CNS inflammation in cognitive 
functioning and cognitive decline. 
 
Systemic Inflammation and Cognitive Functioning 
 
Hypothesis 1 stated that systemic inflammatory markers would be highest in the early 
stages of AD, declining with the progression of the disease. To test this hypothesis, the AD 
group was divided into mild, moderate and more severe AD subgroups based on their 
learning subscale scores. The learning subscale is a proxy for episodic memory impairment 
and has been used by Combrinck et al. (2006) as a proxy of disease status and progression. 
Participants with early or mild AD had significantly higher ESRs when compared with 
controls and moderate AD participants. The ESR is a non-specific marker of inflammation. 
A raised ESR indicates an increase in blood fibrinogen, a clotting factor associated with 
inflammatory conditions.  
 
To my knowledge, this is the first study that has shown a rise in ESR in early AD. Other 
studies investigating non-specific inflammatory markers have focused on CRP as a 
peripheral immune marker. Although CRP was measured to exclude participants with 
infections in this study, the CRP values were not reported. The CRP measure reported by 
the NHLS varied significantly in range and we did not feel that the CRP was a reliable 
measure of peripheral inflammation. Holmes and colleagues (2011) also showed that there 
was no relationship between raised CRP and behavioural symptoms during acute infection. 














inflammation in the elderly and that CRP was not involved in the systemic to CNS 
communication (Holmes et al., 2011).  
 
All participants with overt inflammatory conditions and participants with an ESR over 
40mm per hour were excluded. However, participants with conditions such as ischaemic 
heart disease, osteoarthritis and diabetes were not excluded. These conditions may be 
associated with low-grade systemic inflammation. Of the 13 participants in the mild AD 
group, one participant had ischaemic heart disease and arthritis, one participant had 
arthritis and another had asthma. The control, moderate AD and severe AD groups also 
consisted of participants with these conditions. Therefore, it is unlikely that these three 
participants accounted for the increase in ESR in this group.  
 
Blood IL-1β was also significantly increased in mild AD participants compared with 
controls. In moderate and severe AD participants IL-1β was lower than in mild AD 
participants and similar to control levels. Although these are cross-sectional results, it may 
be assumed that these changes also occur longitudinally as participants progress from 
normal to MCI to moderate and then severe AD. IL-1β is a member of the interleukin 1 
family and is a pro-inflammatory cytokine. IL-1β is produced by activated macrophages 
and is an important mediator in the inflammatory response (Griffin, Sheng, Roberts, & 
Mrak, 1995). IL-1 initiates activation of T cells, up-regulates the expression of adhesion 
molecules and induces the expression of other pro-inflammatory cytokines. The up-
regulation of adhesion molecules, pro-inflammatory cytokines and T-cell activation 
amplify the immune response (Griffin et al., 1995).  
 
Griffin and colleagues first proposed that microglial and astrocyte activation was 
accompanied by an elevated IL-1 expression in the CNS of AD patients in 1989 (Griffin et 
al., 1989). IL-1β levels in serum have also been shown to be associated with decreased 
cognitive functioning (Guerreiro et al., 2007). Licastro et al. (2000) showed that AD 
participants had increased levels of IL-1β and IL-6 in the peripheral blood when compared 
with cognitively healthy controls. These studies, together with the increase in IL-1β in mild 
AD in the current study, are in keeping with a meta-analysis that showed IL-1β was 
significantly raised in peripheral blood when AD participants were compared with controls 















Most studies however, have not investigated IL-1β across the stages of AD progression. 
Although the study by Guerreiro et al. (2007) included an MCI group in their analysis, the 
study did not investigate systemic inflammatory markers at different stages of AD. This 
was also true for the Licastro et al. (2000) study. An increase in IL-1β in early AD might 
account for the overall increase in IL-1β found in the AD group in their studies. Future 
work should compare IL-1β levels at different stages of AD in a larger population, 
involving a longitudinal follow-up of participants from cognitively healthy to advanced 
AD.  
 
The increase in blood ESR and IL-1β in mild AD parallels the early inflammatory changes 
found in the CNS by others (Yermakova & O’Banion, 2001; Hoozemans et al., 2005; 
Combrinck et al., 2006). A post-mortem study of the mid-temporal cortex showed that 
COX-2 expression was increased during the Braak neurofibrillary tangle stages 0 – II. It 
then declined with an increase in AD neurofibrillary tangle pathology (Hoozemans et al., 
2005). Yermakova & O’Banion (2001) report similar findings. They showed that COX-2 
expression was slightly increased in post-mortem human hippocampal samples of mild AD 
patients. COX-2 expression declined and was significantly lower in AD patients with 
Braak staging V – VI and a clinical dementia rating of 5 compared with mild patients and 
controls. An increase in CSF levels of PGE2 was found in early AD participants in a study 
by Combrinck et al. (2006). PGE2 levels declined with disease progression to levels below 
that of controls in more advanced AD (Combrinck et al., 2006). IL-1β has been shown to 
induce COX-2 and PGE2 expression in human neuroblasma cell lines (Hoozemans, 
Veerhuis, Janssen, Rozemuller, & Eikelenboom, 2001).  
 
IL-1 frequently manifests synergistically with the pro-inflammatory marker TNF-α 
(Dinarello, 2000). However, there were no significant between-group differences with 
regards to TNF-α in the current study. This was unexpected, as previous literature has 
shown that AD is accompanied by an increase in TNF-α levels. A study by Guerreiro et al. 
(2000) found that TNF-α levels were increased in MCI participants compared with controls 
and were highest in AD participants. A meta-analysis that pooled 14 studies found that 
TNF-α was significantly elevated in the peripheral blood of AD patients compared with 














severity. High levels of TNF-α were associated with a higher Alzheimer’s Disease 
Assessment Scale Cognitive Subscale (ADAS-COG) score, where a higher score on the 
ADAS-COG indicates more severe disease (Holmes et al., 2011). The lack of significance 
in the current study might be due to a small sample size or technical factors related to assay 
technique: the Luminex technology may be less sensitive than the traditionally used 
ELISA assays at detecting TNF-α.  
 
Another inflammatory marker that was raised in the between-group analysis was the white 
cell count. More severe AD participants had significantly higher total white cell counts 
when compared with moderate AD participants. This may indicate that although there is a 
decline in the pro-inflammatory marker IL-1β, there may still be an inflammatory response 
of a different nature in the systemic circulation. There was however, no significant 
difference between groups when comparing the monocyte count. There was also no 
significant difference between the subgroups with regard to cytokines traditionally 
regarded as anti-inflammatory viz. TGF-β1, TGF-β2 and IL-10. The TGF-β result was 
unexpected. Previous reports had shown an increase in TGF-β in early AD patients. TGF- 
β is an anti-inflammatory cytokine that plays a pivotal role in injury and repair (Finch, 
Laping, Morgan, Nichols, & Pasinetti, 1993). Motta et al. (2007) found an increase in 
TGF-β1 in early AD participants, which then declined with disease progression. The 
MMSE scores of the mild AD participants in the current study were comparable to the 
early AD group in the study by Motta et al. (2007). Swardfager et al. (2010), in a meta-
analysis, also reported an increase in TGF-β in peripheral blood and CSF in AD 
participants compared with controls.  
 
The lack of significant between-group difference with regards to anti-inflammatory 
cytokine IL-10 is in line with the meta-analysis of Swardfager et al. (2010). The latter did 
not find a difference in serum IL-10 in controls and AD patients when 4 studies were 
pooled. Kim et al. (2011) also found no differences in IL-10 between cognitively healthy 
controls, MCI and AD participants. 
 
In summary, the current study showed that the systemic inflammatory profile in AD 
changes with the progression of the disease. Perhaps the decline in cognition from normal 














44). One reason that there was no increase in anti-inflammatory cytokines in the current 
study might be because it did not include a MCI group. During this anti-inflammatory 
stage, macrophage activation may be defined as an alternative activation or an M2 state 
(Boche, Perry, & Nicoll, 2013). Support for the idea that early AD is associated with an 
anti-inflammatory profile comes from Motta et al. (2007) who showed that mild AD was 
accompanied by an increase in TGF-β. Parachikova et al. (2007) also showed that TGF-β 
and IL-10 receptor mRNA was increased in post-mortem prefrontal cortex samples of 
mild/moderate AD participants (MMSE scores ranging from 17 – 22) compared with non-
demented controls. Similarly, CSF samples from early AD participants showed an increase 
in the anti-inflammatory lipid compound, PGE2 (Combrinck et al., 2006). During this early 
phase, inflammation may be beneficial as inflammatory mediators are involved in the 
processes that attempt to clear or phagocytose Aβ plaques (Wyss-Coray et al., 2001).  
 
The early proposed anti-inflammatory response may then followed by a predominately 
pro-inflammatory response as the disease progresses to mild/moderate AD (see Figure 44). 
Macrophage activation might change from M2 to M1 or the classic activation state (Boche 
et al., 2013). In the current study there was a rise in the pro-inflammatory marker IL-1β in 
early/mild AD (defined by a learning subscale of greater than and equal to 11/17). Motta et 
al. (2007) also show an increase in pro-inflammatory cytokines IL-18, IL-16 and IL-12 in 
mild AD (AD participants with MMSE scores ranging from 18 to 20.2).  
 
The reason for the rise in pro-inflammatory cytokine and ESR in early AD in the current 
study is unclear. It is known that a gradual rise in systemic inflammation is a common 
consequence of ageing (Franceschi et al., 2000). Additionally, a lifetime of exposure to 
multiple infections may contribute to this increase. A heightened immune activation in 
early AD may also be the result of the increase in Aβ in the blood. In a study on 
participants with known autosomal dominant mutations for familial AD, Aβ was shown to 
increase in the peripheral circulation years before the onset of disease (Bateman et al., 
2012). Late onset AD is thought to follow a similar pattern to familial AD. The increase in 
systemic inflammation may be an attempt to clear systemic Aβ. The rise in systemic 
inflammatory cytokines may also be due to the pathological changes occurring in the CNS. 
De Simoni et al. (1995) and De Luigi et al. (1998) showed that central inflammation may 














the CNS might activate systemic inflammation through signalling from the CNS to the 
periphery.  
 
The increase in peripheral pro-inflammatory cytokines may also be due to decreased anti-
inflammatory cholinergic innervation by the vagus nerve. The cholinergic hypothesis states 
that in AD there is a decrease in the neurotransmitter, acetylcholine (Bartus et al., 1982). 
The use of cholinesterase inhibitors in AD is thought to improve acetylcholine-mediated 
neurone-to-neurone transmission. However, recent evidence suggests that the benefit of 
cholinesterase inhibitor use may not be restricted to improved neuronal transmission. It 
may, in part, be due to its anti-inflammatory effect. In an animal model, 
acetylcholinesterase inhibitors suppressed TNF-α and IL-1β production in mice with 
experimental autoimmune encephalomyelitis. The vagus nerve may suppress systemic pro-
inflammatory cytokines via acetylcholine. This anti-inflammatory activity of the vagus 
nerve was shown to be mediated by the α7 nicotinic acetylcholine receptor (Nizri et al., 
2006). Decreased vagal-cholinergic activity may lead to a reduced inhibition of 
inflammation in the systemic circulation. This, in-turn, may lead to an unopposed pro-
inflammatory state (van Gool, van de Beek, & Eikelenboom, 2010).  
 
The current study showed that the pro-inflammatory systemic state declined with disease 
progression. Motta et al. (2007) also showed a decline in IL-12, IL-16 and IL-18 from mild 
AD to moderate and severe AD. The decline in pro-inflammatory cytokines may either be 
due to progressive immune dysfunction or to an adaptive immune response. Evidence for 
progressive immune dysfunction comes from Guerreiro et al. (2007). They showed that 
when cells from AD and MCI patients were stimulated with LPS, there was a smaller 
increase in the amount of TNF-α, IL-6, IL-12 and IL-1β secreted in vitro from patients’ 
cells compared with healthy age-matched controls. They suggested that a compromised 
capacity to respond to extra inflammatory challenges occurs in AD (Guerreiro et al., 2007).  
 
The decrease in pro-inflammatory cytokines does not, however, necessarily mean that an 
inflammatory response ceases. It is possible that other inflammatory markers, not 
measured in the current study, are increased in more severe AD. One indication that this 
may be the case is that the total white cell count in the current study was raised in severe 














AD participants was also not significantly different from mild AD participants, who had a 
raised ESR when compared with controls and moderate AD groups. Advanced AD 
participants were not studied and only participants with an MMSE score above 12 were 
included. Inclusion of a more severe AD group and a wider range of inflammatory markers 
should be investigated in future work. However, this may be problematic from an ethical 
and consent point of view.  
 
Systemic Inflammation and Cognitive Decline 
 
In the longitudinal study, Hypothesis 4 predicted that higher levels of baseline systemic 
inflammatory markers would predict a faster rate of cognitive decline. Linear regression 
analysis, controlling for the presence of the APOE ε4 allele, showed that high baseline 
levels of IL-10 were associated with slower decline on the CAMCOG and the MMSE 
when all participants were analysed together and when the AD group was analysed 
separately.  
 
IL-10 is an anti-inflammatory cytokine that inhibits the secretion of pro-inflammatory 
cytokines, thereby suppressing inflammation and modulating disease progression. Rat 
astroglial-microglial cell co-cultures that were incubated with LPS and rat IL-10 showed 
decreased LPS-induced pro-inflammatory cytokines TNF-α, IL-6 and IL-1β, when 
compared with astrogial-microglial cultures that were incubated with LPS alone 
(Ledeboer, Brevé, Poole, Tinders, & van Dam, 2000). Two polymorphisms in the 
regulatory region of the IL-10 gene were found to be associated with both low plasma 
levels of IL-10 and an increased risk of AD. The polymorphisms were not associated with 
APOE genotype. Therefore, the risk of developing AD was independent of APOE (Lio et 
al., 2003; Ma, Tang, Lam, & Chiu, 2005). The finding in the current study that low IL-10 
was associated with greater cognitive decline, together with the genetic evidence (Lio et 
al., 2003) and in vitro studies (Ledeboer et al., 2000), provide evidence that IL-10 is 
protective in AD. This is in keeping with a study showing that high levels of the PGE2 in 
the CSF at baseline were related to longer survival time in AD participants (Combrinck et 
















High levels of the pro-inflammatory cytokine TNF-α at baseline were associated with 
greater decline on the CAMCOG, MMSE and learning subscale when all participants 
(control and AD) were analysed together. Similarly, high levels of TNF-α at baseline were 
associated with greater decline on the CAMCOG in the AD group. Holmes et al. (2009) 
found that the positive change in the ADAS-COG over 6 months was greater in AD 
participants with high baseline blood TNF-α levels when compared with AD participants 
with low baseline TNF-α levels. A greater positive change on the ADAS-COG indicates 
greater decline in cognitive functioning. Lower cognitive scores at follow-up are consistent 
with the increase in neuropsychiatric symptoms at follow-up. A pilot study showed that 
participants with lower TNF-α levels at baseline had lower Neuropsychiatric Inventory 
scores at a 6-month follow-up (Holmes et al., 2011).  
 
In general, the current study showed that high levels of non-specific inflammatory markers 
(white cell count, monocyte count and OPN) at baseline predicted faster decline in one 
year on at least one of the cognitive measures in AD participants. These results add to the 
current literature showing that higher levels of inflammatory markers predict a faster rate 
of cognitive decline. A large, 25-year follow-up study showed that men with high levels of 
CRP, a non-specific marker of inflammation, had a 3-fold increase in the risk of dementia 
(Schmidt et al., 2002a). High baseline levels of alpha 1-antichymotrypsin, a protein 
induced during inflammation, were associated with increased decline on the MMSE over a 
3-year period (Dik, Jonker, Hack, Smit, Comijs, & Eikelenboom, 2005).  
 
In the control group, high baseline levels of ESR predicted a greater decline on the 
learning subscale. This is in line with the above literature linking high levels of systemic 
inflammatory markers with cognitive decline. Controls with high ESRs could also be 
‘preclinical’ AD participants. The current study showed that early AD participants had 
elevated ESRs. The rise in ESR and decline in the learning subscale could indicate that 
these participants have early MCI. Future work following control participants with high 
ESRs to see if they convert to MCI / AD would be interesting.  
 
IL-1β in the current study was not associated with decline on any of the cognitive measures 
when participants were followed-up after 12 months. Holmes and colleagues (2003) found 














compared with AD patients with no detectable levels of IL-1β. None of the patients 
fulfilled the Confusion Assessment Method diagnostic criteria for delirium at baseline or at 
follow-up (Holmes et al., 2003). One explanation for the lack of association between IL-1β 
and cognitive decline in the current study could be that AD participants were grouped 
together, irrespective of the stage of their disease. As discussed previously, IL-1β was 
significantly raised in the early stages of AD, declining with disease progression. During 
the early stages of AD (when IL-1β was highest), cognitive decline over one-year is 
relatively slow compared with decline during moderate disease. This is because cognitive 
decline in AD is not linear and generally follows a decreasing logistic function curve 
(Martins et al., 2005). Ideally, when comparing the rate of decline over one year, studies 
should compare participants at similar clinical stages of the disease process. This will 
control for the differences in the inflammatory markers noted at the different stages of AD. 
Due to small numbers in the AD group at baseline and at follow-up this was not possible in 
the current study. However, clinical disease stage also does not necessarily correlate with 
pathological changes.  
 
Other evidence that increased inflammation leads to an increase in cognitive decline comes 
from studies examining the effect of infection on cognition. Holmes et al. (2009) showed 
that AD patients who experienced an acute inflammatory event in a 6-month period had a 
faster rate of cognitive decline when compared with AD patients who did not experience 
an inflammatory event (Holmes et al., 2009). The mechanism by which high levels of 
cytokines lead to a faster cognitive decline is discussed further in the section: The 
Relationship Between Systemic Inflammation and CNS Inflammation (page 168). 
 
CNS Inflammation and Cognitive Functioning 
 
In the MRS study, Hypothesis 6 predicted that MI, a marker of glial activation, would be 
highest in early AD, declining with disease progression. In order to investigate this 
hypothesis the AD group was divided into a mild/moderate subgroup and advanced 
subgroup based on their learning subscale scores. Results from the one-way ANOVA 
statistical analysis showed that mild/moderate AD participants did not have higher MI 
levels in the posterior cingulate gyrus when compared with controls and more advanced 














higher MI level compared with the mild/moderate AD group, indicating that MI increases 
with progression to later, moderate AD.  
 
An increase in MI levels in both MCI and AD patients has been reported in many studies 
(Miller et al., 1993; Moats et al., 1994; Shonk et al., 1995). Kantarci et al. (2000) found 
that, compared with controls, MCI participants had increased MI levels in the posterior 
cingulate. Martinez-Bishal, Arana, Marti-Bonmati, Mollá, & Celda (2004) found that MCI 
participants had lower MI/Cr ratios in the posterior cingulate gyrus compared with AD 
participants. Wang and colleagues (2009; 2012) also found that MI/Cr was increased from 
controls to MCI to AD participants in the left hippocampus and the posterior cingulate 
respectively (Wang et al., 2009; Wang et al., 2012).  
 
MI has also been shown to be correlated with cognitive scores. Parnetti et al. (1997) found 
that MI correlated inversely with MMSE scores and duration of disease in frontal white 
matter of AD patients. The MI/Cr ratio was also negatively correlated with MMSE scores 
across the cognitive spectrum, from cognitively healthy controls to AD patients (Rose et 
al., 1999). The current study supports these findings: MI tended to be negatively correlated 
with episodic memory scores in AD participants, although not significantly. However, MI 
was not correlated with the MMSE in the control or AD group. The lack of correlation 
between MI and the MMSE may relate to the sensitivity of the MMSE. The MMSE is 
probably less sensitive than the learning subscale to pathological changes occurring in 
individuals within a mild to moderate AD group. Huang et al. (2001) found that although 
MI was increased from controls to MCI participants in the occipital lobe and the left and 
right parietal areas, there was no correlation between MMSE scores and MI across the 
cognitive spectrum from cognitively healthy to AD participants (Huang et al., 2001).  
 
An increase in microglial cell activation in AD has been shown in both post-mortem and 
PET imaging studies. A post-mortem study by Hoozemans et al. (2005) showed that 
microglia activation increased with increasing AD pathology. In this study investigators 
measured glial fibrillary acid protein (a protein expressed by astrocytes), KP1 (a marker of 
phagocytotic microglia) and CR3/43 (a marker of activated microglia) in the mid-temporal 
cortex of post-mortem brain tissue. The density of immune-reactivity of the two microglial 














neurofibrillary tangles and the Aβ deposits. These authors hypothesised that microglial cell 
activation occurs later in the disease process and is highest in Braak stage V – VI 
(Hoozemans et al., 2005), this is in keeping with the increase in MI in later, moderate stage 
AD found in the current study.  
 
Microglial cell activation has also been studied in vivo using Carbon 11-labelled-(R)-
PK1195. [11C]-(R)-PK1195 is a PET ligand that is used as a marker of microglial cell 
activation. MMSE scores correlated inversely with [11C]-(R)-PK1195 binding in the 
posterior cingulate gyrus in AD participants (Edison et al., 2008).  
 
There was no difference between the mild/moderate AD and the control group in the 
current study. One reason for this may be that MI was measured in the posterior cingulate 
gyrus and not the hippocampus. As discussed in the Introduction (page 46), the posterior 
cingulate gyrus has been shown to undergo early metabolic and structural changes in MCI 
and early AD, which is why this area was chosen to be investigated (Nestor et al., 2003; 
Kantarci et al., 2011; Wang et al., 2012). It is also a more homogenous tissue, making it 
ideal for imaging. Unfortunately, for technical reasons, neurometabolites from the 
hippocampal areas could not be measured in the current study. Dixon and colleagues 
(2002) were one of the few groups to examine neurometabolites in the hippocampus. They 
note that the hippocampus was a challenging area to investigate due to its close proximity 
to air and bone. Kantarci et al. (2000) also noted that obtaining spectra from a small voxel 
without partial voluming was difficult. Perhaps results from the hippocampus may have 
been more sensitive to early MI changes. Wang et al. (2009) did not find between-group 
differences with regard to MI/Cr in the posterior cingulate gyrus between control, MCI and 
AD participants. However, they did find between-group differences in MI/Cr in the 
hippocampus. MI/Cr in the hippocampus may therefore be more sensitive in early AD than 
in the posterior cingulate.  
 
The increase in MI may be specific to AD. Shonk et al. (1995) showed that the increase in 
MI/Cr ratio in the occipital lobe was specific to AD and was not found in other dementias. 
Therefore, MI might be a distinguishable marker for AD. Rose et al. (1999) also showed 
that MI levels were relatively stable and did not fluctuate over the course of the day. This 















H-MRS measurements of MI may therefore be useful in monitoring disease progression in 
AD. 
 
In summary, the current study has shown that microglia activation increased in the more 
advanced stages of moderate AD. Research examining activated microglial cells in post-
mortem samples as well as in vivo studies using 
1
H-MRS and PET, taken together with the 
current study’s findings, indicate that microglial cell activation continues to increase with 
progression of the disease.  
 
The Relationship between Systemic Inflammation and CNS Inflammation 
 
Studies have shown that high levels of peripheral inflammation and infection lead to a 
faster rate of cognitive decline in AD participants (Holmes et al., 2009; 2011). However, 
the clinical implications of raised systemic inflammatory markers, in the absence of any 
obvious acute infection, remain unclear. Hypothesis 10 therefore investigated the 
relationship between systemic inflammation and CNS inflammation.  
 
The current data showed that IL-1β tended to be negatively correlated with MI in AD 
participants. The negative correlation between IL-1β and MI suggests that these two 
inflammatory processes are somehow linked. As discussed previously, IL-1β was raised in 
early AD and declined in moderate and severe AD. However, MI was increased in more 
advanced AD participants compared with mild/moderate AD participants. This suggests 
that the rise in IL-1β in the systemic circulation preceded microglial activation in the CNS. 
Therefore, it may well be that the rise in IL-1β in the systemic circulation is the precursor 
to microglia activation in the CNS. 
 
In the normal healthy brain, microglia are in a down-regulated, quiescent state. In the 
presence of AD pathology, microglia are partially activated or “primed” (Perry, 2004). 
This inflammatory response is not the same as that which occurs in acute infection where 
there is a robust increase in inflammatory markers. Systemic inflammatory changes can be 
relayed to the brain via three main routes of systemic-CNS communication. Firstly, 














route of communication is directly to the CNS via the circumventricular organs that lack a 
BBB (Banks et al., 1995). The vagus nerve also transmits signals to the CNS from sensory 
afferent fibres in the thoracic abdominal cavity (Bluthe et al., 1996). For a discussion of 
these mechanisms see the Introduction (page 36). The increased levels of IL-1β and ESR 
may have signalled to the CNS via one or more of these routes. CNS microglia are reactive 
to the systemic inflammatory stimuli and primed microglia are further activated. Further 
activation results in an increase in MI, observed in the later stages of moderate AD in the 
current study. The further activation of microglia leads to an increase in cytokines, 
chemokines, proteases and nitric oxide. These toxic inflammatory molecules, together with 
reactive oxygen species and an increase in glutamate, lead to further neuronal damage and 
more Aβ aggregation (Akiyama et al., 2000). It is most likely via this mechanism that 
systemic infection leads to a decline in cognitive functioning (Combrinck, Perry, & 
Cunningham, 2002; Perry et al., 2007, Holmes et al., 2009).  
 
In conclusion, the rise in systemic inflammatory markers in the early AD participants may 
have triggered or driven the activation of microglia noted in the more moderately-




The nature of the inflammatory response in AD appears to change during the course of the 
disease and may be divided into three phases (see Figure 44). On the basis of previous 
literature, I should like to propose that the initial response in MCI / early AD is “anti-
inflammatory” in nature and may be beneficial as inflammatory cells assist in the attempt 
to remove Aβ plaques (Wyss-Coray et al., 2001; Combrinck et al., 2006; Motta et al., 
2007; Parachikova et al., 2007). Although this study did not delineate the precise timing of 
the anti-inflammatory cytokine increase, the findings do support the hypothesis that anti-
inflammatory cytokines are protective. AD participants with higher levels of the IL-10 at 
baseline declined less on cognitive measures. This is in line with literature showing that 
higher levels of the PGE2 were associated with longer survival in AD patients (Combrinck 
et al., 2006). This predominately anti-inflammatory response is then followed by a more 














of TNF-α, a pro-inflammatory cytokine, and non-specific inflammatory markers, measured 
systemically during early or mild AD were associated with a more rapid cognitive decline. 
The increase in pro-inflammatory molecules might arise from a decrease in the anti-
inflammatory cholinergic vagal response (Nizri et al., 2006). Pro-inflammatory cytokines 
may also be released in response to elevated Aβ in the peripheral blood and/or brain 
(Bateman et al., 2012). A combination of the above mechanisms may also be operating.  
 
There is evidence to support the idea that peripheral pro-inflammatory cytokines are able 
to signal to the CNS. Microglia are sensitive to peripheral immune signalling and primed 
microglia are further activated in response to this signalling (Perry, 2004). Systemic pro-
inflammatory cytokines that are elevated in the early stages of AD might signal to the 




Figure 44: The proposed tri-phasic inflammatory response in the progression from normal 
ageing to advanced Alzheimer’s disease (AD). In the MCI / early AD phase, the 
inflammatory profile is predominantly “anti-inflammatory”. This is then followed by a 
predominantly pro-inflammatory response in early / mild AD. In the later stages of 
moderate AD, there is significant brain microglial activation. 
 
Longitudinal studies, with repeated cytokine measurements together with repeated 
cognitive assessments would better characterise the changes in inflammatory markers and 
lead to a better temporal definition of the aforementioned scheme (Figure 44). The long-
term use of NSAIDs reduces the risk of dementia (Breitner et al., 2011; In’T Veld et al., 
? Anti-inflammatory Pro-inflammatory Microglia Activation 






















2001; Vlad, Miller, Kowall & Felson, 2008; Côte et al., 2012), yet current drug trials 
targeting inflammation in AD patients have failed (Gasparini, Ongini, & Wenk. 2004; 
McGeer & McGeer, 2007). Breitner et al. (2011) showed that NSAIDs taken before the 
onset of dementia reduced the risk of AD. However, they had harmful or no benefit once in 
patients with the disease. Understanding and characterising the different stages of 















NEURONAL INTEGRITY AND ITS RELATIONSHIP WITH SYSTEMIC 
INFLAMMATION, CNS INFLAMMATION AND COGNITION  
 
NAA is thought to be a marker of neuronal integrity. A decrease in NAA in the CNS may 
indicate different processes occurring: either neuronal loss or a decreased level of 
functioning or reduced metabolic integrity of neurones that are still viable (Valenzuela & 
Sachdev, 2001). As discussed, inflammation is thought to drive a neurotoxic cycle leading 
to neurodegeneration and subsequent cognitive decline (Akiyama et al., 2000). The aim of 
Hypothesis 7 was to investigate the relationship between neuronal integrity and cognition 
and the aim of Hypothesis 10 was to investigate the relationship between neuronal integrity 
and both CNS and systemic inflammatory markers.  
 
The Relationship between Neuronal Integrity in the Posterior Cingulate Gyrus and 
Cognitive Functioning 
 
In order to investigate the relationship between NAA+NAAG and cognition, the AD group 
was divided into mild/moderate and more advanced AD groups based on their learning 
subscale. In the current study, NAA+NAAG in the posterior cingulate gyrus was decreased 
in the mild/moderate AD group and the advanced AD group when compared with controls. 
There was no difference between the mild/moderate and more advanced AD group. 
Kantarci et al. (2000) also showed a reduction in NAA/Cr in the posterior cingulate when 
AD patients were compared with controls. Medial temporal lobe reduction in NAA in AD 
patients compared with cognitively healthy controls was also found by Jessen et al. (2000). 
The reduction in medial temporal lobe NAA was not due to generalised atrophy as there 
was no difference in NAA concentrations between control and AD groups in the primary 
motor and sensory cortices (Jessen et al., 2000). Dixon et al. (2002) also found decreased 
NAA levels in the left hippocampal area when AD participants were compared with 
controls. 
 
Although the current study found that NAA+NAAG was decreased in early AD, 
NAA+NAAG levels in the mild/moderate AD and more advanced AD groups were not 














although NAA+NAAG distinguished control participants from AD participants, it was not 
a sensitive marker for disease progression in the posterior cingulate. Another explanation 
may be that AD participants that underwent 
1
H-MRS scanning all had moderate disease 
and therefore NAA+NAAG levels between the mild/moderate and more “advanced” group 
were not distinguishable. I.e. the advanced group (defined by a learning subscale score 
below 7) were still not that advanced. A larger number and wider range of AD patients are 
needed to investigate whether NAA is a sensitive marker for disease stage. However, there 
are ethical considerations and practical difficulties related to scanning more advanced 
disease patients; these would need to be factored into future studies.  
 
The reduction in NAA+NAAG in the mild/moderate AD group is interesting. Some studies 
have suggested that NAA is not a sensitive marker of pathology in MCI or early AD 
(Kantarci et al. 2000; Martinez-Bishal et al., 2004). Huang et al. (2001) divided AD 
patients into severely demented (MMSE scores ≤ 9), moderately demented (MMSE score 
of 10 – 19) and mildly demented (MMSE ≥ 20) groups. The moderately demented and 
severely demented groups had lower NAA levels compared with the control group in all 
three regions of interest (occipital, right and left parietal lobes), whereas the mildly 
demented group didn’t differ from the control group in any of the regions of interest 
(Huang et al., 2001). This study suggested that parietal and occipital reductions in NAA 
occur slightly later in the disease process and continues to decline with disease 
progression. The current data do not support this hypothesis.  
 
NAA was not correlated with the MMSE or learning subscale in the current study. This is 
in keeping with results found by Jessen et al. (2000). In their study, cognitive scores on the 
ADAS-COG also did not correlate with the NAA/Cr ratio. In a follow-up study by the 
same group, they did find a relationship between the MMSE and NAA/Cr. Cognitive 
decline on the MMSE was positively associated with the NAA/Cr decline in individuals 
followed-up after 23 months (Jessen et al., 2001). This suggests NAA may be a useful 
longitudinal marker.  
 
The lack of association between the cognitive scores and NAA+NAAG might be because 
NAA+NAAG was measured in the posterior cingulate cortex in the current study. 














Dixon et al. (2002) found that the total left hippocampal NAA was positively correlated 
with the CAMCOG scores in AD participants. Rose et al. (1999) also found a positive 
correlation between NAA in the hippocampus and MMSE scores in cognitively healthy 
and AD participants. A volumetric study also showed that the NAA/Cho ratio was 
positively correlated with volume reductions in the left hippocampus (Schuff, Amend, 
Knowlton, Norman, Fein, & Weiner, 1999). Therefore, hippocampal NAA measurements 
may be better correlated with cognitive functioning in mild to moderate AD participants 
than the posterior cingulate gyrus because of the area’s early episodic memory 
involvement in AD.  
 
Neuronal Integrity and its Relationship with CNS Inflammation, Systemic 
Inflammation 
 
An increase in inflammatory molecules and cytokines has been associated with an increase 
in neurodegeneration. Hypothesis 10 investigated whether inflammation and neuronal 
integrity were correlated in the population examined.  
 
NAA+NAAG and MI were not correlated in the AD group. This was not surprising given 
that NAA+NAAG was decreased in all AD participants (mild/moderate and more 
advanced AD) and MI was only ignificantly raised in more advanced AD participants. 
These results suggest that a decrease in NAA+NAAG occurs before a significant increase 
in MI and therefore these processes are asynchronous. Other studies have also found that 
the decrease in NAA and the rise in MI are asynchronous. However, these studies showed 
that the rise in MI precedes the decrease in NAA (Kantarci et al., 2000; Wang et al., 2012). 
The rise in MI preceding the decrease in NAA is supported by a study showing that non-
demented Down syndrome adults, who are predisposed to developing AD, had increased 
MI concentrations and no decline in NAA concentrations (Huang et al., 1999). Wang and 
colleagues (2012) showed a difference in MI levels in control, MCI and AD participants in 
the temporal lobes but no difference in NAA levels. These authors suggested that the early 
increase in MI occurred before significant loss of neuronal integrity occurs (Wang et al., 
2012). Huang et al. (2001) also showed that MI increased in the parietal lobes of mild AD 
participants compared with controls, whereas a decrease in NAA was only evident in 














decline in the current study might be due to small numbers in the mild/moderate group. 
The early decrease in NAA+NAAG might also be because the signal strength of 
NAA+NAAG on 
1
H-MRS is much stronger than that of MI, making it easier to detect 
small differences.  
 
Studies using PET imaging with [11C]-(R)-PK1195, a marker of activated microglia, and 
PiB, a marker of Aβ load, support the idea that microglial activation is not correlated with 
Aβ pathology and therefore potentially neurodegeneration. [11C]-(R)-PK1195 did not 
correlate with PiB retention in the posterior cingulate gyrus in AD participants, i.e. 
microglia activation did not correlate with Aβ load (Edison et al., 2008). Wiley et al. 
(2009) also found no correlation between [11C]-(R)-PK1195 and PiB retention in the 
posterior cingulate cortex and the frontal cortex. The lack of correlation between Aβ load 
and microglial cell activation suggests that these pathologies may occur independently 
(Okello et al., 2009). 
 
The current study supports the idea that MI may be  more robust and sensitive indicator of 
AD progression than NAA+NAAG in AD patients as it was correlated with episodic 
memory scores (Siger, Schuff, Zhu, Miller, & Weiner, 2009). However, MI was not shown 
to be sensitive marker in early disease, whereas NAA+NAAG was significantly decreased 
in early AD.  
 
The lack of correlation between MI and NAA+NAAG probably accounted for the 
decreased sensitivity of the MI/NAA+NAAG ratio to disease stage in the current results. 
Others have reported that the MI/NAA+NAAG ratio was sensitive to disease stage that 
MI/NAA was correlated with cognitive scores (Shonk et al., 1995; Ackl et al., 2005). This 
was not found in the current study. However, these studies examined different brain 
regions. Shonk et al (1995) examined the occipital and frontal lobes and Ackl et al. (2005) 
examined the hippocampal area. This could be one reason for the conflicting results.  
 
Studies showing that high levels of systemic inflammation are associated with an increase 
in neurodegeneration (Holmes et al., 2009; Perry et al., 2007) lead to the hypothesis that 














Results from the current study showed that TGF-β1 and TGF-β2 were inversely correlated 
with NAA+NAAG in AD participants. I.e. the higher the systemic levels of TGF-β the 
lower the NAA+NAAG peak in the CNS. As mentioned, TGF- β is an anti-inflammatory 
cytokine. This result suggests that systemic TGF- β increases with neurodegeneration, 
contrary to the proposed hypothesis that anti-inflammatory markers are raised in the 
beginning stages of AD, declining with disease progression (see page 170). This result 
could indicate that the anti-inflammatory profile predominates in the later stages of 
moderate AD. However, in the cross-sectional study, which incorporated a larger number 
of AD participants, there was no rise in TGF-β1 and TGF-β2 with disease progression. The 
finding that TGF-β1 and TGF-β2 correlated with NAA+NAAG might just be due to a Type 
I error. Further studies are needed to clarify this result. 
 
In summary, if NAA+NAAG is assumed to be present exclusively in neurones, the current 
study suggest that neuronal loss and/or dysfunction occurs in mild to moderate AD 
participants in the posterior cingulate gyrus. The early reduction in NAA+NAAG also 
suggests that NAA+NAAG is sensitive to early neuronal changes in the posterior cingulate 
gyrus of AD participants. Neuronal integrity and microglia activation seemed to occur at 
different times or independently of each other.  
 
NAA+NAAG is a useful marker as it measures the viability of neurones. Therefore, NAA 














THE ROLE OF THE APOE GENOTYPE IN COGNITIVE FUNCTIONING AND 
ITS RELATIONSHIP WITH INFLAMMATION AND NEURONAL INTEGRITY  
 
Until recently, with the discovery of TREM 2, the APOE ε4 allele was the only confirmed 
genetic marker that was strongly associated with late-onset AD. The APOE ε4 allele has 
also been shown to be associated with cognitive functioning (Petersen et al., 1995; Bretsky, 
Guralnik, Launer, Albert, & Seeman, 2003) and to be related to inflammatory processes in 
AD and other diseases (Egensperger et al., 1998; Grocott et al., 2001). These associations 
are particularly important in the South African population given the high prevalence of the 
APOE ε4 allele found in the current study. The allelic frequency of the ε4 allele in all 
participants in the current study was 27.6%, with a frequency of 35.6% in AD participants 
and 20.3% in controls. The associations between the APOE ε4 allele, cognition 
(Hypothesis 2 and 5), systemic inflammation (Hypothesis 3) and CNS inflammation 
(Hypothesis 9) were explored.  
 
The Relationship Between the APOE Genotype and Cognition 
 
While the association between the ε4 allelic variant and Aβ load has been clearly 
established in studies from the industrialised world (Tiraboschi et al., 2004; Thal et al., 
2007), the relationship between the APOE genotype and cognition is controversial with 
many studies showing conflicting reports. This study therefore aimed at investigating the 
effect of the APOE ε4 allele on cognition in AD and control participants in a cross-
sectional and longitudinal study.  
 
Hypothesis 2 investigated the effect of the ε4 allele cross-sectionally. It was hypothesised 
that participants in the AD and control groups with at least one APOE ε4 allele would have 
poorer cognitive scores when compared with ε4 non-carriers. AD ε4 carriers tended to 
have poorer scores on the MMSE when compared to ε4 non-carriers. There was no 
difference in the CAMCOG or learning subscale scores of AD ε4 carriers and non-carriers. 
Likewise, in the control group, there was no difference in ε4 carriers versus non-carriers on 
any of the cognitive measures. Other studies have also shown no effect of the ε4 allele on 














& Hyman (1996) found that AD APOE ε4 carriers did not perform more poorly than non-
carriers on cognitive tests. This study was, however, small and may have lacked sufficient 
power. Small et al. (2000) also showed in a cross-sectional analysis that there was no 
significant effect of the APOE ε4 genotype on general cognition in cognitively healthy 
older adults.  
 
Many longitudinal studies in developed countries have shown that control participants 
carrying the ε4 allele were at a higher risk of developing AD compared with controls 
carrying other APOE alleles (Farrer et al., 2007). Therefore, some investigators have 
argued that the poorer cognitive performance found in ε4 positive controls in some studies 
may be due to the over-representation of preclinical AD participants in the control group. 
If participants with preclinical dementia were retrospectively excluded from the analyses in 
the cognitively healthy group, the difference in rate of cognitive decline between ε4 
carriers and non-carriers disappeared (Bondi, Salmon, Galasko, Thomas, & Thal, 1999; 
Bunce Fratiglioni, Small, Winblad, & Backman, 2004). In the current study’s cross-
sectional analysis, similar cognitive scores in controls with or without the ε4 allele support 
the findings that ε4 is not related to cognition in cognitively healthy participants.  
 
In the longitudinal section of this stud , Hypothesis 5 predicted that participants with at 
least one ε4 allele would decline faster over one year when compared with ε4 non-carriers. 
When control participants were followed-up for 12 months, the presence of the ε4 allele 
was associated with a less of a decline on the CAMCOG. However, in AD participants the 
presence of the ε4 allele was associated with a greater decline on the CAMCOG over 12 
months.  
 
The finding that the APOE ε4 allele was associated with increased decline on the 
CAMCOG in AD participants is in agreement with a study by Martins et al. (2005). 
Martins and colleagues (2005) also used the CAMCOG as a measure of cognitive 
functioning in AD participants. The presence of the APOE ε4 allele predicted a faster rate 
of cognitive decline on the CAMCOG when AD ε4 carriers were compared with ε2 
carriers (Martins et al., 2005). The same study also found that APOE ε4 had a dose-
dependent effect on decline on the CAMCOG, with ε4/ε4 patients declining faster than 














dependent effect of ε4 could not be examined. Cosentino et al. (2008) also showed that ε4 
carriers in the early stages of AD had a faster rate of cognitive decline over a 4-year period 
when compared with ε4 non-carriers. Cognitive decline was measured using a composite 
score comprising of various tests that assessed memory, language, visuospatial 
functioning, abstract reasoning and executive speed. The study suggested that the effect of 
ε4 was restricted to participants in early AD and was not evident in more severe 
participants. However, the latter finding may have been due to floor effects on 
neuropsychological tests seen in advanced AD participants.  
 
The mechanisms by which APOE ε4 exerts its detrimental effects after the onset of AD 
pathology may also relate to the role of the ApoE protein in repair and regeneration. ApoE 
is released by microglia in response to neuronal injury (Slezak & Pfrieger, 2003). Soares et 
al. (2012) showed that ApoE protein levels were lower in AD patients with the ε3/ε4 and 
ε4/ε4 genotype compared with patients with the ε2/ε3, ε3/ε3 and ε2/ε4 genotypes. Cultured 
neurones incubated with ApoE4 had fewer neuronal outgrowths when compared with 
neurones cultured with ApoE3 (Nathan et al., 2002). Reduced neuronal outgrowths in ε4 
carriers could lead to impaired neuronal repair due to damage caused by Aβ and tau 
pathology. Clinical evidence from traumatic brain injury patients has also shown that 
patients carrying the APOE ε4 allele were twice as likely to have an unfavourable outcome 
6 months after a traumatic brain injury than ε4 non-carriers (Teasdale, Nicoll, Murray, & 
Fiddes, 1997). This is consistent with the notion that ε4 only influences cognitive 
functioning after the event of neuronal injury (Small et al., 2000).  
 
The ε4 allele has not been associated with cognitive decline in AD patients in other studies. 
Growdon et al. (1996) showed that over an average of 5.5 years, AD ε4 carrier and non-
carrier participants did not differ in their rates of cognitive decline. The authors of this 
study estimated that the APOE genotype of participants accounted for less than 10% of the 
variance in the rate of cognitive decline (Growdon et al., 1996). In the current study, the ε4 
allele was not associated with decline on the MMSE or learning subscale in AD group. 
However, the small scoring range of these two tests may explain this result. On average, 
AD participants declined by 2 points on the MMSE and 1.5 points on the learning 
subscale. Although AD participants did decline, the change in scores on the MMSE and 














year, showing a greater change in functioning. It is therefore important to consider the 
sensitivity of the cognitive test scales when assessing cognitive decline.  
 
It is also important to note that decline on the CAMCOG, as shown by Martins et al. 
(2005), is not linear. Therefore, comparing the rate of decline between two groups of AD 
patients at different stages of AD using linear models needs to be interpreted with caution. 
Ideally one should adjust for the number of years of disease duration when comparing rates 
of cognitive decline so that participants with equivalent disease stages are compared. 
However, this also poses problems as disease duration/symptoms and pathological stages 
of disease may also be asynchronous.  
 
In the current study, control ε4 carriers showed a smaller decline on the CAMCOG than ε4 
non-carriers over one year. Bunce et al. (2004) showed that the ε4 allele did not affect 
cognitive decline in cognitively healthy individuals carrying the ε4 allele. The strength of 
their study was the long duration of participant follow-up, viz 3 and 6 years, respectively. 
One limitation, however, was that their only measure of cognition was the MMSE. 
Although the MMSE is a good screening tool for established dementia, it may not be 
sensitive enough to detect early cognitive changes (especially episodic memory) in 
cognitively healthy and MCI individuals. Smith et al. (1998) also showed that cognitively 
healthy ε4 carriers did not differ on any of the 5 Mayo Cognitive Factor Scores when 
compared with ε4 non-carriers. This study, like the current study, also found that AD ε4 
carriers and AD non-ε4 carriers differed on cognitive measures (Smith et al., 1998). 
 
One reason for the lack of association between ε4 and cognitive decline in controls may be 
that the ε4 allele is a thrifty allele. In the absence of AD pathology, the APOE ε4 allele 
may be protective in our South African participants. APOE is involved in cholesterol 
transport and metabolism (Mahley, 1988). In populations where food supply is low or has 
until recently been scarce and food quality is poor, carrying the ε4 might still be beneficial. 
In these populations, the ε4 allele might help in rebalancing the cholesterol levels that 
might otherwise be too low. However, when the intake of cholesterol is high, the ε4 allele 
becomes detrimental and predisposes one to increased risk of cognitive decline (Scacchi et 















Another explanation for the lack of association between ε4 and decline in cognitive 
functioning in control participants may be that APOE ε4 does not directly influence 
cognitive performance. APOE ε4 may act only as a modulating effect on the processes that 
actually cause cognitive impairment. Therefore, the effects of ε4 on cognitive functioning 
may only be evident after significant onset of Aβ and tau pathology. Kantarci et al. (2012) 
showed that ε4 interacts with Aβ to produce its effect on cognition. In cognitively healthy 
participants, the presence of the ε4 allele modified the relationship between retention of 
PiB (a measure of Aβ load) and cognition. In their study cognitively healthy ε4 carriers had 
the highest retention of PiB, indicating a higher Aβ load. Linear regression analysis also 
showed that the relationship between PiB retention and cognitive functioning was strongest 
in ε4 carriers (Kantarci et al., 2012). The lack of association between ε4 and decline in 
cognitive functioning in controls may therefore be due to the fact that the control 
participants studied lacked sufficient Aβ and tau pathology for the detrimental effects of ε4 
to be observed. In other words, AD pathology is required for ε4 to exert effects on 
cognition. Larger studies utilising sophisticated measures of Aβ quantification, such as PiB 
imaging, are needed to test these hypotheses.  
 
Martins et al. (2005) argue that neuropathological changes, rather than neuropsychological 
changes, may be more sensitive at detecting the effect of ε4. A neuropathological study has 
shown that ε4 carriers had a greater accumulation of Aβ and neurofibrillary tangles in brain 
tissue when compared with participants who were homozygous for the ε3 allele 
(Tiraboschi et al., 2004). Measuring pathological Aβ changes was not within the scope of 
the current study. Ideally one would measure Aβ in the CSF (for which ethics approval was 
not available in the current study) or using the PET tracer PiB.  
 
Another factor to consider is the type of neuropsychological tests used in the current study. 
These tests may be less sensitive to decline in cognition in cognitively healthy participants. 
Participants were also only followed-up for one-year. In a 7-year follow-up study, Bretsky 
et al. (2003) showed that the risk of cognitive decline in highly functioning ε4 carriers was 
greater than non-carriers. However, this effect was less significant at the 3-year time 
interval. The current study’s follow-up time may be too short to examine the true effect of 















It is important to note that the ε4 allele is not the only factor to consider when investigating 
cognitive decline. A number of elderly people remain cognitively healthy despite being 
homozygous for the ε4 gene. Certainly age and education need to be considered. Both 
advancing age and fewer years of education have been associated with cognitive decline 
(Hebert et al., 1995; Kukull et al., 2002). However, environmental factors, such as stress, 
also need to be considered (Breitner & Welsh, 1995).  
 
Summary 
This study found an association between the APOE ε4 allele and cognitive functioning in 
AD participants. In the cross-sectional study AD ε4 carriers tended to have poorer scores 
on the MMSE compared with AD non-carriers. In the longitudinal study, ε4 carriers had a 
greater decline on the CAMCOG. This is in keeping with current literature showing that 
AD patients with the APOE ε4 allele have poorer cognitive functioning and a faster rate of 
cognitive decline compared with non-carriers (Martins et al., 2005; Cosentino et al., 2008).  
 
There was no association between cognitive functioning at baseline and the APOE ε4 allele 
in control participants. APOE ε4 may not directly influence cognitive functioning and may 
only modulate the pathological features of AD that cause cognitive decline. The controls 
studied may have lacked sufficient Aβ and tau pathology for the effect of ε4 to be evident.  
 
The Relationship Between the APOE Genotype and Inflammation 
 
Many studies have investigated the effect of the APOE ε4 genotype on inflammatory 
processes (Egensperger et al., 1998; Lynch et al., 2003; Guo et al., 2004). The current 
study investigated the relationship between APOE genotype, systemic inflammation and 
the CNS inflammatory marker, MI in the posterior cingulate gyrus. 
 
In the cross-sectional study, Hypothesis 3 predicted that participants, either homozygous or 
heterozygous for the APOE ε4 allele, would have higher baseline levels of systemic 
inflammatory markers compared with participants with the other allelic variants. Linear 














associated with higher baseline IL-10 levels. However, in the AD group the ε4 allele was 
associated with lower IL-10 levels.  
 
There are two possible explanations for the difference in the relationship between ε4 and 
IL-10 in controls and AD cases. As discussed, APOE ε4 is a thrifty allele and in the 
absence of AD pathology, APOE ε4 may be beneficial in the South African population. 
The beneficial response in controls might include higher levels of IL-10, an anti-
inflammatory cytokine. The onset of AD pathology might change the “protective” ε4 effect 
to that seen in AD, which is harmful.  
 
A second, and perhaps more plausible explanation for ε4 tending to predict higher IL-10 
levels in controls may be that control ε4 carriers have higher levels of Aβ and tau 
pathology. As discussed, controls carrying the ε4 allele have a higher risk of developing 
AD compared with ε4 non-carriers. In a study by Soares et al. (2012), 25% of the 58 
healthy controls that converted to MCI within one year had at least one ε4 allele. Similarly, 
of the 164 MCI participants that converted to AD, 67.7% were ε4 positive. The rise in IL-
10 levels ε4 positive in control participants may be due to increased AD pathological 
features. As hypothesized before (see The Relationship between Inflammation and 
Cognition, page 157), the rise in IL-10 may be the early protective anti-inflammatory 
response to AD pathology. The use of PET imaging for a measurement of Aβ load will 
help in identifying controls that have increased AD pathology. Monitoring controls with 
high IL-10 for conversion to MCI to AD could be the interesting subject of future studies.  
 
In AD participants, APOE ε4 tended to be associated with lower baseline IL-10 levels. The 
decrease in the anti-inflammatory cytokines may result in an unopposed or predominant 
pro-inflammatory state. This is in keeping with the literature showing that the APOE ε4 
has a pro-inflammatory effect (Lynch et al., 2003; Guo et al., 2004). Guo et al. (2004) 
showed that rat glial cultures that were stimulated with exogenous ApoE4 released more 
IL-1β when compared with glial cell cultures stimulated with ApoE3. Another study also 
showed that mice carrying the human APOE ε4 gene had higher levels of serum pro-
inflammatory markers, TNF-α and IL-6 compared with APOE ε3 counterparts (Lynch et 















The current study also investigated the association between CNS inflammation and the 
APOE ε4 allele. MI was used as the CNS inflammatory marker. Hypothesis 9 predicted 
that participants, either homozygous or heterozygous for the APOE ε4 allele, would have 
higher levels of MI in the posterior cingulate gyrus compared with participants with other 
allelic variants. Linear regression analysis showed that the APOE ε4 allele was associated 
with increased levels of MI, but this was not significant. Kantarci et al. (2002) also found 
no significant effect of APOE ε4 on MI in the posterior cingulate gyrus in both control and 
AD participants. However, both this study and the current study were based on small 
sample sizes. Larger studies are needed to determine whether MI is a sensitive marker for 
detecting differences in glial activation between ε4 carriers and non-carriers. 
1
H-MRS has 
the advantage of measuring in vivo glial activation in a non-invasive way.  
 
Other studies investigating different inflammatory markers have found an association 
between the APOE genotype and inflammatory markers in the CNS (Egensperger et al., 
1998; Lynch et al., 2003). In a post-mortem study by Egensperger et al. (1998), 
hippocampal and frontal cortical tissue derived from AD ε4 positive patients had an 
increased number of activated microglial cells compared with AD cortical tissue from ε3 
carriers. This finding was independent of disease duration and age at death. Lynch and 
colleagues (2003) replicated the finding by Egensperger and colleagues (1998) in an 
animal model. Lynch et al. (2003) used an LPS model of induced inflammation in mice 
that expressed the human ε3 and ε4 genes. This study was performed to establish whether 
systemic and brain inflammatory responses were influenced by the APOE isoform. TNF-α 
levels in brain homogenates of APOE ε4 animals stimulated with LPS were higher 
compared with APOE ε3 animals. IL-6 was also significantly higher in APOE ε4 animals 
compared with APOE ε3 animals (Lynch et al., 2003).  
 
As with cognition and ε4, one mechanism by which the APOE ε4 and inflammation may 
be related is via the decreased release of ApoE in ε4 carriers. ApoE4 production has been 
shown to be decreased compared with the ApoE3 and ApoE2 (Slooter et al., 1998; Sullivan 
et al., 2011). ApoE is thought to protect against bacterial infection. Rats injected 
subcutaneously with LPS in the absence of ApoE emulsion had higher pro-inflammatory 
cytokines TNF-α and IL-1 serum levels when compared with rats administered LPS with 














rates when compared with rats administered LPS with and ApoE. Therefore, ApoE 
decreases LPS induced production of pro-inflammatory cytokines by decreasing the release 
of these cytokines (van Oosten et al., 2001).  
 
ApoE also increases plaque clearance (Thal et al., 2007). Increased release of ApoE in ε4 
non-carriers may result in increased plaque clearance, decreasing plaque pathology. This 
may result in a decrease in plaque-induced inflammation. Similarly, the association 
between inflammation and ε4 may also be due to the increase in Aβ in AD ε4 positive 
patients (Tiraboschi et al., 2004; Fryer et al., 2005). Higher levels of Aβ may result in an 
increased inflammatory response. APOE ε4 has also been shown to decrease IL-1 receptor 
agonist, a cytokine that inhibits pro-inflammatory cytokines. This might lead to an 
unopposed pro-inflammatory effect (Egensperger et al., 1998). 
 
The relationship between the APOE genotype and inflammation is important as it has been 
shown to affect treatment with NSAIDs. Szekely et al. (2008) examined NSAID use and 
the risk of dementia. They found that APOE ε4 carriers who took NSAIDs had a reduced 
risk of developing dementia compared with ε4 carriers who did not take NSAIDs. The 
reduction in risk was not evident in ε4 non-carriers taking NSAIDs. The risk not related to 
whether the person took non-Aβ42 -lowering NSAIDs or Aβ42 -lowering NSAIDs. Aβ42 –
lowering NSAIDS were classified according to evidence that the NSAID selectively 
lowered Aβ42. These findings suggest that ε4 carriers might derive a greater benefit from 
taking anti-inflammatory drugs than non- ε4 carriers (Szekely et al., 2008).  
 
In summary, the APOE ε4 was associated with lower plasma IL-10 levels at baseline in 
AD participants. This is in keeping with the current literature showing that ε4 carriers have 
a predominately pro-inflammatory profile (Lynch et al., 2003; Guo et al., 2004). However, 
in controls APOE ε4 was associated with higher IL-10 levels. One explanation for the 
current finding is that control ε4 carriers have higher Aβ and tau pathology compared with 
non-carriers. The increased pathology may activate the immune system leading to an early 















There was no significant effect of APOE genotype on the CNS inflammatory marker MI. 
This is contrary to other CNS evidence that CNS inflammatory markers are increased in ε4 
carriers (Egensperger et al., 1998; Lynch et al., 2003). Larger studies are needed to 
investigate the effect of ε4 on MI. MI is a useful CNS inflammatory marker as it provides 
non-invasive measure of CNS inflammation, but it may not be sensitive enough to detect 
small differences.  
 
APOE Genotype and Neuronal Integrity  
 
NAA+NAAG is a marker of neuronal integrity and viability. In this study, NAA+NAAG 
was used to determine whether there is a difference in neuronal integrity between APOE ε4 
carriers versus non-carriers. In the MRS study, Hypothesis 9 predicted that AD and control 
participants with the APOE ε4 allele would have lower levels of NAA+NAAG when 
compared with AD and control participants with no ε4 allele, respectively. 
 
In the current study, linear regression analysis showed no significant association between 
the APOE ε4 allele and NAA+NAAG in the posterior cingulate gyrus in controls and AD 
participants. In other words, the presence of the APOE ε4 allele was not associated with 
decreased levels of NAA+NAAG. Kantarci et al. (2002) also found that control and AD ε4 
carriers did not have lower levels of NAA in the posterior cingulate gyrus when compared 
with non-carriers. Similarly, a study investigating NAA in the hippocampus also found no 
difference in NAA levels between ε4 carriers and non-carriers in both the AD and control 
groups (Dixon et al., 2002).  
 
These findings are in keeping with some anatomical and molecular studies. A study in 
community-dwelling mild AD participants found no association between APOE ε4 and 
hippocampal volumes (Walsh, Slater, Nair, & Attia, 2013). A post-mortem study used an 
ELISA technique to measure synaptic protein markers syntaxin 1, synaptophysin and 
PSD95 in the superior temporal cortex of AD patients. It found no association between ε4 
and synaptic protein markers in AD patients (Love, Siew, Dawbarn, Wilcock, Ben-















There are, however, some studies that have shown anatomical and metabolic changes in ε4 
carriers versus non-carriers. Lehtovirta et al. (1995) showed that AD patients with the 
ε4/ε4 genotype had smaller right hippocampal volumes when compared with AD patients 
with other genotypes. Similarly, Tohgi et al. (1997) found reduced right hippocampal 
volumes in cognitively healthy controls who were carriers of the ε4 allele when compared 
with non-carriers. Although Love et al. (2006) did not find an association between APOE 
genotype and synaptic markers in AD patients, they did find an association between the 
synaptic density and APOE genotype in controls. APOE ε2 carriers had a higher synaptic 
density measure (an index that used the cumulative measure of syntaxin 1, synaptophysin 
& PSD95) compared with ε4 carriers whose synaptic density measure was low (Love et al., 
2006). Kantarci et al. (2012) also showed that global cortical (which included the bilateral 
parietal cortex and posterior cingulate gyrus) retention of PiB increased from cognitively 
healthy APOE ε2 carriers to APOE ε3 carriers, with APOE ε4 carriers having the highest 
retention of PiB. 
 
Metabolic changes in the brain have also been shown to be altered in the presence of the ε4 
allele. In AD post-mortem brain tissue, there was an overall trend for increased metabolic 
abnormalities in APOE ε4 carriers compared with AD ε3 carriers. These metabolic 
changes included abnormalities in glycerophosphoethanolamine and phosphocholine 
(Klunk et al., 1998). A decrease in glucose activity in the parietal lobe, measured using 
PET imaging, was also found in ε4 carriers at risk of dementia compared to at-risk non-
carriers. At-risk participants were defined as participants with at least two relatives with 
AD (Small et al., 1995). Decreased metabolic activity is suggestive of decreased neuronal 
activity. The evidence from these anatomical, synaptic density and metabolic studies 
suggests that there is increased neurodegeneration and decreased metabolic activity when 
cognitively healthy and AD ε4 carriers are compared with non-carriers.  
 
The lack of association between ε4 and NAA+NAAG in the current study may be due to 
the small sample size that was used in the imaging section. Kantarci et al. (2002) also 
argued that the effect of APOE ε4 and neuronal integrity (measured by the NAA peak) 
might relate to different pathological features of the disease process and are therefore not 















In summary, APOE ε4 was not associated with decreased NAA+NAAG levels in AD or 
control participants. There are conflicting reports on the association between APOE ε4 and 




In the current study, the APOE ε4 allele was associated with a detrimental effect on 
cognitive function in AD participants. The mechanisms by which ε4 might exert its 
detrimental effects may be through the decreased release of ApoE protein in AD ε4 
patients (Soares et al., 2012). ApoE aids clearance of Aβ and plays a role in regeneration 
and repair (Slezak & Pfrieger, 2003). The ApoE4 isoform may also be less effective in the 
clearance of Aβ and in neuronal repair than the ε3 and ε2 isoform. The ε4 allele was also 
related to decreased levels of protective anti-inflammatory cytokine IL-10 in AD 
participants. This might explain the increased pro-inflammatory state found in AD ε4 
carriers in other studies (Lynch et al., 2003; Guo et al., 2004). 
 
In the control group, the ε4 allele was not associated with cognitive scores at baseline. At 
follow-up, the absence of the ε4 allele was associated with a greater decline on the 
CAMCOG. It could be argued that the reason the ε4 allele was not related to cognitive 
decline in the controls is that in the absence of Aβ and tau pathology, ε4 is beneficial in the 
South African population. The ε4 allele may also modify the relationship between Aβ and 
cognition (Kantarci et al., 2012). Therefore, in the absence of Aβ the detrimental effects of 
the APOE ε4 allele are not observed. An alternative reason may be that the study was 
underpowered and the neuropsychological tests used are not sensitive enough to detect 
small changes in a short follow-up period in cognitively healthy individuals. It is therefore 
proposed that a longer follow-up time is needed to explore the relationship between ε4 and 
cognition in cognitively healthy controls.  
 
Systemic IL-10 was raised in control participants carrying the ε4 allele compared with non-
ε4 carriers. A possible explanation for this is that the ε4 positive controls were at higher 














inflammatory response to early Aβ and tau accumulation. Future work would be needed to 
further explore this relationship.  
 
A clear understanding of the relationship between the ε4 allele, cognition and inflammation 
is important since it might explain the failure of current clinical trials using immuno-




An overall summary of the discussion is outlined in Figure 45. The figure depicts the 
inflammatory and neuronal changes that occur in the progression from cognitively healthy 
to the more advanced stages of AD. The effect of the APOE ε4 allele on cognitive 


















Figure 45: Summary of the Discussion. The figure describes the inflammatory, neuronal and cognitive changes that occur during the 
progression from normal ageing (left) to moderate AD (right). The role of the APOE ε4 genotype in these processes is also outlined.  
Decrease might be due to a 
progressive immune dysfunction 
or an adaptive immune response 
Results in: 
Signal to the CNS 
Priming of MICROGLIA by Aβ and tau pathology 
Increase in PRO-INFLAMAMTORY 
cytokines  
Decrease in PRO-INFLAMAMTORY 
cytokines  
Increased activation of MICROGLIA 
Higher levels of pro-inflammatory cytokines and 
non-specific inflammatory markers increased rate of 
cognitive decline  
Increase in Aβ and tau 
pathology; CNS 
inflammatory signalling to 
systemic circulation;  
decreased vagus-cholinergic 
activity 
Effect of the ε4 allele on 
microglia activation and 
neuronal integrity needs 
clarification Systemic infection         ++ activation 
and accelerated cognitive decline 
Decreased neuronal integrity 
Decline in cognitive functioning 
NORMAL AGEING MCI / EARLY AD EARLY / MILD AD MODERATE AD 
Control ε4 carriers had higher levels of the anti-
inflammatory cytokine IL-10 
AD ε4 carriers had lower levels of IL-10 
Proposed: decrease in ANTI-
INFLAMAMTORY cytokines 
The ε4 allele increased rate of cognitive decline 
Proposed: increase in ANTI-
INFLAMAMTORY cytokines 
AD: Higher levels of the anti-inflammatory cytokine IL-10 
were associated with decreased cognitive decline. Anti-
inflammatory cytokines may therefore be protective 
Future research should investigate:  
a) if the ε4 allele is protective, in the absence of Aβ, in 
the South African population 
b) if controls with high IL-10 and the ε4 allele are 
‘preclinical’ participants with early AD pathology 
A high population 
prevalence of the ε4 
allele was found. AD 
participants had a 
higher allelic frequency 















LIMITATIONS AND RECOMMENDATIONS FOR FUTURE WORK  
 
This study was conducted in a predominantly poor urban population from the greater Cape 
Town metropole. Various difficulties were encountered during its execution. Patients were 
often not easily contactable and transport difficulties meant that if patients arrived, they 
were usually late. The notion of participating in a research study, with no direct beneficial 
effect to the patient, was a difficult concept for many. The lack of benefit of treatment had 
to be emphasised and re-emphasised at the initial consent procedure and subsequent study 
visits. Therefore, there were many limitations in the current study. The following section 
will outline a number of these limitations. Recommendations for future research, that 
might address these limitations, will also be discussed. 
 
A limitation in AD research in general, is the confidence with which the diagnosis of AD 
can be made clinically. A definitive diagnosis of AD is only possible following 
histopathological examination of brain tissue. The positive predictive value of a “probable” 
AD diagnosis is around 90 – 95% compared with CERAD histopathological evidence. The 
specificity for a “possible” AD diagnosis is around 50 – 60% (Hogervorst et al., 2000). 
This study included both possible and probable AD participants, many of whom had 
vascular risk factors. The composition of the AD group was therefore likely to include both 
definite AD participants and those with mixed AD and vascular dementia.  
 
The second limitation in the current research is the small sample size at baseline and at 
follow-up. AD in the underprivileged communities is poorly understood in South Africa. 
AD, like other mental illnesses, also remains a stigmatised condition (Ineichen, 2000).  
Families and caregivers therefore rarely seek help. Alternatively, older adults with 
dementia are taken to see traditional healers. Traditional healers in South Africa 
incorporate psychological, spiritual and some medical elements into their practice 
(Stafforda, Pedersenb, van Stadena, & Jäger, 2008). Therefore, patients with early AD 
rarely enter the health care systems where the recruitment of participants for the study took 
place. Inadequate access to health care settings also means that if/when patients do visit 
















The sample size for the MRS study was also small. This is accounted for by the fact that 
some AD participants were unable to tolerate the full duration of the 20-minute period in 
the scanner, as well as the cost involved in scanning participants. An alternative to direct 
brain imaging would be the analysis of inflammatory markers in the CSF. Ethical approval 
for the collection of CSF for research purposes was not granted for this study and 
consequently could not be used in aiding the characterization of the CNS inflammatory 
markers. A larger longitudinal study investigating the use of 
1
H-MRS may be useful in our 
communities.  
 
Increasing awareness of early symptoms of AD and educating communities about 
dementia will encourage families to seek help early in the disease process. Monitoring and 
longitudinal follow-up of MCI and AD patients may then be facilitated.  
 
The third limitation in the current study is that MCI participants were not investigated. 
MCI is considered the transitional state between cognitively healthy ageing and AD. The 
larger study, in which this study is nestled, aimed to recruit MCI participants. However, 
over the 5-year study period, very few participants were identified as having MCI. Again, 
this highlights the lack of awareness when seeking medical attention for early cognitive 
complaints. Population screening may be a way of identifying MCI participants. Inclusion 
of an MCI group will help identify the factors that contribute to the conversion from MCI 
to AD in our population and enable us to study systemic and CNS inflammatory markers in 
the transitional state between healthy ageing and AD.  
 
Another limitation in the current study relates to medication use and systemic 
inflammatory markers. A full list of medications taken by all participants was obtained. 
Participants were not excluded for taking NSAIDs. Unfortunately, due to the large number 
of older adults on NSAIDs (especially low dose aspirin) the exclusion of participants on 
NSAIDs was not possible. The use of NSAIDs may alter the levels of systemic 
















Participants with clinically overt systemic inflammatory conditions, infections and 
participants with an ESR greater than 40mm per hour were excluded. However, certainty 
that participants did not have some form of subclinical systemic infection or inflammatory 
condition at the time blood was taken was not possible. This again may have influenced the 
inflammatory marker analysis.  
 
Multiple acute systemic infections, over a number of years, have been shown to increase 
the likelihood of dementia in older adults (Dunn, Mullee, Perry, & Holmes, 2005). Acute 
infection has also been associated with a decline in cognitive functioning in AD patients 
(Holmes et al., 2009). These factors are therefore especially important in the South African 
context where poverty and poor access to primary health care facilities result in high rates 
of infection. Therefore, participants with these conditions are extremely relevant in AD 
research and should be incorporated into research. 
 
The fifth limitation is the exclusion of depressed participants from the study. Depressive 
symptoms have been shown to be associated with abnormal memory performance (Basso 
& Bornstein, 1999). Depression is generally regarded as an important differential diagnosis 
to consider in someone suspected of having dementia. Most research studies therefore 
exclude participants with depression. However, because one of the symptoms of AD might 
include depression, excluding participants with cognitive complaints and depression limits 
the sample size. The prevalence of depression in dementia has been shown to range from 
11% to 86% (Burns, 1991). Lyketsos et al. (1997) showed that 27% of AD participants 
suffered from minor depressive episodes. Depressive symptoms have also been shown to 
increase with increasing cognitive impairment (Ross, Arnsberger, & Fox, 1998). Future 
studies need to address the problem of excluding participants with depression while 
making sure that lower scores on cognitive tests are not due to depressive symptoms. 
Perhaps closer monitoring and shorter follow-up intervals of participants with depressive 
symptoms will help identify those who are declining from their baseline cognitive scores; a 
decline in cognitive scores may aid the diagnosis of possible AD.  
 
The sixth limitation addresses cognitive decline measurements in the study. The 
neuropsychological tests applied in the current study have floor and ceiling effects. Floor 














modelling of cognitive decline accounts for the floor and ceiling effects better than linear 
models used in the current studies analysis (Martins et al., 2005). The length of time that 
participants were followed-up was also short, cognitive decline was measured over one 
year. As described, decline in AD does not follow a linear trend (Martins et al., 2005). 
Therefore, patients at the early stages of AD decline more slowly over one year than 
patients in the middle stages of the disease process. Interpretation of cognitive decline 
results, when comparing AD participants who are at different stages of the disease process, 
needs to be done with caution. Examining factors that contribute to decline when the AD 
group is made up of individuals at different stages of the disease may yield results that can 
be difficult to interpret. Individual variability in cognitive decline also poses substantial 
difficulties when comparing AD patients (Plassman & Breitner, 1996).  
 
Ideally, longitudinal cohort studies of longer duration together with much larger numbers 
of participants ought to be conducted so that participants can be followed-up from 
cognitively healthy to advanced stages of AD. Longitudinal studies should also include 
multiple inflammatory measures together with yearly MI and NAA+NAAG measures. The 
current study on inflammatory profiles is cross-sectional and therefore the change in the 
inflammatory profile could only be inferred from differences in controls, mild and 
moderate stages of AD. Longitudinal cohort studies will enable investigators to examine 
the inflammatory profile, neurometabolite changes, effect of APOE genotype and factors 
contributing to cognitive decline at the different stages of AD within individuals. However, 
such studies are also expensive and require numbers of staff in a resource-poor setting, 
such as South Africa.  
 
The current study shows that the research into the relationship between systemic 
inflammation, CNS inflammation, neuronal integrity, the APOE genotype and cognitive 
functioning is worth pursuing in South Africa. Longitudinal studies will help clarify the 
nature of the inflammatory profile through the different stages of the disease process. Also, 
paired comparisons with repeated measures in individuals would then be possible, 



















This is, to my knowledge, the first study to investigate the relationship between systemic 
inflammation, CNS inflammation, APOE genotype, neuronal integrity and cognitive 
functioning in a sample of AD and cognitively healthy older South Africans. It was 
undertaken in a predominately poor urban population under sub-optimal conditions 
compared with studies performed in industrialised countries. Nevertheless, the results from 
the study provide an interesting framework for further investigations. 
 
This study showed that the inflammatory response in AD changes with disease 
progression. I proposed that in the MCI or early stages of AD, there might be a 
predominantly anti-inflammatory response. During this phase inflammation may be 
protective as higher levels of anti-inflammatory cytokines were associated with slower 
cognitive decline. This finding may be important as promotion of this early protective 
response might limit the progression of the disease. The anti-inflammatory phase is then 
followed by one which is predominantly pro-inflammatory. An increase in systemic IL-1β 
in participants with early AD was found in the current study. This study also showed a rise 
in peripheral blood ESR in early AD. Higher levels of pro-inflammatory markers at 
baseline were associated with greater decline in cognition. The increase in pro-
inflammatory cytokines in the systemic circulation might drive the activation of primed 
microglia, leading to the increased microglial activation seen in my study in the moderately 
advanced stages of AD.  
 
An association between the APOE ε4 allele and AD was also found in this study. The 
results confirmed the relationship found in developed countries between the presence of 
the ε4 allele and increased cognitive decline in AD (Henderson et al., 1995; Petersen et al., 
1995; Martin et al., 2005). This is also, to my knowledge, the first study in South Africa to 
show an association between the ε4 allele and lower levels of the anti-inflammatory 
cytokine, IL-10, in AD. The relationship between the ε4 allele, systemic inflammation and 
CNS inflammation is especially important in a South African context where rates of 
systemic infections and the prevalence of the ε4 allele are both high. People infected with 














and the age-associated neurodegenerative diseases. Thus a clearer understanding of the 
association between systemic inflammation, CNS inflammation and neurodegeneration is 
extremely important. My study has been the first to examine the interrelationships between 
various inflammatory and genetic factors in the pathogenesis of AD in a South African 
population. Data from this study may be extrapolated to other conditions of systemic 
infection and inflammation. In doing so it may contribute to the limited knowledge base 
concerning the complex interrelationships of AD with other diseases prevalent in South 
Africa.  
 
Over the past few years the failure of many phase II and phase III trials of disease 
modifying drugs has offered little hope to AD sufferers and their families. The greatest 
benefit from treatment may come from preventing the chain of events that lead to 
neurodegeneration and cognitive decline. Amongst these interventions the prevention and 
prompt treatment of infections in older people may turn out to be very important. This may 
limit systemic inflammation and therefore reduce neuroinflammation and its consequent 
cognitive decline. Characterising inflammation at the different stages of disease, 
identifying reliable biomarkers and understanding how the APOE ε4 allele exerts its 
effects may also lead to better designed clinical trials that are appropriately timed.  
 
Alois Alzheimer first described the clinico-pathological entity of AD over one hundred 
years ago. It continues to be one of the most debilitating health conditions especially of 
ageing populations. The continued lack of research in South Africa leads to poor public 
awareness and education. Poor public awareness increases fears and stigma, leading to 
further social isolation of patients suffering from AD, their carers and their families. 
Further research is also needed to determine the true prevalence of the disease in the 
country and to further elucidate the mechanisms of the disease process. Understanding AD 
in a South African context will help raise awareness and create a positive framework for 
carers, health care workers and the public health services to work together in order to 

















Ackl, N., Ising, M., Schreiber, Y.A., Atiya, M., Sonntag, A., & Auer, D.P. (2005). 
Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer’s 
disease. Neuroscience Letters, 384(1-2), 23-28.  
 
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., et 
al. (2000). Inflammation and Alzheimer’s disease. Neurobiology of Aging, 21, 383-
421. 
 
Albert, M.S., Jones, K., Savage, C.R., Berkman, L., Seeman, T., Blazer, D., & Rowe, J.W. 
(1995). Predictors of cognitive change in older persons: MacArthur studies of 
successful aging. Psychology and Aging, 10(4), 578-589.  
 
Almeida, O.P., Hulse, G.K., Lawrence, D., & Flicker, L. (2002). Smoking as a risk factor 
for Alzheimer’s disease: contrasting evidence from a systematic review of case-
control and cohort studies. Addiction, 97, 15-28. 
 
American Psychiatric Association. (2000) (4th ed., text rev.). Diagnostic and statistical 
manual of mental disorders. Washington, DC: American Psychiatric Association.  
 
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, 
B., & Blennow, K. (2001). Evaluation of CSF-tau and CSF-Aβ42 as diagnostic 
markers for Alzheimer disease in clinical practice. Archives of Neurology, 58(3), 373-
379.  
 
Antuono, P.G., Jones, J.L., Wang, Y., & Li, S.J. (2001). Decreased glutamate + glutamine 
in Alzheimer’s disease detected in vivo with 
1
H-MRS at 0.5 T. Neurology, 56(6), 737-
742.  
 
Banks, W. A., Kastin, A. J., & Broadwell, R. D. (1995). Passage of cytokines across the 
blood-brain barrier. Neuroimmunomodulation, 2(4), 241-248.  
 
Bartus, R., Dean, R., Beer, B., & Lippa, A. (1982). The cholinergic hypothesis of geriatric 
memory dysfunction. Science, 217(4558), 408-414.  
 
Basso, M.R., & Bornstein, R.A. (1999). Relative memory deficits in recurrent versus first-
episode major depression on a word-list learning task. Neuropsychology, 13(4), 557-
563. 
 
Berkris, L.M., Yu, C., Bird, T.D., Tsuang, D.W. (2010). Genetics of Alzheimer disease. 
Journal of Geriatrics, Psychiatry, Neurology, 23(4), 213-227. 
 
Bermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J.M., et al. 
(2008). Differences of peripheral inflammatory markers between mild cognitive 















Bluthé, R.M., Michaud, B., Kelley, K.W., & Dantzer, R. (1996). Vagotomy blocks 
behavioural effects of interleukin-1 injected via the intraperitoneal route but not via 
other systemic routes. Neuroreport, 7(15-17), 2823-2827.  
 
Boche, D., Cunningham, C., Docagne, F., Scott, H., & Perry, V.H. (2006). TGFβ1 
regulates the inflammatory response during chronic neurodegeneration. Neurobiology 
of Disease, 22(3), 638-650.  
 
Boche, D., Perry, V.H., & Nicoll, J.A.R. (2006). Review: Activation patterns of microglia 
and their identification in the human brain. Neuropathology and Applied 
Neurobiology, 39, 3-18.  
 
Bondi, M.W., Salmon, D.P., Galasko, D., Thomas, R.G., & Thal, L.J. (1999). 
Neuropsychological function and apolipoprotein E genotype in the preclinical 
detection of Alzheimer’s disease. Psychology and Aging, 14(2), 295-303.  
 
Bonotis, K., Krikki, E., Holeva, V., Aggouridaki, C., Costa, V., & Baloyannis, S. (2008). 
Systemic immune aberrations in Alzheimer’s disease patients. Journal of 
Neuroimmunology, 193, 183-187. 
 
Borovikov, I.P. & Borovikov, V.P. (1998). STATISTICA: Data Preparation and Analysis. 
Moskow: Filini. 
 
Braak, H. & Braak, E. (1995). Staging of Alzheimer’s disease - related neurofibrillary 
changes. Neurobiology of Aging, 16(3), 271-278. 
 
Breitner, J.C., & Welsh, K A. (1995). Genes and recent developments in the epidemiology 
of Alzheimer’s disease and related dementia. Epidemiologic Reviews, 17(1), 39-47. 
 
Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., 
Brandt, J., et al. (2011). Extended results of the Alzheimer’s disease anti-
inflammatory prevention trial. Alzheimer’s & Dementia, 7(4), 402-411. 
 
Bretsky, P., Guralnik, J.M., Launer, L., Albert, M., & Seeman, T.E. (2003). The role of 
APOE-ε4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. 
Neurology, 60(7), 1077-1081.  
 
Bucks, R.S., Ashworth, D. L., Wilcock, G. K., & Siegfried, K. (1996). Assessment of 
activities of daily living in dementia: development of the Bristol Activities of Daily 
Living Scale. Age and Ageing, 25(2), 113-120.  
 
Bunce, D., Fratiglioni, L., Small, B.J., Winblad, B., & Bäckman, L. (2004). APOE and 
cognitive decline in preclinical Alzheimer disease and non-demented aging. 















Burns, A. (1991). Affective symptoms in Alzheimer’s disease. International Journal of 
Geriatric Psychiatry, 6, 371-376. 
 
Burns, A., Lawlor, B., & Craig, A. (2004) (2
nd
 ed.). Assessment scales in old age 
psychiatry. London: Martin Dunitz. 
 
Burns, A. & Iliffe, S. (2009). Dementia. British Medical Journal, 338, 405-409.  
 
Choo, I.H., Lee, D.Y., Oh, J.S., Lee, J.S., Lee, D.S., Song, I.C., Youn, J.C., et al. (2010). 
Posterior cingulate cortex atrophy and regional cingulum disruption in mild cognitive 
impairment and Alzheimer’s disease. Neurobiology of Aging, 31(5), 772-779.  
 
Clark, C.M., Schneider, J.A., Bedell, B.J., Beach, T.G., Bilker, W.B., Mintun, M.A., 
Pontecorvo, M.J., et al. (2011). Use of Florbetapir-PET for imaging β-amyloid 
pathology. JAMA, 305(3), 275-283. 
 
Combrinck, M.I., Perry, V.H., & Cunningham, C. (2002). Peripheral infection evokes 
exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience, 
112(1), 7-11. 
 
Combrinck, M, Williams, J., De Berardinis, M.A., Warden, D., Puopolo, M., Smith, A.D., 
& Minghetti, L. (2006). Levels of CSF prostaglandin E2, cognitive decline, and 
survival in Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 
77(1), 85-88.  
 
Combrinck, M., & Joska, J. (2008). Inflammation, immunity and Alzheimer’s disease. 
Current Allergy & Clinical Immunology, 21(3), 132-136. 
 
Comi, C., Carecchio, M., Chiocchetti, A., Nicola, S., Galimberti, D., Fenoglio, C., 
Cappellano, G., et al. (2010). Osteopontin is increased in the cerebrospinal fluid of 
patients with Alzheimer’s disease and its levels correlate with cognitive decline. 
Journal of Alzheimer’s Disease, 19(4), 1143-1148.  
 
Corbo, R.M., & Scacchi, R. (1999). Apolipoprotein E (APOE) allele distribution in the 
world. Is APOE ε4 a “thrifty” allele? Annals of Human Genetics, 63(Pt 4), 301-310.  
 
Corder, E.H., Saunders, A.M., Risch, N.J., Strittmatter, W.J., Schmechel, D.E., Gaskell, 
P.C., Rimmler, J.B., et al. (1994). Protective effect of apolipoprotein E type 2 allele 
for late onset Alzheimer disease. Nature Genetics, 7(2), 180-184.  
 
Corrada, M.M., Brookmeyer, R., Berlau, D., Paganini-Hill, A., & Kawas, C.H. (2008). 
Prevalence of dementia after age 90: results from the 90+ study. Neurology, 71(5), 
337-343.  
 
Cosentino, S., Scarmeas, N., Helzner, E., Glymour, M.M., Brandt, J., Albert, M., Blacker, 
D., et al. (2008). APOE ε4 allele predicts faster cognitive decline in mild Alzheimer 















Côté, S., Carmichael, P.H., Verreault, R., Lindsay, J., Lefebvre, J., & Laurin, D. (2012). 
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and 
Alzheimer’s disease. Alzheimer’s & Dementia, 8(3), 219-226.  
 
Cousins, J. (1995). Clinical MR Spectroscopy: Applications, and future fundamentals, 
potential current applications and future potential. American Journal of 
Roentgenology, 164, 1337-1347. 
 
Coyle, J., Price, D., & DeLong, M. (1983). Alzheimer’s disease: a disorder of cortical 
cholinergic innervation. Science, 219(4589), 1184-1190.  
 
Crutcher, K.A., Gendelman, H.E., Kipnis, J., Perez-Polo, J.R., Perry, V.H., Popovich, P.G., 
& Weaver, L.C. (2006). Debate: “is increasing neuroinflammation beneficial for 
neural repair?”. Journal of Neuroimmune Pharmacology, 1(3), 195-211.  
 
Dantzer, R. & Kelley, K.W. (2007). Twenty years of research on cytokine-induced 
sickness behavior. Brain, Behavior, and Immunity, 21(2), 153-160.  
 
Davis, E.J., Foster, T.D., & Thomas, W.E. (1994). Cellular forms and functions of brain 
microglia. Brain Research Bulletin, 34(1), 73-78.  
 
De Luigi, A., Terreni, L., Sironi, M., & De Simoni, M.G. (1998). The sympathetic nervous 
system tonically inhibits peripheral interleukin-1 beta and interleukin-6 induction by 
central lipopolysaccharide. Neuroscience, 83(4), 1245-1250. 
 
De Simoni, M. G., Del Bo, R., De Luigi, A., Simard, S., & Forloni, G. (1995). Central 
endotoxin induces different patterns of interleukin (IL)-1 beta and IL-6 messenger 
ribonucleic acid expression and IL-6 secretion in the brain and periphery. 
Endocrinology, 136(3), 897-902.  
 
de Swardt, C., Puoane, T., Chopra, M., & du Toit, A. (2005). Urban poverty in Cape 
Town. Environment and Urbanization, 17(2), 101-111. 
 
Department of Health. (2006) (2
nd
 Ed.). Guidelines for good clinical practice in the 
conduct of clinical trials with human participants in South Africa. Pretoria, South 
Africa: Department of Health.  
 
Dickson, D.W., Crystal, H.A., Bevona, C., Honer, W., Vincent, I., & Davies, P. (1995). 
Correlations of synaptic and pathological markers with cognition of the elderly. 
Neurobiology of Aging, 16(3), 285-298.  
 
Diedrich, J.F., Minnigan, H., Carp, R.I., Whitaker, J.N., Race, R., Frey, W., & Haase, A.T. 
(1991). Neuropathological changes in scrapie and Alzheimer’s disease are associated 
with increased expression of apolipoprotein E and Cathepsin D in astrocytes. Journal 















Dik, M.G., Jonker, C., Hack, C.E., Smit, J.H., Comijs, H.C., & Eikelenboom, P. (2005). 
Serum inflammatory proteins and cognitive decline in older persons. Neurology, 
64(8), 1371-1377.  
 
Dinarello, C.A. (2000). Proinflammatory Cytokine. Chest, 118, 503-508. 
 
Dixon, R.M., Bradley, K.M., Budge, M.M., Styles, P., & Smith, A.D. (2002). Longitudinal 
quantitative proton magnetic resonance spectroscopy of the hippocampus in 
Alzheimer’s disease. Brain, 125, 2332-2341. 
 
Drabe, N., Zund, G., Grunenfelder, J., Sprenger, M., Hoerstrup, S. P., Bestmann, L., Maly, 
F. E., et al. (2001). Genetic predisposition in patients undergoing cardiopulmonary 
bypass surgery is associated with an increase of inflammatory cytokines. Cardio-
Thoracic Surgery, 20, 609-613. 
 
Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, 
J., Delacourte, A., et al. (2007). Research criteria for the diagnosis of Alzheimer’s 
disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology, 6(8), 734-46.  
 
Dunn, N., Mullee, M., Perry, V.H., & Holmes, C. (2005). Association between dementia 
and infectious disease: evidence from a case-control study. Alzheimer Disease and 
Associated Disorders, 19(2), 91-94. 
 
Edison, P., Archer, H.A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F.E., Hammers, 
A., et al. (2008). Microglia, amyloid, and cognition in Alzheimer’s disease: An 
[11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease, 32(3), 
412-419.  
 
Egensperger, R., Kösel, S., Von, U., & Graeber, M.B. (1998). Microglial activation in 
Alzheimer disease : association with APOE genotype. Brain Pathology, 8, 439-447. 
 
Eikelenboom, P., van Exel, E., Hoozemans, J.J.M., Veerhuis, R., Rozemuller, A.J.M., & 
van Gool, W.A. (2010). Neuroinflammation - an early event in both the history and 
pathogenesis of Alzheimer’s disease. Biology of Neurodegeneration, 7(1-3), 38-41.  
 
Ernst, T., Kreis, R., & Ross, B.D. (1993). Absolute quantitation of water and metabolites in 
the abstract human brain. I . Compartments and Water. Journal of Magnetic 
Resonance, Series B, 102(1), 1-8.  
 
Esch, F.S., Keim, P.S., Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., 
McClure, D., et al. (1990). Cleavage of amyloid beta peptide during constitutive 
processing of its precursor. Science, 248(4959), 1122-1124. 
 
Farrer, L., Cupples, A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., 
et al. (1997). Effects of age, sex, and ethnicity on the association between 















Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., et al. 
(2005). Global prevalence of dementia: a Delphi consensus study. The Lancet, 
366(9503), 2112-2117.  
 
Finch, C.E., Laping, N.J., Morgan, T.E., Nichols, N.R., & Pasinetti, G.M. (1993). TGF-
beta 1 is an organizer of responses to neurodegeneration. Journal of Cellular 
Biochemistry, 53(4), 314-22.  
 
Folstein, M.F., Folstein, S.E., & McHugh, P.R. (1975). “Mini-mental state”. A practical 
method for grading the cognitive state of patients for the clinician. Journal of 
Psychiatry, 12, 189-198. 
 
Franceschi, C., Bonafè, M., Valensin, S., & Benedictis, G.D.E. (2000). Inflammaging: An 
evolutionary perspective on immunosenescence. Annals New York Academy of 
Science, 908, 244-254. 
 
Fratiglioni, L., Paillard-borg, S., & Winblad, B. (2004). An active and socially integrated 
lifestyle in late life might protect against dementia. The Lancet Neurology, 3, 343-
353. 
 
Fryer, J.D., Simmons, K., Parsadanian, M., Bales, K.R., Paul, S.M., Sullivan, P.M., & 
Holtzman, D.M. (2005). Human apolipoprotein E4 alters the amyloid-β 40:42 ratio 
and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor 
protein transgenic model. The Journal of Neuroscience, 25(11), 2803-2810.  
 
Gao, S., Hendrie, H.C., Hall, K.S., & Hui, S. (1998). The relationships between age, sex, 
and the incidence of dementia and Alzheimer disease: a meta-analysis. Archives of 
General Psychiatry, 55(9), 809-815.  
 
Gasparini, L., Ongini, E., & Wenk, G. (2004). Non-steroidal anti-inflammatory drugs 
(NSAIDs) in Alzheimer’s disease: old and new mechanisms of action. Journal of 
Neurochemistry, 91(3), 521-536.  
 
Giunta, B., Fernandez, F., Nikolic, W.V., Obregon, D., Rrapo, E., Town, T., & Tan, J. 
(2008). Inflammaging as a prodrome to Alzheimer’s disease. Journal of 
Neuroinflammation, 5(51).  
 
Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, 
L., et al. (1991). Segregation of a missense mutation in the amyloid precursor protein 
gene with familial Alzheimer’s disease. Nature, 349(6311), 704-706.  
 
González-Scarano, F. & Baltuch, G. (1999). Microglia as mediators of inflammatory and 















Gorlovoy, P., Larionov, S., Pham, T.T.H., & Neumann, H. (2009). Accumulation of tau 
induced in neurites by microglial proinflammatory mediators. The FASEB Journal, 
23(8), 2502-2513.  
 
Griffin, T.W.S., Sheng, J.G., Robert, G.W., & Mrak, R.E. (1995). Interleukin-1 expression 
in different plaque types in Alzheimer’s disease : significance in plaque evolution. 
Journal of Neuropathology & Experimental Neurology, 3000. 
 
Griffin, W.S., Stanley, L.C., Ling, C., White, L., MacLeod, V., Perrot, L.J., White, C.L., et 
al. (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down 
syndrome and Alzheimer disease. PNAS, 86(19), 7611-7615.  
 
Grocott, H.P., Newman, M.F., El-Moalem, H., Bainbridge, D., Butler, A., & Laskowitz, 
D.T. (2001). Apolipoprotein E genotype differentially influences the proinflammatory 
and anti-inflammatory response to cardiopulmonary bypass. The Journal of Thoracic 
and Cardiovascular Surgery, 122(3), 622-623.  
 
Growdon, J.H., Locascio, J.J., Corkin, S., Gomez-Isla, T., & Hyman, B.T. (1996). 
Apolipoprotein E genotype does not influence rates of cognitive decline in 
Alzheimer’s disease. Neurology, 47, 444-448. 
 
Guerreiro, R.J., Santana, I., Brás, J.M., Santiago, B., Paiva, A., & Oliveira, C. (2007). 
Peripheral inflammatory cytokines as biomarkers in Alzheimer’s disease and mild 
cognitive impairment. Neurodegenerative Diseases, 4(6), 406-412.  
 
Guo, L., Ladu, M.J., & Eldik, L.J.V. (2004). A dual role for apolipoprotein E in 
neuroinflammation. Journal of Molecular Neuroscience, 23, 205-212. 
 
Gureje, O., Ogunniyi, A., Baiyewu, O., Price, B., Unverzagt, F.W., Evans, R.M., Smith-
Gamble, V., et al. (2006). APOE ε4 is not associated with Alzheimer’s disease in 
elderly Nigerians. Annals of Neurology, 59(1), 182-185.  
 
Guyton, A.C. & Hall, J.E. (2006) (11
th
 ed.). Textbook of Medical Physiology. Philadelphia: 
Elsevier Saunders. 
 
Haass, C., Hung, A.Y., Schlossmacher, M.G., Teplow, D.B., & Selkoe, D.J. (1993). β-
Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. 
The Journal of Biological Chemistry, 268(5), 3021-3024. 
 
Hajek, M. & Dezortova, M. (2008). Introduction to clinical in vivo MR spectroscopy. 
European Journal of Radiology, 67(2), 185-93.  
 
Hansen, R.A., Gartlehner, G., Webb, A.P., Morgan, L.C., Moore, C.G., & Jonas, D.E. 
(2008). Efficacy and safety of donepezil, galantamine, and rivastigmine for the 
treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clinical 















Hart, B.L. (1988). Biological basis of the behavior of sick animals. Neuroscience & 
Biobehavioral Reviewa, 12, 123-137. 
 
He, W., Muenchrath, M.N., & Kowal, P. (2012). Shades of Gray: A cross-country study of 
health and well-being of the older populations in SAGE countries, 2007-2010. U.S. 
Census Bureau, International Populations Reports, P95/12-1. Washington, DC: 
Government Printing Office.  
 
Hebert, L.E., Scherr, P.A., Beckett, L.A., Albert, M.A., Pilgrim, D.M., Chown, M.J., 
Funkenstein, H., et al. (1995). Age-specific incidence of Alzheimer’s disease in a 
community population. JAMA, 273(17), 1354-1359.  
 
Heckmann, J.M., Low, W., de Villiers, C., Rutherford, S., Vorster, A., Rao, H., et al. 
(2004). Novel presenilin 1 mutation with profound neurofibrillary pathology in an 
indigenous Southern African family with early-onset Alzheimer's disease. Brain, 127, 
133-142. 
 
Henderson, A.S., Easteal, S., Joem, A.F., Mackinnon, A.J., Korten, A.E., Christensen, H., 
Croft, L., et al. (1995). Apolipoprotein E allele ε4, dementia, and cognitive decline in 
a population sample. The Lancet, 346, 1387-1390. 
 
Hendrie, H. C., Ogunniyi, A., Hall, K. S., Baiyewu, O., Unverzagt, F. W., Gureje, O., et al. 
(2011). Incidence of Dementia and Alzheimer Disease in 2 Communities. JAMA, 
285(6), 739-747. 
 
Hess, A.T., Tisdall, M.D., Andronesi, O.C., Meintjes, E.M., & van der Kouwe, A.J. 
(2011a). Real-time motion and B0 corrected single voxel spectroscopy using 
volumetric navigators. Magnetic Resonance in Medicine, 66, 314-323.  
 
Hess A.T., Van der Kouwe A.J., Meintjes E.M. (2011b). Water-independent frequency- 
and phase-corrected spectroscopic averaging using cross-correlation and singular 
value decomposition. In: Proceedings of the International Society for Magnetic 
Resonance in Medicine, ISMRM 19
th
 Scientific Meeting. Montréal, Canada, May 
2011. ISSN# 1545-4428, 148. 
 
Hixson, J.E. & Vernier, D.T. (1990). Restriction isotyping of human apolipoprotein E by 
gene amplification and cleavage with HhaI. Journal Of Lipid Research, 31, 545-548. 
 
Hogervorst, E., Barnetson, L., Jobst, K.A., Nagy, Z., Combrinck, M., & Smith, A.D. 
(2000). Diagnosing dementia: interrater reliability assessment and accuracy of the 
NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer’s 
disease. Dementia and Geriatric Cognitive Disorders, 11(2), 107-113.  
 
Holmes, C. & Lovestone, S. (2003). Long-term cognitive and functional decline in late 















Holmes, C., El-Okl, M., Williams, A.L., Cunningham, C., Wilcockson, D., & Perry, V. H. 
(2003). Systemic infection, interleukin 1β, and cognitive decline in Alzheimer’s 
disease. Journal of Neurology, Neurosurgery & Psychiatry, 74, 788-790. 
 
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., et 
al. (2009). Systemic inflammation and disease progression in Alzheimer disease. 
Neurology, 73(10), 768-774.  
 
Holmes, C, Cunningham, C., Zotova, E., Culliford, D., & Perry, V.H. (2011). 
Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology, 
77(3), 212-8. 
 
Hoozemans, J.J.M., Veerhuis, R., Janssen, I., Rozemuller, A.J.M., Eikelenboom, P. (2001). 
Interleukin-1b induced cyclooxygenase 2 expression and prostaglandin E2 secretion 
by human neuroblastoma cells : implications for Alzheimer’s disease. Experimental 
Gerontology, 36, 559-570. 
 
Hoozemans, J.J.M., van Haastert, E.S., Veerhuis, R., Arendt, T., Scheper, W., 
Eikelenboom, P., & Rozemuller, A.J.M. (2005). Maximal COX-2 and ppRb 
expression in neurons occurs during early Braak stages prior to the maximal 
activation of astrocytes and microglia in Alzheimer’s disease. Journal of 
Neuroinflammation, 2, 27.  
 
Hoozemans, J.J.M., Veerhuis, R., Rozemuller, J.M., & Eikelenboom, P. (2006). 
Neuroinflammation and regeneration in the early stages of Alzheimer’s disease 
pathology. International Journal of Developmental Neuroscience, 24(2-3), 157-165.  
 
Huang, W., Alexander, G.E., Daly, E.M., Shetty, H.U., Krasuski, J.S., Rapoport, S.I., et al. 
(1999). High Brain myo-Inositol Levels in the predementia phase of Alzheimer’s 
disease in adults with Down’s syndrome : A 
1
H-MRS study. American Journal of 
Psychiatry, 156(12), 1879-1886. 
 
Huang, W., Alexander, G.E., Chang, L., Shetty, H.U., Krasuski, J.S., Rapoport, S.I., & 
Schapiro, M.B. (2001). Brain metabolite concentration and dementia severity in 
Alzheimer’s disease: A 
1
H-MRS study. Neurology, 57(4), 626-632.  
 
Huppert, F.A., Brayne, C., Gill, C., Paykel, E.S., & Beardsall, L. (1995). CAMCOG -A 
concise neuropsychological test to assist dementia diagnosis: Socio-demographic 
determinants in an elderly population sample. British Journal of Clinical Psychology, 
34(4), 529-541.  
 
In’t Veld, B.A., Ruitenberg, A., Hofman, A., Launer, L.J., van Duijn, C.M., Stijnen, T., 
Breteler, M.M.B, et al. (2001). Nonsteroidal antiinflammatory drugs and the risk of 
Alzheimer's disease. The New English Journal of Medicine, 345(21), 1515-1521. 
 
Ineichen, B. (2000). The epidemiology of dementia in Africa: a review. Social Science & 















Jelsma, J., Mkoka, S., Amosun, L., & Nieuwveldt, J. (2004). The reliability and validity of 
the Xhosa version of the EQ-5D. Disability and Rehabilitation, 26, 103-108. 
 
Jessen, F., Block, W., Traber, F., Keller, E., Flacke, S., Papassotiropoulos, A., Lamerichs, 
R., et al. (2000). Proton MR spectroscopy detects a relative decrease of N-
acetylaspartate in the medial temporal lobe of patients with AD. Neurology, 55(5), 
684-688. 
 
Jessen, F., Block, W., Traber, F., Keller, E., Flacke, S., Lamerichs, R., Schild, H. H., et al. 
(2001). Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of 
AD patients. Neurology, 57(5), 930-932.  
 
Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., 
Stefansson, H., et al. (2012). A mutation in APP protects against Alzheimer’s disease 
and age-related cognitive decline. Nature, 488(7409), 96-99.  
 
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., 
Bjornsson, S., et al. (2013). Variant of TREM2 associated with the risk of 
Alzheimer’s disease. The New England Journal of Medicine, 368(2), 107-116. 
 
Kandel, E.R., Shwartz, J.H., Jessell, T.M. (2006) (4
th
 ed.). Principals of Neural Science. 
New York: McGraw-Hill. 
 
Kantarci, K., Jack, C.R., Xu, Y.C., Campeau, N.G., O’Brien, P.C., Smith, G.E., Ivnik, R.J., 
et al. (2000). Regional metabolic patterns in mild cognitive impairment and 
Alzheimer’s disease: A 
1
H-MRS study. Neurology, 55(2), 210-217.  
 
Kantarci, K., Smith, G.E., Ivnik, R.J., Petersen, R.C., Bradley, F., Knopman, D.S., 
Tangalos, E.G., et al. (2002). 1H magnetic resonance spectroscopy, cognitive 
function, and apolipoprotein E genotype in normal aging, mild cognitive impairment 
and Alzheimer’s disease. Journal of the International Neuropsychological Society, 
8(7), 934-942. 
 
Kantarci, K., Lowe, V., Przybelski, S.A., Senjem, M.L., Weigand, S.D., Ivnik, R.J., 
Roberts, R., et al. (2011). Magnetic resonance spectroscopy, β-amyloid load, and 
cognition in a population-based sample of cognitively normal older adults. Neurology, 
77(10), 951-958.  
 
Kantarci, K., Lowe, V., Przybelski, S.A., Weigand, S.D., Senjem, M.L., Ivnik, R.J., 
Preboske, G.M., et al. (2012). APOE modifies the association between Aβ load and 
cognition in cognitively normal older adults. Neurology, 78(4), 232-240.  
 
Kelly, M.E., Clay, M.A., Mistry, M.J., Hsieh-Li, H.M., & Harmony, J.A.K. (1994). 
Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: 
production of interleukin 2 with reduced biological activity. Cellular Immunology, 















Kim, J., Basak, J.M., & Holtzman, D.M. (2009). The role of apolipoprotein E in 
Alzheimer’s disease. Neuron, 63(3), 287-303.  
 
Kim, S.M., Song, J., Kim, S., Han, C., Park, M.H., Koh, Y., Jo, S.A., et al. (2011). 
Identification of peripheral inflammatory markers between normal control and 
Alzheimer’s disease. BMC Neurology, 11(51). 
 
Kinsella, K. & He, W. (2008). An Ageing World: 2008. U.S. Census Bureau, International 
Populations Reports, P95/09-1. Washington, DC: Government Printing Office.  
 
Kirkpatrick, L.A. & Feeney, B.C. (2008). A simple guide to SPSS for windows version 
16.0. Florence: Cengage Learning. 
 
Klunk, W.E., Panchalingam, K., McClure, R.J., Stanley, J.A., & Pettegrew, J.W. (1998). 
Metabolic Alterations in Postmortem Alzheimer’s disease brain are exaggerated by 
Apo-E4. Neurobiology of Aging, 19(6), 511-515. 
 
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstro, M., 
et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh 
Compound-B. Annals of Neurology, 55, 306-319. 
 
Kukull, W.A., Higdon, R., Bowen, J.D., McCormick, W.C., Teri, L., Schellenberg, G.D., 
Belle, G.V., et al. (2002). Dementia and Alzheimer disease incidence. Archives of 
Neurology, 59, 1737-1746. 
 
LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., & Frail, D.E. 
(1994). Isoform-specific binding of apolipoprotein E to β-amyloid. The Journal of 
Biological Chemistry, 269(38), 23403-23406.  
 
Lamere, C.A., Blusztajn, J.K., Yamaguchi, H., Wiseniewski, T., Saido, T.C., & Selkoe, 
D.J. (1996). Sequence of deposition of heterogeneous amyloid β-peptides and the 
APOE in Down syndrome: Implication for the initial events in amyloid plaque 
formation. Neurobiology of Disease, 3, 16-32. 
 
Lanctôt, K.L., Herrmann, N., Yau, K.K., Khan, L.R., Liu, B.A., LouLou, M.M., & 
Einarson, T.R. (2003). Efficacy and safety of cholinesterase inhibitors in Alzheimer’s 
disease: a meta-analysis. Canadian Medical Association Journal, 169(6), 557-564. 
 
Lawn, S.D., Bekker, L.G., Middelkoop, K., Myer, L., & Wood, R. (2006). Impact of HIV 
infection on the epidemiology of tuberculosis in a peri-urban community in South 
Africa: the need for age-specific interventions. Clinical Infectious Diseases, 42(7), 
1040-1047.  
 
Lazeyras, F., Charles, H.C., Tupler, L.A., Erickson, R., Boyko, O.B., & Krishnan, K.R.R. 
(1998). Metabolic brain mapping in Alzheimer’s disease using proton magnetic 















Ledeboer, A., Brevé, J.J.P., Poole, S., Tilders, F.J.H., & Van Dam, A.M. (2000). 
Transforming growth factor- α differentially regulate production of pro-inflammatory 
cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia, 30, 
134-142. 
 
Lehtovirta, M., Laakso, M.P., Soininen, H., Helisalmi, S., Mannermaa, A., Helkala, E.L., 
Partanen, K., et al. (1995). Volumes of hippocampus, amygdala and frontal lobe in 
Alzheimer patients with different apolipoprotein E genotypes. Neuroscience, 67(1), 
65-72. 
 
Lenger, V., de Viliers, C., & Louw, S. J. (1996). Informant questionnaires as screening 
measures to detect dementia. A pilot study in the South African context. South 
African Medical Journal, 86, 737-741.  
 
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D., Oshima, J., Pettingell, W., Yu, C., et 
al. (1995). Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. 
Science, 269(5226), 973-977.  
 
Lewiston, N., Theodore, J., & Robin, E. (1976). Intracellular edema and dehydration: 
effects on energy metabolism in alveolar macrophag s. Science, 191(4225), 403-404.  
 
Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L.J., Ferri, C., Casadei, V., et al. 
(2000). Increased plasma levels of interleukin-1, interleukin-6 and α-1-
antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or 
signals from the brain? Journal of Neuroimmunology, 103(1), 97-102.  
 
Lin, A., Ross, B.D., Harris, K., & Wong, W. (2005). Efficacy of proton magnetic 
resonance spectroscopy in neurological diagnosis and neurotherapeutic decision 
making. The Journal of the American Society for Experimental NeuroTherapeutics, 2, 
197-214. 
 
Lio, D., Licastro, F., Scola, L., Chiappelli, M., Grimaldi, L.M., Crivello, A., Colonna-
Romano, G., et al. (2003). Interleukin-10 promoter polymorphism in sporadic 
Alzheimer’s disease. Genes and Immunity, 4(3), 234-238.  
 
Love, S., Siew, L.K., Dawbarn, D., Wilcock, G.K., Ben-Shlomo, Y., & Allen, S.J. (2006). 
Premorbid effects of APOE on synaptic proteins in human temporal neocortex. 
Neurobiology of Aging, 27(6), 797-803.  
 
Lupien, S.J., de Leon, M., de Santi, S., Convit, A., Tarshish, C., Nair, N.P., Thakur, M., et 
al. (1998). Cortisol levels during human aging predict hippocampal atrophy and 
memory deficits. Nature Neuroscience, 1(1), 69-73.  
 
Lyketsos, C.G., Steele, C., Baker, L., Galik, E., Kopunek, S., Steinberg, M., & Warren, A. 
(1997). Major and minor depression in Alzheimer’s disease: prevalence and impact. 














Lynch, J.R., Tang, W., Wang, H., Vitek, M.P., Bennett, E.R., Sullivan, P.M., Warner, D.S., 
et al. (2003). APOE genotype and an ApoE-mimetic peptide modify the systemic and 
central nervous system inflammatory response. The Journal of Biological Chemistry, 
278(49), 48529-48533.  
 
Ma, S.L., Tang, N.L.S., Lam, L.C.W., & Chiu, H.F.K. (2005). The association between 
promoter polymorphism of the interleukin-10 gene and Alzheimer’s disease. 
Neurobiology of Aging, 26(7), 1005-1010.  
 
Mader, I., Rauer, S., Gall, P., & Klose, U. (2008). 
1
H-MR spectroscopy of inflammation, 
infection and ischemia of the brain. European Journal of Radiology, 67(2), 250-257.  
 
Mahley, W. (1988). Apolipoprotein E : Cholesterol protein with expanding role in cell. 
Advancement of Science, 240(4852), 622-630. 
 
Mahley, R.W. & Rall, S.C. (2000). Apolipoprotein E: far more than a lipid transport 
protein. Annual Review of Genomics in Human Generics, 1(59), 507-537. 
 
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010). 
Alzheimer’s disease: clinical trials and drug development. The Lancet Neurology, 
9(7), 702-716.  
 
Martínez-Bisbal, M.C., Arana, E., Martí-Bonmatí, L., Mollá, E., & Celda, B. (2004). 
Cognitive impairment: classification by 1H magnetic resonance spectroscopy. 
European Journal of Neurology, 11(3), 187-193.  
 
Martins, C.A.R., Oulhaj, A., de Jager, C.A., & Williams, J.H. (2005). APOE alleles predict 
the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology, 
65(12), 1888-1893.  
 
Matsuoka, Y., Picciano, M., Malester, B., LaFrancois, J., Zehr, C., Daeschner, J. M., 
Olschowka, J.A., et al. (2001). Inflammatory responses to amyloidosis in a transgenic 
mouse model of Alzheimer’s disease. The American Journal of Pathology, 158(4), 
1345-1354.  
 
Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., 
Yarasheski, K. E., et al. (2010). Decreased clearance of CNS β-amyloid in 
Alzheimer’s disease. Science, 330, 1774. 
 
McCusker, J., Cole, M., Dendukuri, N., Belzile, E., & Primeau, F. (2001). Delirium in 
older medical inpatients and subsequent cognitive and functional status: a prospective 
study. CMAJ, 165(5), 575-583. 
 
McGeer, P.L., Itagaki, S., & McGeer, E.G. (1988). Expression of the histocompatibility 















McGeer, E.G. & McGeer, P.L. (2003). Inflammatory processes in Alzheimer’s disease. 
Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27(5), 741-749.  
 
McGeer, P.L. & McGeer, E.G. (2007). NSAIDs and Alzheimer disease: epidemiological, 
animal model and clinical studies. Neurobiology of Aging, 28(5), 639-647.  
 
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. 
(1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA 
Work Group* under the auspices of Department of Health and Human Services Task 
Force on Alzheimer's disease. Neurology, 34(7), 939-944.  
 
McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., 
Klunk, W.E., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: 
recommendations from the National Institute on Aging-Alzheimer's Association 
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer’s & 
Dementia, 7(3), 263-269.  
 
Mickes, L., Wixted, J.T., Fennema-Notestine, C., Galasko, D., Bondi, M.W., Thal, L.J., 
Salmon, D.P. (2007). Progressive impairment on neuropsychological tasks in a 
longitudinal study of preclinical Alzheimer’s disease. Neuropsychology, 21, 696-705. 
 
Miller, B.L., Moats, R.A., Shonk, T., Ernst, T., Woolley, S., & Ross, B.D. (1993). 
Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR 
spectroscopy. Radiology, 187, 433-437. 
 
Minati, L., Edginton, T., Bruzzone, M. G., & Giaccone, G. (2009). Current concepts in 
Alzheimer’s disease: a multidisciplinary review. American Journal of Alzheimer’s 
Disease and other Dementias, 24(2), 95-121.  
 
Minghetti, L. (2005). Role of inflammation in neurodegenerative diseases. Current 
Opinion in Neurology, 18(3), 315-321.  
 
Moats, R.A., Ernst, T., Shonk, T.K., & Ross, B.D. (1994). Abnormal cerebral metabolite 
concentrations in patients with probable Alzheimer disease. Magnetic Resonance in 
Medicine, 32, 110-115.  
 
Motta, M., Imbesi, R., Di Rosa, M., Stivala, F., & Malaguarnera, L. (2007). Altered plasma 
cytokine levels in Alzheimer’s disease: correlation with the disease progression. 
Immunology Letters, 114(1), 46-51.  
 
Nagy, Z.S., Esiri, M.M., Jobst, K.A., Johnston, C., Litchfield, S., Sim, E., & Smith, A.D. 
(1995). Influence of the apolipoprotein E genotype on amyloid deposition and 

















Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991). Apolipoprotein 
E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in 
Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain 
Research, 541, 163-166.  
 
Nathan, B.P., Jiang, Y., Wong, G.K., Shen, F., Brewer, G.J., & Struble, R.G. (2002). 
Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in 
cultured adult mouse cortical neurons through the low-density lipoprotein receptor-
related protein. Brain Research, 928, 96-105.  
 
Nestor, P.J., Fryer, T.D., Smielewski, P., & Hodges, J.R. (2003). Limbic hypometabolism 
in Alzheimer’s disease and mild cognitive impairment. Annals of Neurology, 54(3), 
343-351.  
 
Nielsen, H., Lolk, A., Andersen, K., Andersen, J., & Kragh-Sørensen, P. (1999). 
Characteristics of elderly who develop Alzheimer's disease during the next two 
years—a neuropsychological study using CAMCOG. The Odense study. 
International Journal of Geriatric Psychiatry, 14, 957-963. 
 
Nizri, E., Hamra-Amitay, Y., Sicsic, C., Lavon, I., & Brenner, T. (2006). Anti-
inflammatory properties of cholinergic up-regulation: A new role for 
acetylcholinesterase inhibitors. Neuropharmacology, 50(5), 540-547.  
 
O’Connor, D.W., Pollitt, P.A., Brook, C.P.B., & Reiss, B.B. (1989). The validity of 
informant histories in a community study of dementia. International Journal of 
Geriatric Psychiatry. 4, 203–208.  
 
Okello, A., Edison, P., Archer, H.A., Turkheimer, F.E., Kennedy, J., Bullock, R., Walker, 
Z., et al. (2009). Microglial activation and amyloid deposition in mild cognitive 
impairment: a PET study. Neurology, 72(1), 56-62.  
 
Osotimehim, B. (2012). Ageing in the twenty-first century: A celebration and a challenge. 
New York: United Nations Population Fund (UNFPA), and London: HelpAge 
International.  
 
Osuntokun, B.O., Sahota, A., Ogunniyi, A.O., Gureje, O., Baiyewu, O., Adeyinka, A., 
Oluwole, S.O., et al. (1995). Lack of an association between apolipoprotein E epsilon 
4 and Alzheimer’s disease in elderly Nigerians. Annals of Neurology, 38, 463-465. 
 
Parachikova, A., Agadjanyan, M.G., Cribbs, D.H., Blurton-Jones, M., Perreau, V., Rogers, 
J., Beach, T.G., et al. (2007). Inflammatory changes parallel the early stages of 
Alzheimer disease. Neurobiology of Aging, 28(12), 1821-1833.  
 
Parnetti, L., Tarducci, R., Presciutti, O., Lowenthal, D.T., Pippi, M., Palumbo, B., Gobbi, 
G., et al. (1997). Proton magnetic resonance spectroscopy can differentiate 
Alzheimer’s disease from normal aging. Mechanisms of Ageing and Development, 















Pengas, G., Hodges, J.R., Watson, P., & Nestor, P.J. (2010). Focal posterior cingulate 
atrophy in incipient Alzheimer’s disease. Neurobiology of Aging, 31(1), 25-33.  
 
Perry, V.H. (2004). The influence of systemic inflammation on inflammation in the brain: 
implications for chronic neurodegenerative disease. Brain, Behavior, and Immunity, 
18(5), 407-413.  
 
Perry, V.H., Cunningham, C., & Holmes, C. (2007). Systemic infections and inflammation 
affect chronic neurodegeneration. Nature Reviews. Immunology, 7(2), 161-167.  
 
Petersen, R.C., Smith, G.E., Ivnik, R.J., Tnagalos, E.G., Schaid, D.J., Thibodeau, S.N., 
Kokmen, E., et al. (1995). Apolipoprotein E status as a predictor of the development 
of Alzheimer’s disease in memory-impaired individuals. JAMA, 273(16), 1274-1278.  
 
Petersen, R.C., Stevens, J.C., Ganguli, M., Tangalos, E.G., Cummings, J.L., & DeKosky, 
S.T. (2001a). Practice parameter: early detection of dementia: mild cognitive 
impairment (an evidence-based review): Report of the Quality Standards 
Subcommittee of the American Academy of Neurology. Neurology, 56(9), 1133-
1142.  
 
Petersen, R. C., Doody, R., Kurz, a, Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., 
et al. (2001b). Current concepts in mild cognitive impairment. Archives of neurology, 
58(12), 1985-92. 
 
Plassman, B.L. & Breitner, J.C.S. (1996). Apolipoprotein E and cognitive decline in 
Alzheimer’s disease. Neurology, 47(2), 317-320. 
 
Provencher S.W. (2008). LCModel & LCMgui User's Manual. Available at:  http://www.s-
provencher.com/pages/lcm-manual.shtml 
 
Ritchie, K. & Fuhrer, R. (1996). The validation of an informant screening test for 
irreversible cognitive decline in the elderly: performance characteristics within a 
general population. International Journal of Geriatric Psychiatry, 11, 149-156. 
 
Rodriguez, H., Brathwaite, D., & Dorsey, S. (2002). Depression and social support in the 
elderly population: a study of rural South African elders. Association of Black 
Nursing Faculty in Higher Education Journal, 13(2), 45-48.  
 
Rose, S., De Zubicaray, G., Wang, D., Galloway, G., Chalk, J., Eagle, S., Semple, J., et al. 
(1999). A 1H MRS study of probable Alzheimer’s disease and normal aging: 
implications for longitudinal monitoring of dementia progression. Magnetic 
Resonance Imaging, 17(2), 291-299.  
 
Rosenberg, P.B. (2005). Clinical aspects of inflammation in Alzheimer’s disease. 















Ross, L.K., Arnsberger, P., & Fox, P.J. (1998). The relationship between cognitive 
functioning and disease severity with depression in dementia of the Alzheimer’s type. 
Aging & Mental Health, 2(4), 319-327.  
 
Ross, A.J. & Sachdev, P.S. (2004). Magnetic resonance spectroscopy in cognitive research. 
Brain Research Reviews, 44(2-3), 83-102.  
 
Rossor, M. (1993). Alzheimer’s disease. British Medical Journal, 307, 779-782. 
 
Roth, M., Huppert, F.A., Mountjoy, C.Q., Tym, E. (1988). CAMDEX-R: The Cambridge 
Examination for Mental Disorders of the Elderly – Revised. Cambridge U.K.: 
Cambridge University Press. 
 
Rozemuller, J.M., Eikelenboom, P., & Stam, F.C. (1986). Role of microglia in plaque 
formation in senile dementia of the Alzheimer type. Virchows Archiv B Cell 
Pathology Including Molecular Pathology, 51(1), 247-254.  
 
Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., 
et al. (1989). Amyloid A4 protein and its precursor in Down’s syndrome and 
Alzheimer's disease. The New England Journal of Medicine, 320(22), 1446-1452.  
 
Sadeghi, H. M., Schnelle, J. F., Thomas, J. K., Nishanian, P., & Fahey, J. L. (1999). 
Phenotypic and functional characteristics of circulating monocytes of elderly persons. 
Experimental Gerontology, 34(8), 959-70.  
 
Sandholzer, C., Delport, R., Vermaak, H., & Utermann, G. (1995). High frequency of the 
apo ε4 allele in Khoi San from South Africa. Human Genetics, 95(1), 46-48.  
 
Sayi, J.G., Patel, N.B., Premkumar, D.R., Adem, A., Winblad, B., Matuja, W.B., Mtui, 
E.P., et al. (1997). Apolipoprotein E polymorphism in elderly East Africans. East 
African Medical Journal, 74(10), 668-670.  
 
Scacchi, R., Corbo, R.M., Rickards, O., Mantuano, E., Guevara, A., & De Stefano, G.F. 
(1997). Apolipoprotein B and E genetic polymorphisms in the Cayapa Indians of 
Ecuador. Human Biology, 69(3), 375-382. 
 
Scatena, M., Liaw, L., & Giachelli, C.M. (2007). Osteopontin: a multifunctional molecule 
regulating chronic inflammation and vascular disease. Arteriosclerosis, Thrombosis, 
and Vascular Biology, 27(11), 2302-2309.  
 
Schmidt, R., Schmidt, H., Curb, J. D., Masaki, K., White, L. R., & Launer, L. J. (2002a). 
Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging 















Schmidt, S., Barcellos, L.F., Desombre, K., Rimmler, J.B., Lincoln, R.R., Bucher, P., 
Saunders, A.M., et al. (2002b). Association of polymorphisms in the apolipoprotein E 
region with susceptibility to and progression of multiple sclerosis. American Journal 
of Human Genetics, 70, 708-717. 
 
Schrijvers, E.M.C., Koudstaal, P.J., Hofman, A., & Breteler, M.M.B. (2011). Plasma 
clusterin and the risk of Alzheimer disease. JAMA, 305(13), 1322-1326.  
 
Schuff, N., Amend, D. L., Knowlton, R., Norman, D., Fein, G., & Weiner, M. W. (1999). 
Age-related metabolic changes and volume loss in the hippocampus by magnetic 
resonance spectroscopy and imaging. Neurobiology of Aging, 20(3), 279-285. 
 
Schwartz, M. & Shechter, R. (2010). Systemic inflammatory cells fight off 
neurodegenerative disease. Nature Reviews. Neurology, 6(7), 405-410.  
 
Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque, G., Ikeda, M., Chi, H., 
et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial 
Alzheimer’s disease. Nature, 375(6534), 754-760.  
 
Shonk, T.K., Moats, R.A., Gifford, P., Michaelis, T., Mandigo, J.C., Izumi, J., & Ross, 
B.D. (1995). Probable Alzheimer disease: diagnosis with proton MR spectroscopy. 
Radiology, 195(1), 65-72.  
 
Siger, M., Schuff, N., Zhu, X., Miller, B.L., & Weiner, M.W. (2009). Regional myo-
inositol concentration in mild cognitive impairment using 1H magnetic resonance 
spectropic imaging. Alzheimer Disease and Associated Disorders, 23(1), 57-62. 
 
SigmaPlot; version 11. User's Manual. Available at: 
http://www.scribd.com/doc/81681782/Sigma-Plot-11-Users-Guide 
 
Slezak, M. & Pfrieger, F.W. (2003). New roles for astrocytes: regulation of CNS 
synaptogenesis. Trends in Neurosciences, 26(10), 531-535.  
 
Slooter, A. J., de Knijff, P., Hofman, A., Cruts, M., Breteler, M.M., Van Broeckhoven, C., 
Havekes, L.M., et al. (1998). Serum apolipoprotein E level is not increased in 
Alzheimer’s disease: the Rotterdam study. Neuroscience Letters, 248(1), 21-24. 
 
Sly, L.M., Krzesicki, R.F., Brashler, J.R., Buhl, A.E., Mckinley, D.D., Carter, D.B., & 
Chin, J.E. (2001). Endogenous brain cytokine mRNA and inflammatory responses to 
lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of 
Alzheimer’s disease. Brain Research Bulletin, 56(6), 581-588. 
 
Small, G.W., Mazziotta, J.C., Collins, M.T., Baxter, L.R., Phelps, M.E., Mandelkern, M., 
Kaplan, A., et al. (1995). Apolipoprotein E type 4 allele and cerebral glucose 
















Small, B.J., Graves, A.B., McEvoy, C.L., Crawford, F.C., Mullan, M., & Mortimer, J.A. 
(2000). Is APOE-ε4 a risk factor for cognitive impairment in normal aging? 
Neurology, 54(11), 2082-2088.  
 
Smith, G.E., Bohac, D.L., Waring, S.C., Kokmen, E., Tangalos, E.G., Ivnik, R.J., & 
Petersen, R.C. (1998). Apolipoprotein E genotype influences cognitive “phenotype” 
in patients with Alzheimer’s disease but not in healthy control subjects. Neurology, 
50(2), 355-362. 
 
Soares, H.D., Potter, W.Z., Pickering, E., Kuhn, M., Immermann, F.W., Shera, D.M., 
Ferm, M., et al. (2012). Plasma biomarkers associated with the apolipoprotein E 
genotype and Alzheimer disease. Archives of Neurology, 69(10), 1310-1317.  
 
Sonnen, J.A., Montine, K.S., Quinn, J.F., Kaye, J.A., Breitner, J.C.S., & Montine, T.J. 
(2008). Biomarkers for cognitive impairment and dementia in elderly people. The 
Lancet Neurology, 7(8), 704-714.  
 
Sorbi, S., Nacmias, B., Piacentini, S., Repice, A., Latorraca, S., Forleo, P., & Amaducci, L. 
(1995). ApoE as a prognostic factor for post-traumatic coma. Nature Medicine, 1(9), 
852. 
 
Stafford, G.I., Pedersen, M.E., van Staden, J., & Jäger, A.K. (2008). Review on plants with 
CNS-effects used in traditional South African medicine against mental diseases. 
Journal of Ethnopharmacology, 119(3), 513-537. 
 
Statistics South Africa (2012). 2011 Census Report. Statistical release (Revised) P0301.4. 
Pretoria: Statistics South Africa 
 
Stern, Y. (2006). Cognitive reserve and Alzheimer’s disease. Alzheimer’s Disease and 
Associated Disorders, 20, 112-117.  
 
Stern, Y. (2009). Cognitive reserve. Neuropsychologia, 47(10), 2015-2028.  
 
Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., Pericak-
Vance, M., Schmechel, D., et al. (1993). Binding of human apolipoprotein E to 
synthetic amyloid β peptide: isoform-specific effects and implications for late-onset 
Alzheimer disease. PNAS, 90(17), 8098-8102.  
 
Sullivan, P.M., Han, B., Liu, F., Mace, B.E., Ervin, J.F., Wu, S., Koger, D., et al. (2011). 
Reduced levels of human apoE4 protein in an animal model of cognitive impairment. 
Neurobiology of Aging, 32(5), 791-801. 
 
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. 
















Szekely, C.A., Breitner, J.C.S., Fitzpatrick, A.L., Rea, T.D., Psaty, B.M., Kuller, L.H., & 
Zandi, P.P. (2008). NSAID use and dementia risk in the cardiovascular health study: 
role of APOE and NSAID type. Neurology, 70(1), 17-24.  
 
Teasdale, G.M., Nicoll, J.A.R., Murray, G., & Fiddes, M. (1997). Association of 
apolipoprotein E polymorphism with outcome after head injury. The Lancet, 350, 
1069-1071. 
 
Thal, D.R., Rüb, U., Orantes, M., Braak, H. (2002). Phases of Aβ-depostion in the human 
brain and its relevance for the development of AD. Neurology, 58, 1791-1800.  
 
Thal, D.R., Larionov, S., Abramowski, D., Wiederhold, K.H., Van Dooren, T., 
Yamaguchi, H., Haass, C., et al. (2007). Occurrence and co-localization of amyloid 
beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and 
APP-transgenic mice. Neurobiology of Aging, 28(8), 1221-1230.  
 
Tiraboschi, P., Hansen, L.A., Masliah, E., Alford, M., Thal, L.J., & Corey-Bloom, J. 
(2004). Impact of APOE genotype on neuropathologic and neurochemical markers of 
Alzheimer disease. Neurology, 62(11), 1977-1983.  
 
Tohgi, H., Takahashi, S., Kato, E., Homma, A., Niina, R., Sasaki, K., Yonezawa, H., et al. 
(1997). Reduced size of right hippocampus in 39- to 80-year-old normal subjects 
carrying the apolipoprotein E ε4 allele. Neuroscience Letters, 236(1), 21-24.  
 
Tracey, K.J. (2002). The inflammatory reflex. Nature, 420, 853-859. 
 
U.S. Census Bureau. (2012). International database. Accessed November 27, at 
www.census.gov/population/international/data/idb/informationGateway.php 
 
Utermann, G., Langenbeck, U., Beisiegel, U., & Weber, W. (1980). Genetics of the 
apolipoprotein E system in man. American Journal of Human Genetics, 32(3), 339-
347.  
 
Valenzuela, M. & Sachdev, P. (2001). Magnetic resonance spectroscopy in AD. 
Neurology, 56(1), 592-598.  
 
van den Elzen, P., Garg, S., León, L., Brigl, M., Leadbetter, E.A., Gumperz, J.E., Dascher, 
C.C., et al. (2005). Apolipoprotein-mediated pathways of lipid antigen presentation. 
Nature, 437(7060), 906-910.  
 
Van Duijn, C.M., Clayton, D., Chandra, V., Fratiglioni, L., Graves, A. B., Heyman, A., 
Jorm, A. F., et al. (1991). Familial aggregation of Alzheimer’s disease and related 
disorders: A collaborative re-analysis of case-control studies. International Journal of 















van Gool, W.A, van de Beek, D., & Eikelenboom, P. (2010). Systemic infection and 
delirium: when cytokines and acetylcholine collide. The Lancet, 375(9716), 773-775.  
 
Van Oosten, M., Rensen, P.C., Van Amersfoort, E.S., Van Eck, M., Van Dam, A.M., 
Breve, J.J., Vogel, T., et al. (2001). Apolipoprotein E protects against bacterial 
lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-
negative sepsis. The Journal of Biological Chemistry, 276(12), 8820-8824.  
 
Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, 
D.B., et al. (1999). β-Secretase cleavage of Alzheimer’s amyloid precursor protein by 
the transmembrane aspartic protease BACE. Science, 286(5440), 735-741.  
 
Vasto, S., Candore, G., Balistreri, C.R., Caruso, M., Colonna-Romano, G., Grimaldi, M.P., 
Listi, F., et al. (2007). Inflammatory networks in ageing, age-related diseases and 
longevity. Mechanisms of Ageing and Development, 128(1), 83-91. 
 
Vehmas, A.K., Kawas, C.H., Stewart, W.F., & Troncoso, J.C. (2003). Immune reactive 
cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiology of 
Aging, 24, 321-331. 
 
Vlad, S.C., Miller, D.R., Kowall, N.W., & Felson, D.T. (2008). Protective effects of 
NSAIDs on the development of Alzheimer disease. Neurology, 70(19), 1672-1677.  
 
Walker, Z., Allen, R.L., Shergill, S., & Katona, .L. (1997). Neuropsychological 
performance in Lewy body dementia and Alzheimer's disease. The British Journal of 
Psychiatry, 170, 156-158. 
 
Walsh, B., Slater, S., Nair, B., & Attia, J. (2013). The relationship between the 
apolipoprotein E ε4 allele and hippocampal magnetic resonance imaging volume in 
community-dwelling individuals with mild Alzheimer’s disease. Degenerative 
Neurological and Neuromuscular Disease, 3, 11-14. 
 
Wang, Z., Zhao, C., Yu, L., Zhou, W., & Li, K. (2009). Regional metabolic changes in the 
hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance 
spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta 
Radiologica, 50(3), 312-319.  
 
Wang, T., Xiao, S., Li, X., Ding, B., Ling, H., Chen, K., & Fang, Y. (2012). Using proton 
magnetic resonance spectroscopy to identify mild cognitive impairment. International 
Psychogeriatrics, 24(1), 19-27.  
 
Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., et 
al. (2001). A subset of NSAIDs lower amyloidogenic Aβ42 independently of 
cyclooxygenase activity. Nature, 414(6860), 212-216.  
 
Weninger, S.C. & Yankner, B.A. (2001). Inflammation and Alzheimer’s disease: The 















Whitmer, R.A, Sidney, S., Selby, J., Johnston, S.C., & Yaffe, K. (2005). Midlife 
cardiovascular risk factors and risk of dementia in late life. Neurology, 64(2), 277-
281.  
 
Whitmer, A., Karter, A.J., Yaffe, K., Quesenberry, C.P., & Selby, J.V. (2009). 
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes 
mellitus. JAMA, 301(15), 1565-1572.  
 
Wiley, C.A, Lopresti, B.J., Venneti, S., Price, J., Klunk, W.E., DeKosky, S.T., & Mathis, 
C.A. (2009). Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-
PK11195 positron emission tomographic imaging in Alzheimer disease. Archives of 
Neurology, 66(1), 60-67.  
 
Wilson, R.S., Barnes, L.L., Bennett, D.A., Li, Y., Bienias, J.L., Mendes de Leon, C.F., & 
Evans, D.A. (2005). Proneness to psychological distress and risk of Alzheimer disease 
in a biracial community. Neurology, 64(2), 380-382.  
 
Wimo, A., Winblad, B., & Jönsson, L. (2007). An estimate of the total worldwide societal 
costs of dementia in 2005. Alzheimer’s & Dementia, 3(2), 81-91. 
 
Wisniewski, K.E., Wisniewski, H.M., & Wen, G.Y. (1985). Occurrence of 
neuropathological changes and dementia of Alzheimer’s disease in Down's syndrome. 
Annals of Neurology, 17(3), 278-282. 
 
World Health Organization (WHO). (2012). Dementia, A public health priority. United 
Kingdom: WHO. 
 
Wung, J.K., Perry, G., Kowalski, A., R. Harris, P., Bishop, G.M., Trivedi, M.A., Johnson, 
S., et al. (2007). Increased expression of the remodeling- and tumorigenic-associated 
factor osteopontin in pyramidal neurons of the Alzheimer's disease brain. Current 
Alzheimer Research, 4(1), 67-72.  
 
Wyss-Coray, T, Lin, C., Yan, F., Yu, G.Q., Rohde, M., McConlogue, L., Masliah, E., et al. 
(2001). TGF-β1 promotes microglial amyloid-beta clearance and reduces plaque 
burden in transgenic mice. Nature Medicine, 7(5), 612-618.  
 
Wyss-Coray, T., Loike, J. D., Brionne, T.C., Lu, E., Anankov, R., Yan, F., Silverstein, 
S.C., et al. (2003). Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. 
Nature Medicine, 9(4), 453-457. 
 
Wyss-Coray, T. & Rogers, J. (2012). Inflammation in Alzheimer disease - a brief review of 
the basic science and clinical literature. Cold Spring Harbor Perspectives in 
Medicine, 2, a006346. 
 
Ye, S.M. & Johnson, R.W. (1999). Increased interleukin-6 expression by microglia from 















Yermakova, A.V. & O'Banion, M.K. (2001). Downregulation of neuronal cyclooxygenase-
2 expression in end stage Alzheimer’s disease. Neurobiology of Aging, 22, 823-836. 
 
Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M., & Leirer, V.O. 
(1983). Development and validation of a geriatric depression screening scale: a 
preliminary report. Journal of Psychiatric Research, 17(1), 37-49.  
 
Zannis, V.I., Kardassis, D., & Zanni, E.E. (1993). Genetic mutations affecting human 


















   
 
 
MRI Volunteer Screening Form 
                         
Volunteer Information:   
Name Contact number 
Date of Birth Project name 
Weight Principle investigator 
 
The following information is very important to ensure your safety and to prevent any interference during the 
MR procedure. 
 
Please answer the following questions (mark with an X):                   Yes          No           Don’t 
know 
Pacemaker    
Aneurism clips    
Artificial heart valve    
Vena cava filter    
Prosthesis (e.g. eye, breast etc)    
Shrapnel in eye or body    
Neurostimulator    
Cochlear implant (ear) or hearing aid    
? Diabetic    
? Renal impairment    
? Asthma    
? Allergies    
? Any other implants (e.g. screws, plates, joint replacements)    
? Pregnant    
? Previous MRI investigation with intravenous contrast    
Is there any other device implanted or are there 
any other ailments that you think that we should be 
aware of? 
   
                                                                                                                      
I hereby acknowledge that the potential risks of the examination have been explained to me and that during 
the course of the investigation it may be necessary for the intravenous injection of a contrast agent. 
 
Attention: It is the policy of this institution not to discuss results of the MR investigation with the patients for 
ethical reasons.  All enquiries in this regard should be directed to the referring physician. 
 
 
















PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: Risk factors for the development of cognitive 
impairment in the elderly  
 
PROTOCOL NUMBER:   
 
PRINCIPAL INVESTIGATOR: Dr Marc I Combrinck 
 
ADDRESS:   Divisions of Neurology and Geriatric Medicine, Department of Medicine, E7 Room 63, 
Groote Schuur Hospital, Private Bag X3, Observatory, Cape 7935 
 
CONTACT NUMBER: +27 21 404 3198 or 404 3120 
 
We are inviting you to participate in a research project. Please take some time to read the information 
presented here. It explains the details of the project. If there are any aspects of the project you do not 
understand, please do not hesitate to ask the study staff or doctor.  It is important that you are fully satisfied 
that you clearly understand what this research entails and how you could be involved.  Your participation in 
the study is entirely voluntary and you are free to decline to participate.  If you say no, this will not affect you 
negatively in any way whatsoever.  It will not affect any future medical treatment you may need. You are 
also free to withdraw from the study at any point, even if you did initially agree to take part. You do not have 
to give a reason for withdrawing. 
 
This study has been approved by the Research Ethics Committee of the Faculty of Health Sciences of 
the University of Cape Town. It will be conducted according to the ethical guidelines and principles of 
the International Declaration of Helsinki, the South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
This trial is being run by the Division of Neurology and the Institute of Ageing in Africa in the Department 
of Medicine at the University of Cape Town. We aim to recruit a total of 150 participants over a period of 3 
years. 
 
What is this research study all about?  
 
Some people develop memory problems as they get older. Many elderly people have mild memory 
difficulties.  However, in a few, the problem may be more severe. We are interested in finding out more 
about what causes the difficulties with memory and other higher brain functions.  In order to do so, we 
should like to investigate these possible causes using a number of methods. These include blood tests, 
questions you would need to answer about yourself, tests of memory and other higher brain functions, a CT 
scan of the brain, and tests of your saliva. In some instances we may, with your special permission, perform 
tests on the fluid covering your brain and spine by doing a lumbar puncture.  We shall also ask some of you 
to undergo a special scan known as an MRI at our research facility at Tygerberg Hospital. 
 
We are interested in testing people both with memory difficulties and those without, so that we can compare 
the two groups. In this way we might be able to identify causes of memory impairment. Our research 




If you agree to take part in the study and you meet all the conditions required to enter the study, you will be 
invited to visit our clinic on two separate days.  At these visits to our clinic we shall: 
 
(1) take a detailed history.  
(2) interview your relative/friend (someone who knows you well) to find out whether he/she thinks 













(3) perform a full physical examination. This will include measuring your blood pressure, listening to 
your heart and chest, examining the nervous system and testing your urine. 
(4) take approximately 36 ml (7 tablespoons) of blood to look for possible causes of memory 
impairment. These will include: 
 
(i) a blood sugar (glucose) (for diabetes) 
(ii) a blood cholesterol level 
(iii) tests of liver, kidney and thyroid gland function 
(iv) haemoglobin, blood cell counts 
(v) tests for vitamins or vitamin deficiences (vitamin B-12 and homocysteine) 
(vi) a test for syphilis. (This test is routinely performed in hospital clinics because syphilis 
used to be a common cause of impairment of higher brain function in the past)  
(vii) a sample to measure inflammation in the blood (cytokines) 
 
(viii) one sample will be used to prepare DNA from your blood. We shall test this for a gene 
called apolipoprotein E (APOE). Some forms of this gene may be associated with a 
higher risk of developing memory problems. However, this test does not diagnose that 
you have, or will necessarily develop, memory problems. We are doing it purely for 
research; it may help us to better understand some causes of memory difficulties.  
 
(ix) A test for a chemical in the blood known as clusterin.  This chemical may be increased 
in people with memory difficulties. 
 
(5) We shall ask you to complete questionnaires about yourself and we shall perform tests of your 
memory and other higher mental functions. These will be conducted in a quiet, relaxed 
atmosphere. We expect that these tests will be of about two hours’ duration. However, there will 
be opportunities to rest in-between tests. 
 
(6) We shall perform a CT scan of the brain. This is a special X-ray photograph that will show us the 
structure of your brain. It can detect lumps or masses inside the head and it might also give us 
some idea about brain shrinkage.  It will also show any obvious strokes that you might have had. 
If you like, we shall show you the pictures at the second visit. 
 
(7) In some instances we may wish to perform a lumbar puncture to obtain a sample of the fluid (the 
cerebrospinal fluid or CSF) that surrounds the brain and the spinal cord. We shall only perform 
this test with your special permission and if we think the test will help diagnose and treat the cause 
of your memory problems.  We shall send the sample to the laboratory to test for infection or 
inflammation. We shall also store a sample in the freezer to be analysed at a later stage for 
chemicals related to inflammation (cytokines). 
   
If we think a lumbar puncture is necessary and if you agree, the test will be performed in our Neurology 
Ward at the Groote Schuur Hospital. You will need to rest in bed, lying flat, for a couple of hours afterwards. 
The test is usually well tolerated, especially in elderly people, and there are usually no side-effects. 
Occasionally some people develop headaches after the test, often a day or two later. We generally advise 
people to have a restful two days after the procedure and to drink plenty of fluids.  Should headaches occur, 
they are usually relieved by lying down flat and taking simple pain-killers like paracetamol. Very rarely, 
some people (usually young adults) develop quite bad headaches and for this we may need to re-admit you to 
our hospital ward for pain relief.  We shall telephone all participants a day or two after the lumbar puncture 
to make sure they are okay. 
 
(8) We shall measure the levels of a stress hormone, cortisol, in your saliva (“spit”).  You or your 
relative will be asked to swab a sample of your saliva on three consecutive mornings at 09h00 a.m. 
We shall provide the swabs and the containers as well as clear instructions about how to collect 
and store the samples. The samples need to be kept refrigerated and one of the staff of our study 
group will collect them from you. 
 
If we find any abnormal results that we think will need further treatment, we shall contact you. With your 
permission, we shall refer you to to the appropriate health services. For example, we may diagnose 













memory problem that is interfering with your daily living activities, we shall refer you to a Memory Clinic. 
Your permission will always be sought first. 
 
(9) Some participants in the study will be asked to undergo a special type of brain scan which will be 
performed at the Cape Universities Brain Imaging Centre (CUBIC) at Tygerberg Hospital. This 
scan is called an MRI (magnetic resonance imaging) scan. It provides a detailed picture of the 
brain including the parts involved in memory. We are also able to measure chemicals in parts of 
the brain using what’s known as magnetic resonance spectroscopy (MRS).  
We shall provide transport for you to the facility at Tygerberg Hospital where necessary. On arrival we 
shall ask you and your relative questions regarding the following: whether you have had a cardiac 
pacemaker, a neuro-stimulator, previous eye injuries or a foreign body, previous neurosurgery, previous 
other surgery involving metal implants, a cochlear implant, whether you have been a welder or metal 
grinder and whether you are claustrophobic or not. The scan will require you to lie on your back on a table 
that will move into the scanning machine for the 30 to 40 minutes it will take for the scan to be completed. 
During this time you will be able to close your eyes and rest. You will also be able to talk to the study 
doctor/assistant at all times during the scan should you experience any discomfort. The scan is a safe 
procedure if you have been screened correctly for the presence of any magnetic material on or inside your 
body. As the scan is done in a relatively confined space, occasionally some people become anxious. This 
does not happen often, and if you feel anxious beforehand, we will spend time allowing you to get used to the 
surroundings before we begin. When the magnet in the machine is switched on, it will make some loud 
banging noises, but you will be clearly warned when this will take place. At this time you will feel nothing 
and the noise is not harmful to you in any way. To minimise the possible discomfort associated with this, we 
will give you some soft earplugs and will also put earphones on so that you can listen to music if you so 
choose.  
After the two baseline visits and the three collectins of saliva, we would like to re-assess your memory 
functions again at one, two and three years later, respectively, provided you continue to consent to 
participation in the study. 
 
What will your responsibilities be? 
You will be required to attend the study visit at the appropriate time and to participate as fully as you can 
with the tests and questionnaires. You should answer the questions as fully and honestly as you can. If there 
are any questions that you cannot, or do not wish to answer, you should tell us so. 
Will you benefit from taking part in this study? 
You will receive little direct benefit from the study. 
However, you will undergo a thorough medical check-up as part of the research protocol. As previously 
indicated, we shall, with your permission,  refer you to the appropriate medical services if any treatable 
abnormalities are found. 
Are there any risks in your taking part in this research? 
 
You may feel uncomfortable about answering some of the questions about yourself or your friend/relative. 
Some people don’t like talking, or knowing about, problems related to memory or thinking. You should feel 
free to mention your feelings or concerns to any member of the study team. 
 
If you do not agree to take part, what alternatives do you have? 
You are free not to participate in the study or to refuse parts of the study.  
 
Who will have access to your medical records? 
The information collected about you will be treated as confidential and protected.  If it is used in a 
publication or thesis, your identity will remain anonymous.  Only the direct study team will have full access 
to the information. If we need to refer you to a clinic for treatment, we will provide them with the relevant 
information needed to treat your condition.  
Will you be paid to take part in this study and are there any costs involved? 
You will not be paid to take part in the study but your transport costs will be covered for the study 















Is there anything else that you should know or do? 
 You should inform your family practitioner or usual doctor that you are taking part in a 
research study.   
 You can contact Dr Marc Combrinck at tel 021-4043198 or 404 3120 if you have any further 
queries or encounter any problems. 
 You can contact the Research Ethics Committee of the Health Sciences Faculty of the 
University of Cape Town 021-4066338 if you have any concerns or complaints that have not 
been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
Declaration by participant and/or friend/relative/guardian 
By signing below, I …………………………………..…………., hereby agree to take part in the research 
study entitled: “Risk Factors for Cognitive Impairment in the Elderly” 
 
I declare that: 
 I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to take 
part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher feels it 
is in my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2012. 
 
 ....................................................................................  
Signature of participant Signature of witness 
 ....................................................................................  
Signature of relative/friend/guardian Signature of witnes 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign the 
declaration below). 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2012. 
 
 
















Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium of Afrikaans / Xhosa 
(delete whichever is not applicable). 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2012. 
 
 ....................................................................................  .................................................................................  
 















Deterioration Cognitive Observee (DECO) 
 
We would like you to tell us how your relative was a year ago. The following questions ask about a number 
of everyday situations. We would like you to tell us whether in these situations he/she is doing about the 
same, not as well or much worse, than a year ago. Place a tick in the relevant column to show your response.  
 







1. Does he/she remember as well as before which day of the week 
and which month it is? 
   
2. When he/she goes out of the house, does he/she know her way as 
well as before? 
   
3. Have there been changes in his/her ability to remember his/her 
own address or telephone number 
   
4. In the house, does he/she remember as well as before where things 
are usually kept? 
   
5. And when an object isn’t in its usual place, is he/she capable of 
finding it again? 
   
6. In comparison with a year ago, how well is he/she able to use 
household appliances (washing machine, etc….)? 
   
7. Has his/her ability to dress or undress changed at all?    
8. How well does he/she manage his/her money, for example, doing 
the shopping? 
   
9. Apart from difficulties due to physical problems, has there been a 
reduction in his/her activity level? 
   
10. How well can he/she follow a story on television, in a book or 
told by someone? 
   
11. And writing letters for business or to friends; does he/she do this 
as well as a year ago? 
   
12. How well does he/she recall a conversation you had with him/her 
a few days ago? Has this changed over the past year? 
   
13. And if you remind him/her of this conversation, does he/she still 
have difficulty remembering it in comparison to a year ago? 
   
14. Does he/she forget what he/she wanted to say in the middle of a 
conversation? Has this changed over the past year? 
   
15. In a conversation, does he/she sometimes have difficulty finding 
the right word? 
   
16. In comparison with a year ago, how well does he/she recognize 
the faces of people he/she knows well? 
   
17. And how well does he/she remember the names of these people?    
18. In comparison with a year ago, how well does he/she remember 
other details concerning people he/she knows well; where they live, 
what they do? 
   
19. Over the past year, have there been changes in his/her ability to 
remember what has happened recently? 

















The Bristol Activities of Daily Living Scale (BADLS) 
 
This questionnaire is designed to reveal the everyday ability of people who have 
memory difficulties of one form or another. For each activity (Nos. 1-20), statements 
a-e refer to a different level of ability. Thinking of the last 2 weeks, tick the box that 
represents your relative's/friend's ability. 
Only 1 box should be ticked for each activity. 
(If in doubt about which box to tick, choose the level of ability which represents their 
average performance over the last 2 weeks). 
 
1. FOOD  
 a. Selects and prepares food as required      [    ]  
 b. Able to prepare food if ingredients set out     [    ]  
 c. Can prepare food if prompted step by step     [    ]  
 d. Unable to prepare food even with prompting and supervision  [    ] 
 e. Not applicable        [    ]  
 
2. EATING  
 a. Eats appropriately using correct cutlery     [    ] 
 b. Eats appropriately if food made manageable and/or uses spoon [    ] 
 c. Uses fingers to eat food        [    ] 
 d. Needs to be fed         [    ] 
 e. Not applicable         [    ] 
 
3. DRINK 
 a. Selects and prepares drinks as required     [    ] 
 b. Can prepare drinks if ingredients left available    [    ] 
 c. Can prepare drinks if prompted step by step     [    ] 
 d. Unable to make a drink even with prompting and supervision  [    ] 
 e. Not applicable         [    ] 
 
4. DRINKING 
 a. Drinks appropriately        [    ] 
 b. Drinks appropriately with aids, beaker/straw etc.    [    ] 
 c. Does not drink appropriately even with aids but attempts to   [    ] 
 d. Has to have drinks administered (fed)      [    ] 
 e. Not applicable         [    ] 
 
5. DRESSING 
 a. Selects appropriate clothing and dresses self    [    ] 
 b. Puts clothes on in wrong order or back to front or dirty clothing [    ] 













 d. Unable to assist and requires total dressing    [    ] 
 e. Not applicable        [    ] 
 
6. HYGIENE 
 a. Washes regularly and independently     [    ] 
 b. Can wash self if given soap, flannel, towel,    [    ] 
 c. Can wash self if prompted and supervised    [    ] 
 d. Unable to wash self and needs full assistance    [    ] 
 e. Not applicable        [    ] 
 
7. TEETH 
 a. Cleans own teeth/dentures regularly and independently   [    ] 
 b. Cleans teeth/dentures if given appropriate items    [    ] 
 c. Requires some assistance, toothpaste on brush, brush to mouth, etc. [    ] 
 d. Full assistance given        [    ] 
 e. Not applicable          [    ] 
8. BATH/SHOWER 
 a. Bathes regularly and independently      [    ] 
 b. Needs bath to be drawn/shower turned on but washes independently  [    ] 
 c. Needs supervision and prompting to wash     [    ] 
 d. Totally dependent, needs full assistance      [    ] 
 e. Not applicable          [    ] 
 
9. TOILET/COMMODE 
 a. Uses toilet appropriately when required      [    ] 
 b. Needs to be taken to the toilet and given assistance     [    ] 
 c. Incontinent of urine or faeces       [    ] 
 d. Incontinent of urine and faeces        [    ] 
 e. Not applicable         [    ] 
  
10. TRANSFERS 
 a. Can get in/out of chair unaided       [    ] 
 b. Can get into a chair but needs help to get out     [    ] 
 c. Needs help getting in and out of a chair      [    ] 
 d. Totally dependent on being put into and lifted from chair    [    ] 
 e. Not applicable             [    ] 
 
11. MOBILITY 
 a. Walks independently        [    ] 
 b. Walks with assistance, i.e. furniture, arm for support     [    ] 
 c. Uses aids to mobilize, i.e. frame, sticks etc.     [    ] 
 d. Unable to walk          [    ] 















 a. Fully orientated to time/day/date etc.       [    ] 
 b. Unaware of time/day etc but seems unconcerned       [    ] 
 c. Repeatedly asks the time/day/date      [    ] 
 d. Mixes up night and day        [    ] 
 e. Not applicable         [    ] 
 
13.  ORIENTATION—SPACE 
 a. Fully orientated to surroundings       [    ] 
 b. Orientated to familiar surroundings only     [    ] 
 c. Gets lost in home, needs reminding where bathroom is, etc.   [    ] 
 d. Does not recognize home as own and attempts to leave   [    ] 
 e. Not applicable         [    ] 
 
14. COMMUNICATION  
 a. Able to hold appropriate conversation     [    ] 
 b. Shows understanding and attempts to respond verbally with gestures[    ] 
 c. Can make self understood but difficulty understanding others  [    ] 
 d. Does not respond to or communicate with others   [    ] 
 e. Not applicable        [    ] 
 
15. TELEPHONE 
 a. Uses telephone appropriately, including obtaining correct number [    ] 
 b. Uses telephone if number given verbally/visually or predialled [    ] 
 c. Answers telephone but does not make calls    [    ] 
 d. Unable/unwilling to use telephone at all     [    ] 
 e. Not applicable         [    ] 
 
16. HOUSEWORK/GARDENING 
 a. Able to do housework/gardening to previous standard   [    ] 
 b. Able to do housework/gardening but not to previous standard [    ] 
 c. Limited participation even with a lot of supervision   [    ] 
 d. Unwilling/unable to participate in previous activities   [    ] 
 e. Not applicable        [    ] 
 
17. SHOPPING 
 a. Shops to previous standard      [    ] 
 b. Only able to shop for 1 or 2 items with or without a list  [    ] 
 c. Unable to shop alone, but participates when accompanied  [    ] 
 d. Unable to participate in shopping even when accompanied  [    ] 















 a. Responsible for own finances at previous level    [    ] 
 b. Unable to write cheque but can sign name and recognizes  
  money values        [    ] 
 c. Can sign name but unable to recognize money values   [    ] 
 d. Unable to sign name or recognize money values   [    ] 
 e. Not applicable        [    ] 
19. GAMES/HOBBIES 
 a. Participates in pastimes/activities to previous standard  [    ] 
 b. Participates but needs instruction/supervision    [    ] 
 c. Reluctant to join in, very slow, needs coaxing    [    ] 
 d. No longer able or willing to join in     [    ] 
 e. Not applicable        [    ] 
 
20. TRANSPORT 
 a. Able to drive, cycle or use public transport independently  [    ] 
 b. Unable to drive but uses public transport or bike etc   [    ] 
 c. Unable to use public transport alone     [    ] 
 d. Unable/unwilling to use transport even when accompanied  [    ] 
 e. Not applicable        [    ] 
 
















Geriatric Depression Scale (GDS) 
Choose the best answer for how you have felt over the past week: 
1. Are you basically satisfied with your life?     YES / NO 
2. Have you dropped many of your activities and interests?    YES / NO 
3. Do you feel that your life is empty?      YES / NO  
4. Do you often get bored?        YES / NO 
5. Are you in good spirits most of the time?      YES / NO 
6. Are you afraid that something bad is going to happen to you?   YES / NO 
7. Do you feel happy most of the time?      YES / NO 
8. Do you often feel helpless?       YES / NO 
9. Do you prefer to stay at home, rather than going out and doing new things? YES / NO 
10. Do you feel you have more problems with memory than most?   YES / NO 
11. Do you think it is wonderful to be alive now?     YES / NO 
12. Do you feel pretty worthless the way you are now?    YES / NO 
13. Do you feel full of energy?       YES / NO 
14. Do you feel that your situation is hopeless?     YES / NO 
















Bio-Plex Pro Assay (Biorad), manufactures booklet: Pages 4 and 5. 
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Assay Quick Guide 
For experienced users, the following guide can be used to prepare and IUl a 
si1gIa 96-well assay plate. For more infoonation on a given step, refer to the 
detaled instructions i1 the corresponding section of the ma'lUai 
....... 1. __ quick ""Ide. 
5. -.,-. single vial of __ In eoo ~I of tho appropriate 
4 diluent. _ex om __ 00 100 (30 mini 
• For serum and plasma samplee. u.- Bb-Au. standard dikaTr 
• For Ct.JItln supeti ...... l. usecufture meclum" 
• F« ""'-- _ 0< _1Iu1el, uao butler _to sample· 
B. ~ the 8 point __ dlUlion _ om blank. 
• Add 721'1 di_t to lube 81, om 150 1'1 diluont to 
tubes $2-8 and blank. 
• Transfer 128 loll reconstituted standW Into S1 
• Then serially dilute 4 fold from 81 thru sa by transferring 50 1-11 
between tubes. Vortex between b'anafera 
5 7. Once thawed, prepare 1x lampl •• 
• Activate TGF-Ii samples by adding 1 volume of 1 N Hel to 
5 volumes of sample (eg, 5 ..-1 to 26 IJI of ample). Vortex, incubate at 
AT 1 0 min. Neutralize by adding the eame volume (5 j.l0 
• Dilute serum, plasma and Iyuteliin Bio-Plex ample diluent 
• Dilute culture supernatants In culture medium" 
• Dilute lavage, sputum, or other fluid In buffer similar to sample** 
e 8. Prepare 1x coupled beads In assay buffer. protect from light 
• From 1Oxstock: Add 575I0Il beads to 5.176 ~ buffer 
• From 20x stock: Add 288 ~ bead8 to 6,4721J1 buffer 
Refer to section 4 for instructions on preparilg an appropriate standard dJuent far TGF-P 
8888y8 when rurrilg aerun or pBsma~. 
- Make sura to add protein CMier such as BSA to B frIa concentration of 0.5% to lavage, 
eputun, IV'ld 8El\Jrn free autura medi.m SEVJ1)IeB as deSCribed n sectioo s. ~ end 
standards shotJd be reconstituted WldI or dlJted n this same medum. 
4 
_1. "-... Ick ........ CGII'L 
I~ 
7 11. .. , with 1 00 ~I _ buller , ...... u, 
2. Add 50 1'1 of Ix beads to the ..... y pla1e 
3. W..h 2 dm .. with 100 III wah butTer 
4. Add 60 III samples, standards, blank, controls 
5. Cover and incubate in the dark at RT with shaking at SOD RPM 
• 30 min - Human Group I,ll and Mouse Group I,ll 
• 1 hour - Mouse Group III and Rat Group I 
• 2 hours - TGF-~ 
WiII110 min _"90 _Ix DeIectIon Ab In cIIotectIon dbody diluent. 
• From lOx stock: Add 300 1'1 Ab to 2,700 ~I diluent 
• From 20x stock: Add 150 1'1 Ab to 2,850 ~I diluent 
6. _3 __ 100111 __ 
7. Add 251'1 of __ dbody 
8. Cover and Inct.t>ate In the dark at RT with IIhaklng at 300 RPM 
• 30 min - Human Group 1.11; Mouse Group 1.11,111; and Rat Group I 
• 1 hour - TGF-II 
B Meanwhile, prepare software protocol: enter normalized standard 81 values 
7 With 10 min remaining, prepare 1 x SA-PE in ueav buffer, From 1 OOX stock: 
Add 60 ~I SA-PE to 5.940 ~I assay buller. Protec:t from light 
8. W..h 3 dm .. with 100 III wah butTer 
10. Add 60 ~I of otrepavldln-PE 
11. Cover _ incubate in the dark at RT with .-,g at 300 RPM 
• 10 min - Human Group I,ll; Mouse Group 1,11)11; and Rat Group I 
• 30 min - TGF-P 
112. _3 __ 100,,1 __ 
B 13. Resuspend beads in 1251'1 assay bufter, _ at 1100 RPM for 30 sec 
14. Read plate 
• Low PMT (Low RP1) - H..,.., group 1,1; _ group ~"II_ TGF-II 
• High PMT (High RPl) • Rat group I 
trt
1 .. n.n 
9 l n ., a
I I n i t rn 'l 8
,...,.. 1. quick guide • 
.. . 
" 1. Plan the plale layout 
1 2. Start uplwann up the Bla-Plu system (up to 30 min) 
• Meanwhile, equilibrate aeeay l"8aQente to room temperature (RTJ 
• Begin to thaw sampl .. 
2 3. Prime wash station or calibrate vacuum manifold 
1 4. C8ibrate the 8y8tem (now, or later dur1ng an Incubation) 
.mstItuIe. 
4 il e t.  and on Ice (  i i 
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Luminex, TGF-β Mulitplex (R&D), manufactures booklet: Pages: 6-9.
Luminex' Performance Assay 
TGF-p Multiplex Kit 
Catalog Number lKTIlO1 
For the simultaneous quantitative determination of transforming growth factor beta 
1, 2, and 3 (TGF-p1, TGF-~2, and TGF-~3) concentrations in cell culture supernates, serum, 
plasma, urine, and human milk. 
This package insert must be read in its entirety before using this product. 



















   
ArnvmONIIIEUTIW.IZAnOIi REAGlNT PIlPARAnOll 
nte following JOIutions may.,. stond at room tampwlltura few up to on. month in 
potfPl"OP)'lel. bottles. 
c.ution: Wear protective clothing and safety glasses during prepamtion or use of these reagents. 
Refer to the appropriate MSDS prior to use. 
IN Hel (100mL)-Slowlyadd 8.33 mLof12N Ha to 91 .67 mLofdelonlzed water. Mixweli. 
1.2N NaOH/0.5M HEPES (100 mL) - Slowly add 12 mLofl0N NaOH to 7S mLofdeionized 
water. Mix well, and add 11.9 9 of HEPES. Mix well, and bring the final volume to 100 mL with 
deionized water. 
SAMPLE ACTIVATION PROaDURE 
To activate latent TGF~ to immunoreactive TGF~ detectable In this assay, follow the activation 
procedure outlined below for all sample types. rusay samples Immediately after neutralization 
(pH7.2-7 .6) . Usa,*-,Ione_tu_Donot_tha~5tandonlCocktalL 
1. lf samples contain partirulates, centrifuge for 2 minutes at SOOO x 9 before proceeding. 
2. Add 20 III of IN HCI to 100 III of sample. Mix well, and Incubate for 10 minutes at room 
temperature. 
3. Add 20 ~L of l.2N NaQHlO.5M HEPES. Mix thoroughly. 
SAMPLl PREPARATION 
Activated cell culture 5upernates and activated urine samples require a 1 :357 dilution in 
Calibrator Diluent RD5-49 after activation. This Is a 1:5 final dilution factor. A suggested 1 :3.57 
dilution is 1 1 2IJL of activated/neutralized sample + 288IJL of Calibrator Diluent RDS-49. Mix 
thoroughly. 
Activated serum, plasma, and human milk samples require a 1:10.70 dilution in Calibrator 
Di luent RD6-S0 after activation. This is a 1:15 final dilution factor. A suggested 1 :10.70 dilution 
Is 50 ~L of activated/neutralized sample + 48S ~L of calibrator Diluent RD6-S0. Mix thoroughly. 
For research use only. Not for use in diagnosttc proC!dures. 
REAGENT PREPARATION 
Bring all reagents to room temperature before use. 
Wash Buffer · If crystals have formed in the concentrate, warm to room temperature and mix 
gently unt il the crystals have completely d issolved. Add 20 mL of Wash Buffer Concent rate to 
deionized or dist il led water to prepa re 500 mL of Wash Buffer. 
Standa rd - Reconst itute the Standard Cocktail w ith Ca librator Diluent RDS-49 (for cell culture 
supernate and urine samples) or Calibrator Diluent RD6·50 (for serum, plasma, and human milk 
samples). Refer to the Standard Card for the reconst itution vo lume and assigned values. Allow 
the sta ndard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions. 
Pipette 500 ~L of t he reconst it uted Standard into the Standard , tube. Pipette 200 ~L of the 
appropria te Ca librator Diluent into the remaining tubes. Use Standard 1 to produce a H old 
d ilut ion series (below). M ix each tube thoroughly before the next transfer. Standard 1 serves as 
the high standard. The appropriate Calibrator Di luent serves as the blank. 
1 00 ~L 100 ~L 100 ~L 100 ~L 100 ~L 
/"""lIl /"""lIl /"""lIl /"""lIl /"""lIl 
Standard Standard 1 Standard 2 Standard 3 Standard 4 Standard 5 Standard 6 Sta ndard 7 
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DIWTED MICIIOPARTICLE COCKTAIL PREPARATION 
1. Centrifuge the Microparticle Concentrate vial for 30 seconds at 1000 x 9 prior to removing 
the cap. 
2. Gently vortex the vial to resuspend the microparticles, taking precautions not to invert the 
vial. 
3. Dilute the Mlcropartlcle Concentrate In the mixing bottle provided. 
Number of Wells Used Mknlparlide Caoc!nIrab! + Mlaopartlde Diluent 
96 l00~l + S.OOmL 
72 375~L + 3.75mL 
48 250 .. + 250m! 
2. 125 .. + 115m! 
Nobi: Protect m;croparticles from light during handling. Diluted microparticies cannot be stored. 
Prepare microparticles within 30 minutes of use. 
DIWTED BIOTIN ANTIBODY coeDAIL PREPARATION 
1. Centrifuge the Biotin Antibody Concentrate vial for 30 seconds at 1000 x 9 prior to removing 
the cap. 
2. Gently vortex the vial, taking precautions not to invert the vial. 
3. Add 500 IJl of Biotin Antibody Concentrate to the Biotin Antibody Diluent. Mix gently. 
STREPTAYIDIN·PE PREPARATION 
Use. polypropylene.mba, bottle or I polypropylene tube wrlpped with Iluminum foil. 
Protect Strepmvldln-PE from light during handling and .torage. 
1. Centrifuge the Streptavidin-PE vial for 30 seconds at 1000 x g prior to removing the cap. 
2. Gently vortex the vial, taking precautions not to invert the vial. 
3. Dilute the 1 OOX Streptavidin-PE to a 1 X concentration by adding 55 ~L of Streptavidin-PE to 
S.5 mL of Wash Buffer. 
INSTRUMENT SmlNGS 
Adjust the probe height setting on the Luminex analyzer to avoid puncturing the membrane. 
Refer to the instrument manual. 
a) Assign the bead region for each analyte being measured (see page 1) 
b) 50 events/bead 
c) Minimum events: 0 
d) Flow rate: 60 ~L/mlnute (fast) 
e) Sample size: 50 ~L 
f) Doublet Discriminator gates at approximately 7500 and 15,500 
g) Collect Median Fluorescence Intensity (MFI) 
Noh: For the Bio-Rad Bio-Plex analyzer, set the gates at 4300 and 10,000. The CA12 setting for the 
Bio-Rad Bio-Plex analyzer should be set at the low RP1 target value. 
For researdl use only. Not for use In dlagnostk procedures. 
ASSAY PROCEDURE 
Bring all rug.nts and .ampl •• to room t.mperatur-. Wor-. UN. It I. Ncomm.nd.d th. 
all Amples and .tend.rds be assayed in duplicate. 
Nota: Protect mieroparticJes and Streptavidin-PE from light at all times. 
1. Prepare all reagents, working standards, and samples* as directed In the previous sections. 
2. Pre-wet the filter-bottomed microplate by filling each well with 1 00 ~L of Wash Buffer. 
Remove the liquid through the filter at the bottom of the plate using a vacuum manifold 
designed to accommodate a microplate. 
Noh: After eaeh final wash cycle and subsequent reagent addition, blot the bottom of the plate 
with a paper towel to prevent wieking. 
3. Add 50 ~L ofStandard or activated sample per well. 
4. Resuspend the diluted microparticie mixture by inversion or vortexing. Add 50 ~L of the 
mlcropartlcie cocktail to each well of the pre-wetfilter-bottomed microplate. Securely 
cover with a foil plate sealer. Incubate for 2 hours at room temperature on a horizontal 
orbital microplate shaker (0.12-orbit) set at 500 ± 50 rpm. A plate layout Is provided to 
record standards and samples assayed. 
5. Using a vacuum manifold device designed to accommodate a microplate, wash by 
removing the liquid, filling each well with Wash Buffer (1 00 ~L) and removing the liquid 
again. All of the liquid must be removed through the filter at the bottom of the plate 
to avoid any loss of microparticies. Complete removal of liquid is essential for good 
performance. Perform the wash procedure three times. 
6. Add 50 ~L of diluted Biotin Antibody Cocktail to all wells. Securely cover with a foil plate 
sealer and incubate for 1 hour at room temperature on the shaker set at 500 ± 50 rpm. 
7. Repeat the wash as in step 5. 
8. Add 50 ~L of diluted Streptavidin-PE to all wells. Securely cover with a foil plate sealer and 
incubate for 30 minutes at room temperature on the shaker set at 500 ± 50 rpm. 
9. Repeat the wash as in step 5. 
10. Resuspend the microparticies by adding 1 00 ~L of Wash Buffer to each well. Incubate for 
1 minute on the shaker set at 500 ± 50 rpm. 
11. Read within 90 minutes using the Luminex or BioRad Analyzer. 
*Samples require activation and dilution. See the Sample Activation and Sample Preparation 
sections. 
CALCULATION OF RESULTS 
Use the Standard concentrations on the Standard Value Card and calculate 3-fold dilutions for 
the remaining levels. Average the duplicate readings for each standard and sample and 
subtract the average blank Median Fluorescence Intensity (MFI). 
Create a standard curve for each analyte by reducing the data using computer software 
capable of generating a five parameter logistic (5-PU curve-fit. 
Since samples have been diluted, the concentration read from the standard curve must be 
multiplied by the dilution factor. 
www.RnDSystems.com • 
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II .. UNOASSAY PROCEDURE 
• Prior to beginning this assay, tt is imperative to read this protocol completety and to 
thoroughly understand the T echnk:al Gukleline&. 
• Allow all reagents to warm to room temperature (20-25-C) before use in the assay. 
• Diagram the placement 01 Standards (0 (Background), StandaRl 7, 6, 5, 4, 3, 2, and 1(, 
COntrols 1 and 2, and Samples on Well Map Worksheet In a vertical configuration. (Note: 
Most instrunenls will only read the 96-well plate vertlc:aly by default) II is recommended 
to run the assay in duplicate. 
• Set the fitter plate on a plate holder at all times during reagent dispensing and incubation 
steps so that the bottom of the plate does not touch any surface. 
1. Prewet the filter plate by pipetling 200 ~L of 
Assay Buffer into each well of the Microliter 
Filter Plate. Seal and mix on a plate shaker for 
10 minutes at room temperature (2D-2S"C). 
2. Remove Assay Buffer by vacuum. (NOTE: DO 
NOT IIVEAT PLATE.) Blot excess Assay 
Buff11M' from the bottom of the plate with an 
absorbent pad or paper lowefs. 
3. Add 25 tJI. Assay Buffer to aI weIs. 
4. Add 25 J!l of each Standard or Control Into the 
appropriato weIs. As&y Butler should be UI8d 
for the 0 pwmL standaRl (Background). 
5. Add 25 ~L 01 Assay Butler to the sarrll>e wells. 
6. Add 25 ~l of Serum Matrix to the background, 
standards, and control wells. 
7. Add 25 loll of Sample into the appropriate wells. 
(Serum and plasma samples should be diluted 
1:4 in Assay Buffer.) 
8. Vortex Mixing Bottle and add 25 IJl of the 
Mixed Beads to each well. (Note: During 
addition of Beads, shake bead bottle 
intennittently to avoid settling.) 
9. Seal the plate with a plate sealer, cover It with 
the lid. Wrap a rubber band around the plate 
holder, plalB and lid and incubate with agitation 
on a plate shaker overnight (16-20 hours) at 
4'C. 
(Tho total volume shoold be 100 tJI. in each wei 
for the overrO{llt incWation.) 
I 
Add 200 ~L As&y Buffer per 
""II 
I Shake 10 min, RT 
..J Vacul.m 
• Ack:I25 pl Assay Buffer to 
all werts 
Add 25 ~L S1andard or 
Control to appropriate wells 
• Add 25 pl Assay Buffer to 
background and sample 
wells 
• Add 25 pl Serum Matrix to 
background, standards and 
oontrol wells 
• Add 25 pl Samples to 
sample wells 
Add 25 ~L -. to each 
wei 
l Incubate owmight a14'Cwithshaking 
1 O.Gently remove fluid by vacuum. (NOTE: DO 
NOT INVERT PLATE.) 
11. Wash plate 3 times w~h 200 ~LJweIl 01 Wash 
Buffer, removing Wash Buffer by vacuum 
Ilitration between each wash. Blot excess 
Wash Buffer from the bottom of the plate with 
an absorbent pad or paper towels. 
12. Add 50 ~L 01 Detection Antibodies into each 
well. (Note: Allow the Detection Antibodies to 
warm to room temperature prior to addition.) 
13. Seal, cover with lid, and incubate with agitation 
on a plate shaker for f hour at room 
temperature (20-25 "C). DO NOT VACUUM 
AFTER INCUBATION. 
14.Add 50 ~L Streptavidin-Phycoerythrin to each 
well containing the 50 ~L 01 Detection 
AnIIlodies, 
15. Seal, cover with lid and incubate with agitation 
on a plate shaker for 30 minutes a1 room 
temperature (20-25"C). 
16.Gently remove all contents by vacuum. (NOTE: 
DO NOT INVERT PLATE.) 
17. Wash plate 311me. with 200 ~Llwell Wash 
Buffer, removing Wash Buffer by vacuum 
filtration between each wash. Wipe any excess 
buffer on the bottom of the plate with a tissue. 
18. Add 1 00 ~L of Sheath Fluid to all wells. 
Resuspend the beads on a plate shaker for 5 
minutes. 
19.Run plate on Lumlnex tOO"" IS, 200 .... , or HTS. 
20. Seve and analyze the Median Fluorescent 
Intensity (MFI) data using a weighted 5-
parameter logistic or spline curve-litting method 
for calculating anaIyte concentrations in 
samples. 
I 
Vacuum and wash 
3X with 200 ~L 
Wash Buffer 
Add 50 ~L Detection 
Antibodies per well 
Incubate 1 hour 
I atRT Do Not Vacuum 
Add 50 ~L Streptavidin-
Phycoerythrin per well 
Incubate for 30 
I minutes at RT Vacuum and wash 3X with 200 ~L 
Wash Buffer 
I Add 1 00 ~L Sheath Auid per 
well 
I Read on Luminex (50 ~L, 
50 bead. per bead set) 
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Table A – E contains the raw data from the cross-sectional and longitudinal studies.  
 
Abbreviations and measurements are as follows: 
Sex = M - Male; F - Female 
CAMCOG 1 = CAMCOG at baseline 
MMSE 1 = Mini-Mental State Examination at baseline 
LS 1 = learning subscale at baseline 
CAMCOG 2 = CAMCOG at follow-up 
MMSE 2 = Mini-Mental State Examination at follow-up 
LS 2 = learning subscale at follow-up 
WCC = white cell count (x10
9
/l) 
MC = monocyte count (x10
9
/l) 
ESR = erythrocyte sedimentation rate (mm in 1 hour)   
IL-1β = Interleukin 1 beta (pg/mL)  
IL-10 = interleukin 10 (pg/mL)  
TNF-α = tumor necrosis factor alpha (pg/mL) 
TGF-β1 and TGF-β2 = transforming growth factor beta 1 and 2 (pg/mL)  
OPN = osteopontin (pg/mL)  
 
Note: Missing data are represented by blank cells. In the CAMCOG 2, MMSE, LS 2 
columns, missing data from these columns means that the person was not followed-up. 

































No of E4 
alleles  WCC MC ESR IL-1β  IL-10 TNF-α  OPN TGF-β1 TGF-β2  
1 AD 78 F 6 66 21 14 62 20 11 1 9.86 0.55 30 2.50 3.80 3.50 714.50 1216.00 5.00 
2 AD 74 F 6 49 14 7       1 5.3 0.49 16 2.30 6.30 2.50 2570.30 933.00 6.50 
3 AD 62 F 14 77 24 14 62 20 8 0 9.8 0.57 25 4.00 4.30 6.00 584.50 2924.00 11.00 
4 AD 91 M 9 57 17 8 46 16 2 0 7.64 0.55 5 1.50 4.80 3.00 2029.30 1612.50 6.00 
5 AD 84 F 8 41 17 4 51 17 3 0 7.51 0.55 20 2.30 4.00 3.00 122.30 1912.50 7.00 
6 AD 60 M 10 68 18 10 60 20 4 1 8.69     2.00 4.30 3.50 970.00 2096.30 8.50 
7 AD 71 F 9 76 23 4 74 25 6 1 5.04 0.34 5 2.00 4.30 3.80 882.80 1738.50 7.00 
8 AD 90 F 5 45 14 3       1 6.29 0.43 10 1.50 6.50 3.50 2308.30 1253.00 10.30 
9 AD 72 M 8 50 16 3 47 13 3 1 7.11 0.37 10 2.00 4.00 2.50 368.80 1245.80 8.00 
10 AD 85 F 13 75 23 5 64 19 3 1 7.41 0.42 3 2.30 5.00 3.50 248.80 1453.30 6.30 
11 AD 76 F 16 78 24 7 66 20 4 1 5.67 0.35 6 2.00 4.50 4.00 169.00 1873.50 7.00 
12 AD 67 M 13 87 28 11 88 26 10 1 5.66 0.29 1 4.50 7.00 4.50 240.50 1709.00 5.80 
13 AD 78 F 10 54 21 7       1 5.66 0.27 13 1.00 4.00 3.00 1312.50 1723.00 7.00 
14 AD 82 F 5 52 17 7 45 11 6 0 4.11 0.24 8 2.00 4.50 2.50 757.80 1533.50 4.50 
15 AD 91 F 5 56 17 13       1 4.98 0.32 34 3.00 5.50 5.00 4375.50 1100.00 10.00 
16 AD 93 F 8 68 22 11       0 9.67 0.4 30 3.50 7.00 5.80 1293.80 1829.50 15.50 
17 AD 78 F 9 73 27 12       0 11.49 0.8 19 2.50 5.00 3.00 416.80 1430.50 7.00 
18 AD 91 F 8 68 24 12 83 24 14 0 3.38 0.31 36 3.00 66.30 3.00 853.00 577.80 3.00 
19 AD 81 F 8 38 13 5       0 5.01 0.29 18 1.50 3.00 3.50 2127.00 885.50 9.00 
20 AD 63 M 5 72 23 10 79 28 11 0 5.41 0.36 1 3.00 164.80 4.00 319.80 877.50 5.00 
21 AD 73 M 7 45 12 4       0 6.94 0.37 7 2.50 3.80 3.00 1066.50 1369.50 7.50 
22 AD 59 M 12 73 23 2 74 24 2 0 6.06 0.41 2 1.50 4.50 5.50 151.00 1725.30 6.80 
23 AD 72 F 6 45 13 7 37 17 5 1 7.24 0.54 11 2.50 4.50 3.80 2673.80 2222.50 9.50 
24 AD 67 M 11 79 22 10 73 26 7 2 5.91 0.42 2             
25 AD 69 F 12 86 27 10       1 6.27 0.32 6 2.00 4.30 4.30 325.00 175.00 1.50 
26 AD 72 M 17 70 20 7       1 5.31 0.45 4 2.00 6.50 2.50 300.30 997.00 4.00 
27 AD 82 M 8 69 23 3 
      




































No of E4 
alleles WCC MC ESR IL-1β  IL-10 TNF-α  OPN TGF-β1 TGF-β2  
28 AD 77 M 16 63 19 3 54 13 2 1 5.3 0.3 8 2.50 3.30 3.00 183.00 748.30 3.50 
29 AD 83 F 4 81 27 12 
      
0 4.91 0.23 23 2.50 5.00 3.50 138.00 914.30 4.00 
30 AD 78 M 8 78 27 11 72 23 6 1 7.32 0.43 12 2.00 5.00 4.00 1060.00 470.00 2.80 
31 AD 73 F 11 75 23 7 
68 20 8 
1 7.42 0.3 11 2.00 4.50 5.00 421.30 1671.30 5.30 
32 AD 82 F 13 67 26 5 
      
0 7.61 0.54 8 1.50 3.50 3.00 41.80 350.00 2.50 
33 AD 63 M 10 59 22 10 48 18 8 1 7.01 0.55 12 2.00 4.00 2.50 109.00 1458.80 5.50 
34 AD 61 F 8 61 20 2 54 23 3 0 10.91 0.53 26 2.00 6.30 3.80 172.30 109.80 1.00 
35 AD 74 F 5 49 14 6 65 21 6 0       2.50 7.00 3.50 159.50 1551.00 7.50 
36 AD 85 F 8 57 24 6 
40 14 1 
0 8.48 0.53 22 2.00 3.30 13.50 245.80 298.50 2.00 
37 AD 79 F 8 44 14 4 35 10 2                     
38 AD 66 F 9 73 21 7 
49 17 2 
2 9.8 0.59 33 1.50 5.00 4.00 449.30 378.00 6.80 
39 AD 82 F 7 51 14 1 45 19 2 2 9.99 0.3 8 3.50 11.00 5.00 573.00 741.50 3.50 
40 AD 69 F 14 80 24 9 68 22 4 2 5.46 0.21 16 1.50 2.50 3.00 1629.80 1262.30 13.50 
41 AD 66 F 8 64 21 1       2 7.78 0.34 20 1.00 3.50 3.50 1153.80 2105.30 15.00 
42 AD 78 M 8 61 21 4 51 16 6 1 8.17 0.42 7 2.00 5.30 2.50 232.00 186.50 1.50 
43 AD 68 F 8 56 25 7 50 18 6 0 2.96 0.18 5 2.00 6.30 3.00 142.80 451.30 2.50 
44 AD 71 M 15 83 27 13       0 5.71 0.39 20 11.30 73.00 19.50 331.30 81.00 1.00 
45 AD 79 M 12 76 24 9 72 19 8 1 5.71 0.29 3 3.00 6.80 4.00 203.80 80.30 1.00 
46 AD 85 F 6 42 14 8 42 15 6 1 6.4 0.33 25 2.00 4.00 4.00 1572.50 218.30 5.00 
47 AD 81 F 9 52 16 4 41 17 2 1 6.18 0.29 5 1.00 8.00 3.00 1016.80 120.80 3.50 
48 AD 78 M 9 84 25 14       1 5.51 0.37 4 1.00 3.00 2.50 1394.50 136.50 4.00 
49 AD 87 F 8 51 16 2       1 6.16 0.31 38 1.50 3.50 3.50 1276.50 175.80 4.50 
50 AD 79 M 10 84 28 14       0 4.94 0.27 17 1.00 3.00 3.30 870.80 138.30 5.00 
51 AD 88 F 14 67 20 5       2 7.59 0.59 9 2.00 3.00 4.50 1801.50 192.30 4.00 
52 AD 77 M 12 79 21 11       2 3.4 0.21 4 1.00 3.00 3.50 1321.50 97.00 3.30 
53 AD 79 M 10 76 26 10       0 
2.89 0.28 5 






































No of E4 
alleles WCC MC ESR IL-1β  IL-10 TNF-α  OPN TGF-β1 TGF-β2  
54 AD 84 F 8 79 26 10       0 9.74 0.51 31 1.50 5.50 4.00 1533.80 520.50 6.30 
55 AD 80 F 8 49 15 3       0 9.84 0.49 26 1.50 3.00 3.50 1600.50 559.50 7.00 
56 AD 79 F 16 74 25 1       0 7.11 0.53 25 1.00 2.00 3.00 2279.30 118.30 3.00 
57 AD 80 F 8 44 12 5       1 9.18   14 1.00 2.00 3.00 552.50 1069.00 8.00 
58 AD 83 F 12 77 26 8       0 7.59 0.51 1 1.00 2.50 4.00 701.00 119.50 5.50 
59 AD 77 M 12 75 22 8       0 7.54 0.55 0 1.50 4.00 3.50 593.50 89.00 5.25 
60 AD 78 F 7 57 16 2       2 7.17 0.48 35 2.75 5.00 4.00 850.00 1243.00 10.00 
1 Control 66 M 11 94 29 13 91 27 16 1 6.64 0.35 8 2.00 4.30 2.80 311.80 1581.80 9.00 
2 Control 59 F 14 100 29 17 103 30 16 0 7.36 0.52 14             
3 Control 62 F 9 99 30 16 98 30 17 1 5.35 0.56 3 2.00 5.00 3.50 5040.50 2372.50 13.50 
4 Control 66 F 19 94 28 16 95 25 14 1 8.42 0.41 34 2.00 4.30 2.50 152.00 1982.00 8.50 
5 Control 76 M 12 91 29 15 93 30 12 1 6.62 0.43 26 2.50 3.00 4.00 1833.30 1385.00 7.00 
6 Control 69 F 8 91 24 15 92 28 14 0 8.54 0.5 13 2.00 4.50 4.30 1409.30 1814.80 6.50 
7 Control 70 F 15 81 28 13 78 27 13 0 6.11 0.43 3 1.50 4.50 3.50 305.80 1436.50 6.50 
8 Control 67 F 16 94 28 15 94 30 15 0 6.85 0.44 13 5.50 5.00 4.30 740.30 1823.30 8.00 
9 Control 63 F 15 97 29 15 97 30 17 0 6.64 0.33 18 2.00 4.50 3.00 770.50 1369.50 5.50 
10 Control 61 F 10 89 28 12 93 27 15 1 3.87 0.25 6             
11 Control 89 M 12 87 26 14 85 27 14 0 3.43 0.23 12 2.50 5.50 3.00 999.00 334.00 3.00 
12 Control 69 F 16 87 28 14 94 29 16 0 4.95 0.33 10 2.00 3.50 3.00 809.30 1408.30 5.00 
13 Control 84 F 9 85 26 13 85 27 13 0 7.97 0.5 34 2.00 6.50 3.50 594.00 1563.00 6.00 
14 Control 83 F 3 87 28 14 89 28 15 0 7.89 0.42 4 3.00 5.80 4.00 359.00 1500.50 6.50 
15 Control 75 F 8 85 28 15 93 29 16 1 7.68 0.56 10 2.00 3.30 2.50 504.80 1943.00 7.00 
16 Control 100 F 8 84 24 13         8.32 0.37 30 2.80 5.00 3.00 1005.30 962.80 6.00 
17 Control 58 F 9 91 30 13 96 28 16 0 8.03 0.51 17             
18 Control 75 F 8 87 28 13 87 26 15 0 6.68 0.36 22 3.50 3.80 6.30 3503.00 2395.30 4.50 






































No of E4 
alleles WCC MC ESR IL-1β  IL-10 TNF-α  OPN TGF-β1 TGF-β2  
20 Control 59 F 7 84 28 12 88 28 17 1 7.23 0.51 7             
21 Control 83 M 12 89 27 13 86 29 11 0 4.99 0.36 1 1.80 4.80 3.00 562.80 696.00 3.50 
22 Control 81 F 12 85 28 11 86 27 14 0 8.01 0.58 20 2.50 14.30 3.50 367.30 1320.00 4.00 
23 Control 83 F 18 93 30 14 97 29 14 1 6.82 0.38 10 2.00 5.00 3.50 854.00 719.30 4.00 
24 Control 83 M 23 96 28 13 97 30 14 0 13.87 0.79 12 2.50 7.00 3.50 913.80 1092.00 4.50 
25 Control 79 F 14 94 29 15 93 30 15 1 4.61 0.39 3 2.50 5.50 3.50 948.00 1452.50 7.00 
26 Control 79 M 20 95 29 12 94 27 15 0 5.55 0.39 2 2.50 5.30 4.00 243.80 778.00 3.50 
27 Control 69 F 18 96 28 15 97 29 15 0 4.98 0.32 15 3.30 5.00 4.80 899.30 1476.50 6.00 
28 Control 80 F 18 88 28 11 90 29 16 0 8.68 0.53 10 2.50 5.30 3.50 498.00 2565.30 8.30 
29 Control 72 F 11 91 27 14 93 25 14 1 5.27 0.41 10 3.00 5.80 4.00 154.30 1197.50 5.50 
30 Control 81 M 18 90 28 11 94 27 13 0 6.27 0.35 0 2.00 4.80 4.50 466.50 1358.00 5.50 
31 Control 78 M 12 95 29 12 96 27 15 0 6.8 0.44 2 1.00 3.50 3.50 923.50 1125.30 11.50 
32 Control 81 F 9 87 29 13       0 7.45 0.31 36 2.00 5.50 4.00 1021.50 1503.50 13.50 
33 Control 65 F 15 90 30 14 97 29 17 2 7 0.29 3 1.50 13.00 3.50 1804.50 1387.50 9.80 
34 Control 66 F 18 100 29 15       0 6.01 0.53 1 1.50 4.00 3.50 782.80 1393.50 10.00 
35 Control 67 F 22 97 30 16       1 5.31 0.29 6 1.00 2.50 3.00 1883.00 778.00 8.50 
36 Control 66 F 3 96 30 15                           
37 Control 62 F 13 95 29 13 96 30 13 0 5.76 0.32 18 1.30 3.00 4.00 1148.50 941.30 9.50 
38 Control 85 F 10 86 24 13       1 7.84 0.44 15 2.00 37.00 2.50 154.50 1836.50 9.00 
39 Control 82 F 11 96 29 15 97 28 15 0 5.91 0.38 8 2.50 4.50 3.50 1107.30 927.30 5.50 
40 Control 62 F 14 98 30 15 94 30 12 0 8.74 0.48 20 2.00 7.00 5.00 1149.00 1027.25 10.50 
41 Control 71 F 22 95 30 14 96 30 14 2 6.8 0.43 1 1.50 2.50 4.00 377.80 178.30 5.00 
42 Control 70 M 23 100 29 16 99 28 14 0 6.67 0.37 3 2.80 2.50 3.00 98.30 530.00 5.50 
43 Control 72 F 8 86 29 14       1 6.65 0.34 23 2.00 4.80 3.50 446.30 1770.80 6.00 
44 Control 62 F 16 98 30 14 100 30 14   6.3 0.43 6 2.00 6.50 4.00 1354.00 1193.50 13.00 






































No of E4 
alleles WCC MC ESR IL-1β  IL-10 TNF-α  OPN TGF-β1 TGF-β2  
46 Control 73 F 12 99 29 17 97 29 15 0 5.92 0.17 27 1.50 3.80 2.50 445.30 72.50 0.50 
47 Control 73 F 12 101 30 15 96 28 15 0 6.61 0.28 9 2.50 7.50 2.50 477.00 130.00 1.50 
48 Control 69 F 25 91 28 13 98 30 14 1 3.97 0.23 3 2.00 3.80 2.50 236.80 81.30 0.50 
49 Control 77 F 17 96 28 15 96 29 14 1 6.15 0.44 17 2.00 5.30 3.50 127.30 1738.50 5.50 
50 Control 68 F 10 96 29 15 98 30 17 1 6.05 0.28 5 2.00 3.30 3.00 552.80 128.30 1.50 
51 Control 61 F 14 88 29 13 90 30 12 1 11.7 0.43 30 3.50 5.50 4.80 317.00 106.00 1.00 
52 Control 63 F 20 98 30 15       0 7.16 0.5 18 2.00 3.50 4.50 397.50 168.50 4.50 
53 Control 63 M 20 95 30 14 96 30 13 1 6.5 0.43 7 3.00 18.30 5.50 940.00 106.00 3.50 
54 Control 62 F 16 94 30 13 95 27 14 1 8.16 0.29 25 1.50 2.50 3.50 4184.30 99.30 3.50 
55 Control 67 F 12 94 29 14 90 29 13 0 6.55 0.33 6 2.50 3.50 4.30 304.00 49.50 0.00 
56 Control 76 M 10 91 29 12 92 30 14 0 5.99 0.31 8 1.30 7.00 4.50 583.50 280.00 6.30 
57 Control 82 F 15 92 29 13       0 6.51 0.32 2 1.00 3.00 2.50 1105.80 115.00 3.50 
58 Control 82 F 15 91 29 12       0 6.03 0.43 3 1.00 3.00 3.30 1955.50 142.00 2.80 
59 Control 66 F 14 98 29 14 100 29 15 1 5.23 0.27 19 1.00 119.30 3.50 641.50 108.80 4.50 
60 Control 64 M 12 96 30 14       0 7.7 0.52 13 1.00 3.50 3.30 409.80 742.30 8.00 
61 Control 60 F 13 97 29 13       0 4.26 0.31 1             
62 Control 73 M 10 96 28 15       0 8.52 0.48 9 1.50 3.00 3.50 477.00 244.00 4.50 
63 Control 65 F 16 96 30 11       0 9.13 0.38 7 1.00 3.00 3.50 993.80 133.50 3.50 
64 Control 66 F 15 93 26 14       0 4.66 0.48 5 1.50 3.00 4.50 719.80 999.00 8.00 
65 Control 61 F 22 100 30 15       0 5.17 0.23 2             
66 Control 60 F 13 96 30 13       0 4.66 0.36 2             
67 Control 76 M 16 96 29 14       1 7.57 0.47 8 2.00 5.25 5.00 552.00 71.50 5.00 




















Table A – B contains the raw data from the MRS Study.  
 
Abbreviations and measurements are as follows: 
Sex = M - Male; F - Female 
MMSE = Mini-Mental State Examination  
LS = learning subscale  
WCC = white cell count (x10
9
/l) 
MC = monocyte count (x10
9
/l) 
ESR = erythrocyte sedimentation rate (mm in 1 hour)   
IL-1β = Interleukin 1 beta (pg/mL)  
IL-10 = interleukin 10 (pg/mL)  
TNF-α = tumor necrosis factor alpha (pg/mL) 
TGF-β1 and TGF-β2 = transforming growth factor beta 1 and 2 (pg/mL)  
OPN = osteopontin (pg/mL)  
MI = myo-inositol (parts per million) 
NAA+NAAG = N-acetylaspartate and N-acetylaspartylglutamate 
MI:NAA+NAAG = ratio of MI to NAA+NAAG 
 
Note: Missing data are represented by blank cells. Names and study numbers for 






















Group Age Sex 
Year of 
Education 
No of E4 





1 AD 62 F 14 0 7 18 8,57 0,58 27 4 5,5 5,5 721,25 538,3 10 3,654 5,523 0,7 
2 AD 67 M 13 1 10 27 5,08 0,31 3 2 3,8 3 537,00 1121,5 10,5 3,863 5,593 0,7 
3 AD 63 M 5 0 13 25 4,29 0,27 3 3,5 117 7 696,75 83,5 3 4,161 5,684 0,7 
4 AD 59 M 12 0 0 19 5,37 0,51 1 2 3 4 863,25 1124 9,5 5,341 5,404 1,0 
5 AD 67 M 11 2 3 27 5,49 0,45 1 2 3 4 857,75 118,5 5 4,994 6,601 0,8 
6 AD 73 F 11 1 8 20 
   
2 3,5 4,5 847,00 1919,5 12 3,569 5,411 0,7 
7 AD 63 M 10 1 5 18 6,54 0,48 8 2 5 4,3 135,00 149 5 5,685 5,647 1,0 
8 AD 85 F 8 0 1 14 6,22 0,48 31 2 3 9,5 2264,00 119,5 4,5 4,42 6,332 0,7 
9 AD 78 M 8 1 6 16 6,22 0,42 1 2 4,5 4 2910,25 220,5 6 5,073 5,785 0,9 
10 AD 68 F 8 0 4 18 3,1 0,23 2 2 4 4 587,75 572,5 8,5 5,063 5,708 0,9 
11 AD 79 M 12 1 8 19 5,82 0,41 1 1,5 5,5 3,5 510,50 943 9,5 4,805 5,385 0,9 
12 AD 81 F 9 1 2 17 4,68 0,3 4 2,3 5 4 656,75 1000,8 8 5,961 5,565 1,1 
13 AD 87 F 8 1 2 12 
         
4,279 5,904 0,7 
14 AD 79 M 10 0 13 28 4,67 0,22 12 3,5 5,5 6 917,25 91 4,5 4,213 6,046 0,7 
15 AD 79 M 10 0 13 21 3,34 0,3 12 2,5 4,5 4 1311,75 588,5 7,5 5,262 5,103 1,0 
16 AD 80 F 8 0 5 14 8,15 0,35 10 3 5 4,5 1765,50 610 8 4,498 5,075 0,9 
17 AD 83 F 12 0 9 24 7,24 0,4 2 2 4 4,8 633,00 731 7,5 4,278 6,057 0,7 
18 AD 77 M 12 0 8 22 7,54 0,55 0 1,5 4 3,5 593,50 89 5,3 4,319 5,99 0,7 
1 Control 66 M 11 1 16 29 
   
2 4,5 4 1044,25 1237,5 12 4,842 6,121 0,8 
2 Control 59 F 14 0 17 29 6,35 0,32 11 2,3 4,5 4 1872,50 1158 10,5 4,158 5,687 0,7 
3 Control 62 F 9 1 15 29 5,13 0,31 6 2 4 3,5 633,50 1797 12,5 4,945 6,281 0,8 
4 Control 76 M 12 1 13 30 6,04 0,45 26 2 4 4,5 870,75 83,5 4,5 5,33 6,806 0,8 
5 Control 70 F 15 0 13 29 12,03 0,66 8 2 4,5 3,5 2600,75 473,3 7 4,235 6,021 0,7 
6 Control 67 F 16 0 15 27 7,56 0,38 7 2 4 3 484,00 209,5 6 4,72 6,16 0,8 
7 Control 63 F 15 0 16 28 7,42 0,42 2 
      
4,978 6,893 0,7 























 Group Age Sex 
Year of 
Education 
No of E4 





9 Control 80 F 18 0 16 29 7,74 0,47 2 2,3 4 4,5 1119,75 466,3 7,5 4,577 6,26 0,7 
10 Control 81 M 18 0 15 27 7,09 0,46 1 3 4 3,8 1662,00 529,5 7 5,249 6,263 0,8 
11 Control 78 M 12 0 15 27 7,72 0,63 5 2 4,5 4 1084,00 1385,3 11,8 5,265 7,083 0,7 
12 Control 73 F 12 0 15 30 5,19 0,27 7 2,5 4 5 835,75 729,3 8,3 4,193 5,786 0,7 
13 Control 68 F 10 1 15 28 6,83 0,4 3 2 3,5 5 1219,75 72 4 4,091 5,844 0,7 
14 Control 76 M 10 0 14 30 6,32 0,47 7 3,3 6 4 1004,00 1329,3 9,5 4,427 6,657 0,7 
15 Control 73 M 10 0 13 29 
         
3,436 5,736 0,6 
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